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There is widespread agreement that neurobiology plays a role in psychological distress 
and that psychiatric diagnosis and associated psychopharmacological interventions can be 
helpful. However, there are also unresolved issues surrounding the limits of empirical 
support for current diagnostic criteria, shortcomings in neurobiological explanations of 
psychopathology, and unanswered questions about the mechanism, safety, and efficacy of 
psychiatric medications. This has implications for treatment errors which can precipitate 
negative socio-economic and health consequences, particularly for vulnerable groups like 
the Consumer/Survivor/Ex-Patient (c/s/x) population. It is for these reasons that the 
training psychologists receive to prescribe should, in addition to integrating the critiques 
of conventional thinking about the etiology and diagnosis of mental distress, discuss the 
c/s/x movement. Extent research on psychologist postdoctoral psychopharmacology 





study used content analysis and was the first to examine a selection of psychologist 
postdoctoral psychopharmacology training materials to understand the extent to  
 which they were (a) integrating critiques of neurobiological hypotheses for depression’s 
etiology, (b) challenging the rigor of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM) and, (c) informing students about the consumer/survivor/ex-patient 
movement. Results indicated that the examined body of materials did not consistently and 
comprehensively critique the majority of neurobiologically based etiological hypotheses 
for depression that were being disseminated. Next, challenges to the DSM’s empirical 
rigor within the examined materials primarily focused on construct validity versus inter-
rater reliability, and without the provision of statistical analyses. Finally, the only 
substantial c/s/x content within the examined materials was limited to one book which 
students were not required to read. The limits of these findings and a variety of socio-
cultural, ethical, legal, and professional advocacy considerations are discussed. The 
electronic version of this dissertation is at AURA: Antioch University Repository and 
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Chapter I: Introduction 
Background 
 A compelling body of scientific evidence points to a variety of plausible 
neurobiological explanations for the etiology of psychological distress and the potential 
benefits of psychotropic drug interventions (Julien, Advokat, & Comaty, 2011; 
Schatzberg & Nemeroff, 2009; Stahl, 2013). The value of using formal diagnostic criteria 
to conceptualize, research, and discuss mental health problems in addition to aiding in the 
selection of psychopharmacological treatments has also been well documented 
(American Psychiatric Association, 2000; Fischer, 2012; Nemeroff et al., 2013). 
 Conversely, there are unresolved issues surrounding the limits of empirical 
support for current diagnostic criteria, shortcomings in neurobiological explanations of 
psychopathology, and unanswered questions about the mechanism, safety, and efficacy of 
psychiatric medications (Moncrieff, 2009; Whitaker, 2010). This has implications for 
treatment errors which can precipitate negative socio-economic and health consequences, 
particularly for vulnerable groups like the Consumer/Survivor/Ex-Patient (c/s/x) 
population (Chamberlin, 1990; Kallert, Mezzich, & Monahan, 2011; LeFrancois et al., 
2013; Whitaker, 2010). It is for these reasons that the training psychologists receive to 
prescribe should, in addition to integrating the critiques of conventional thinking about 
the etiology and diagnosis of mental distress, discuss the c/s/x movement. 
 The extent research on the psychologist prescriptive authority movement has 
focussed on its legitimacy (Evans & Murphy, 1997; Fox et al., 2009; Heiby, 2002; 




Stock, 2004; U. S. General Accounting Office [GAO], 1997, 1999; Vector Research, Inc., 
1996),  safety considerations (American College of Neuropsychopharmacology, 1998, 
2000; Evans, 2003; GAO, 1997, 1999; Lavoie & Fleet, 2002; Newman, Phelps, 
Sammons, Dunivan, & Cullen, 2000; Robiner et al., 2002; Vector Research, Inc., 1996), 
and curricula requirements (Levant & Shapiro, 2002; McGrath, 2010; Sammons & 
Brown, 1997; Resnick, Ax, Fagan, & Nussbaum, 2012; Robiner, et al.,  2002; Sechrest & 
Coan, 2002; Tulkin & Stock, 2004).  
 This study was the first to examine a selection of psychologist postdoctoral 
psychopharmacology training materials to understand the extent to which they were 
integrating critiques of neurobiological hypotheses for depression, challenging the rigor 
of conventional diagnostic practices, and addressing a particularly vulnerable population 
with mental health concerns (i.e., the consumer/survivor/ex-patient movement).    
 I chose to focus on depression’s etiology because the disorder is the most 
commonly diagnosed form of mental distress (Moncrieff, 2009; Whitaker, 2010), with 
some experts speculating that by the year 2020 depression will be the second leading 
cause of disability worldwide (Julien et al., 2011). Additionally, neurobiologically based 
hypotheses for depression are used to support claims about psychiatric medications’ 
mechanism of action as well as the rationale of prescribing this class of drugs (Julien et 
al., 2011; Schatzberg & Nemeroff, 2009; Stahl, 2013).  
 Next, as noted, in spite of technological advancements with neuroimaging and 
associated research, experts continue to disagree about the particular neurophysiological 
determinants of depression (i.e., the role of neurotransmitters, receptors, neurotrophins, 




mechanisms, and safety of antidepressants with the potential for serious iatrogenic effects 
(Andrews, Kornstien, Halberstadt, Gardner, & Neale, 2011; Berton & Nestler, 2006; 
Healy, 2008; Krishnan & Nestler, 2008; Moncrieff, 2009; Rose & Abi-Rached, 2013; 
Valenstein, 1998; Whitaker, 2010).   
 Similarly, substantial limitations with the DSM’s inter-rater reliability and 
construct validity have also been identified (Caplan & Cosgrove, 2004; Frances, 2013; 
Kirk & Kutchins, 1994; Valenstein, 1998). Additionally, there are concerns that 
shortcomings of the manual’s rigor and potential errors in characterizing the extent and 
type of psychological distress associated with the DSM’s empirical limits might 
negatively impact employment opportunities, insurance coverage, child custody and other 
legal proceedings, economic opportunities, and human rights (Caplan, 2012; Caplan & 
Cosgrove, 2004; Frances, 2013; Kallert et al., 2011; Whitaker, 2010; Zur & Nordmarken, 
2010).  
 The c/s/x population represents a particularly important group to consider within 
the context of this study because the c/s/x movement was initiated in response to 
allegations of human rights abuses stemming from psychiatric treatments—treatments 
that have been based upon questionable scientific evidence. Further, the c/s/x population 
is especially vulnerable to treatment errors because its members tend to suffer from 
intersecting forms of discrimination such as poverty, racism, homophobia, and sexism—
in addition to the stigmatization of mental illness (LeFrancois et al., 2013).    
 The c/s/x movement has taken a strong stance against coercive psychiatric 
practices including forced drugging, forced confinement, and misinformation (i.e., 




treatment of mental distress (Campbell & Gardner, as cited in Sammons et al., 2003; 
Oaks, as cited in Kallert et al., 2011). This has ethical and legal implications for the 
process of obtaining informed consent for psychiatric services such as diagnosis and 
psychotropic interventions (Bassman, 2005; Gopal et al., 2012; Gottstein, 2008; Kallert et 
al., 2011; Mendez, 2013). The importance of conservative prescription practices and 
informed consent, in light of gaps in the body of etiological and diagnostic evidence used 
to support psychotropic interventions, is highlighted by a growing body of research 
documenting the potential for iatrogenic risks associated with antidepressant use (i.e., 
increased risk of stroke, suicidality, mortality, and complications during pregnancy) 
(Andrews et al., 2011). 
 In the United States, forced drugging is an accepted practice for mitigating a 
person’s potential risk of harm to self and/or other(s). However, concerns have been 
raised by the c/s/x movement and others, in some cases litigiously, about the 
constitutional legality of these practices which can profoundly impact a person’s human 
rights, physical, and psychological health (Gottstein, 2008; Mendez, 2013; Oaks, 2011).   
 In the same vein, the American Psychological Association’s Ethical Principles of 
Psychologists and Code of Conduct (2010) and Practice Guidelines for Psychologists’ 
Involvement in Psychopharmacological Issues (2011) tenets uphold the importance of 
informed consent that acknowledges the limits of evidence upon which interventions are 
based. Further these documents outline the importance of a culturally sensitive approach 
to practice that would dictate being knowledgeable about marginalized groups like the 
c/s/x population and its movement. For example, the importance of listening to patients’ 




consent by reviewing the strengths and limits of evidence supporting diagnoses, 
etiological hypotheses, and psychotropic treatments (American Psychological 
Association, 2010, 2011).   
In terms of advocacy, professional allies of the c/s/x population (e.g., 
psychiatrists, psychologists, physicians, social workers, and prescribing psychologists) 
have identified the importance of considering the history, mission, and needs of the c/s/x 
movement and population when it comes to the provision of collaborative mental health 
care practices (MindFreedomInternational, 2015; Sammons et al., 2003). 
It is for these social, economical, health, ethical, legal and professional advocacy 
related reasons that psychologist  postdoctoral psychopharmacology training materials 
warrant examining to determine the extent to which they are integrating information 
about the c/s/x population and critiques of conventional perspectives about the etiology of 
depression and rigor of the DSM.The following paragraphs will provide a critical 
examination of the literature on curricula research and the three topics of analysis in 
addition to outlining the rationale for the study in greater detail. 
Critical Review of the Literature  
 The following section will critically examine the literature surrounding 
(a) curricula research, (b) neurobiological hypotheses for the etiology of depression, 
(c) the rigor of the DSM, and (d) considerations pertaining to the c/x/s population and the 
c/s/x movement. Additionally, the rationale for this study will be discussed in greater 




Curricula Research   
One method for determining how students within a particular discipline are being 
trained is to examine curricula. According to Douglas Clements (2007) “curriculum is a 
written instructional blueprint and set of materials for students’ acquisition of certain 
culturally valued concepts, procedures, intellectual dispositions, and ways of reasoning” 
(p. 36).  An area of focus for curricula research within the discipline of psychology has 
been diversity—in particular, ethnicity and gender (Dionne & Albanese, 2005; Hogben & 
Waterman, 1997; Peterson & Kroner, 1992). The American Psychological Association 
has established task forces to address the issue of multicultural sensitivity within the 
discipline. For example, the Report of the APA Task Force on the Implementation of the 
Multicultural Guidelines (2008) noted that the discipline of Psychology:  
has traditionally been defined by and based upon Anglo Western middle class, 
Eurocentric perspectives and assumptions. The traditional approaches to 
psychological  research, education and practice have not always considered the 
influence and impact of culture, race and ethnicity, and their roles in 
psychological theory, research, and therapy have largely gone unexplored. There 
has been a growing need to develop a deeper knowledge and awareness of race 
and ethnicity in psychology and to integrate race and ethnicity into the practice, 
research, education and ethics of psychology. (Historical Summary para. 1)  
 
 To this end, the American Psychological Association’s Division of State, 
Provincial, and Territorial Affairs, published a Diversity  handbook with the goal of 
involving “more ethnic minority psychologists in membership and leadership positions in 
State Provincial or Territorial Psychological Associations” (2009b, Diversity Defined 
para. 4). In the same vein, some of the discipline’s history textbooks have been critiqued 
for ignoring psychology’s participation within the eugenics movement and in the 




Harris, 1997).  Additionally, concerns about occupational biases (Firmin, Johnson, & 
Wikler, 2009) and over-reliance on secondary sources (Devitt, Honts, & Vondergeest, 
1997) within psychology textbooks have been raised.   
In discussing the impetus for co-authoring the first edition of Psychology, social 
psychologist and feminist Carol Tavris stated that:  
Most of all, we wanted to build a book around the principles of critical thinking. 
We wanted to show students that psychology can teach them how to think better: 
how to ask questions, how to think about answers and examine the evidence for 
them, what explanations are possible, what emotional biases we bring to our 
explanations, and so on. (Shermer, 1999, The Measure of a Woman, para. 39)  
 
More recently, Tavris (2004) asserted that the failure to sufficiently address core 
principles of critical and scientific thinking was “widespread in graduate clinical 
psychology programs and psychiatric residencies, where students can earn a PhD or an 
MD without ever having considered the basic epistemological assumptions and methods 
of their profession” (p. xi). Citing ethnographic research, Tavris (2004) asserted that 
“rarely do [psychiatric residents] learn to be skeptical about questions, analyze research, 
or consider alternative explanations or treatments” (p. xi).      
The researcher could only find one study examining the degree to which curricula 
were integrating alternative explanations about psychopharmacotherapy. The study was 
conducted by social workers Lacasse and Gomory (2003) in response to concerns that 
their discipline was diverging from its “commitment to exploring non-mainstream 
positions” (p. 384).  The researchers sought to establish whether the 35,000 masters of 
social work students being trained in the United States at the time were “receiving the 
best scientific information, evaluation of evidence, and critical analysis currently 




Lacasse and Gomory (2003) acquired 71 psychopathology course syllabi from 
fifty-eight of the top 80 graduate schools of social work listed in the U.S. News and 
World Report’s rankings for the year 2000.  The researchers examined the syllabi and 
required readings for the 2001/2002 academic year and, using content analysis, focused 
attention on four topics: (a) concepts of mental health issues, (b) the reliability and 
validity of psychiatric diagnoses, (c) biological etiology, and (d) drug treatment. The 
study looked at the syllabi’s course descriptions, goals and objectives, lecture topics, 
organization and structure, and required readings to ascertain the degree to which 
evidence-based critiques of the aforementioned mental health issues were being 
addressed.   
Results indicated that less than half of the syllabi (47.9%, n = 34) required 
students to read an article of any kind—meaning that most of the psychopathology 
courses relied solely on secondary sources (Lacasse & Gomory, 2003).  Next, with regard 
to the conceptualization of mental disorders, the authors found that the syllabi rarely 
mentioned any critics of the biomedical model. For example, Lacasse and Gomory noted 
that Thomas Szasz, a psychiatrist with extensive publications critiquing mainstream 
psychiatry, was only listed as the author of a required reading in 5.6% (n = 4) of syllabi, 
and placed on the recommended reading list or bibliography within 2.8% (n = 2) of the 
syllabi.  
In total, 39.4% (n = 28) of the syllabi identified one or more alternative non-
medical perspectives (i.e., psychodynamic (31%), ecosystems/family systems (12.7%), 
cognitive behavioural (9.9%), behavioural (4.2%)) for the etiology of mental distress. 




Thomas Scheff, well known within the discipline for their non-medical 
conceptualizations of mental illness.   
In terms of content addressing the DSM’s empirical rigor, the study found that 
87.3% (n = 62) of syllabi did not mention the words “reliability” or “validity” (Lacasse & 
Gomory, 2003).  A more detailed analysis of relevant required readings conducted for 
95.8% (n = 69) of the courses, revealed that 28.1% (n = 20) of the syllabi had assigned a 
textbook which did not address any empirical problems with the DSM-IV. In addition, 
these courses did not assign any articles addressing this issue.  
The required textbook readings for 10 of the syllabi (14.1%) included content on 
the DSM’s reliability and validity (Lacasse & Gomory, 2003). The researchers described 
this content as “ranging from a short acknowledgment of extant critiques to briefly 
summarizing the empirical literature” (p. 391). While Lacasse and Gomory noted that 
29.6% (n = 21) of the syllabi required one or more readings “which offered some critical 
discussion relevant to the practice of psychiatric diagnosis,” they posited that there was 
an absence of any empirical data driven approaches to accomplish this (p. 392). 
 For the biological etiology of depression, Lacasse and Gomory (2003) discovered 
that 71.8% (n = 51) of courses used materials which supported the chemical imbalance 
hypothesis for mental distress, while slightly more than one quarter of the syllabi (25.3%, 
n = 18) “included course goals or descriptions representative of the chemical imbalance 
theory” (p. 394). The researchers asserted that 43.6% (n = 31) of required textbooks 
contained “bioreductionistic content” (p. 394). Of the five syllabi (7%) which included 
readings that critiqued the biomedical model of mental distress—three were 




The researchers identified “misleading content” in certain textbooks (Lacasse & 
Gomory, 2003). For example, one text used photographs of positron emission 
tomography (PET) to differentiate between the brains of people who had been diagnosed 
with Attention Deficit Hyperactivity Disorder (ADHD) and those whose brains were 
considered to be healthy. The authors of the text in question attributed these differences 
to problems with cerebral glucose metabolism resulting in impulsivity—a conclusion 
with little empirical evidence to support it (Moncrieff, 2009; U.S. Department of Health 
and Human Services, 1999).       
Findings for the fourth topic (psychotropic medications), indicated that less than 
half (47.9%, n = 34) of the syllabi explicitly stated that this subject would be addressed. 
Twenty-one of the courses (29.6%) that made no mention of medications within the 
syllabi assigned a textbook with some psychopharmacology content.  In total, three 
syllabi (4.2%) contained a reading which discussed safety concerns surrounding 
psychotropic drugs; one of these readings was required for one course.    
Based on these findings, Lacasse and Gomory (2003) concluded that:  
There is little evidence that [social work] graduate psychopathology courses cover 
viewpoints other than the most conventional and institutional—that of biomedical 
psychiatry. A small handful of secondary (textbooks) rather than primary 
(research articles) sources provide the majority of the mental health content in 
these courses. (p. 383)  
 
The researchers referred to an “apparent one-sided approach” towards 
psychopathology courses for graduate social work students and posed the following 
question: 
Given the tentativeness of what is ‘known’ about mental disorderliness based on 
current research, and the emphasis placed, even by mainstream psychiatric 




many of which are considered strengths of social work, should we not then offer 
these alternatives for the critical consideration of our students? (Lacasse & 
Gomory, 2003, pp. 401–402)   
        
While these findings raised concerns about the extent to which the examined 
social work programs were integrating critiques of conventional perspectives about 
psychopharmacology, the study had a number of limitations. For example, it utilized a 
cross sectional design and academic syllabi can change significantly from year to year 
(Lacasse & Gomory, 2003). In addition, only 58 of the 153 Council on Social Work 
Education’s accredited master’s programs were ultimately analyzed. Further, the analyses 
of the curricula materials were not exhaustive meaning that relevant content may have 
been missed. Finally, content analysis requires interpretation meaning that results can be 
impacted by the researcher’s subjective biases.  
 In terms of psychologist postdoctoral psychopharmacology training, members of 
the medical establishment have questioned the safety of psychologists prescribing and the 
sufficiency of the associated programs’ prerequisites, didactic training, and internships 
(Heiby, 2002, 20009; Lavoie & Fleet, 2002; McGrath, 2010; Robiner et al., 2002). 
Additionally, Heiby (20009) suggested that prescriptive authority for psychologists will 
negatively impact collaborations between psychologists and physicians.  
 The limited body of research examining the safety of prescriptive authority for 
psychologists has not identified any risks (American College of 
Neuropsychopharmacology, 1998; GAO, 1997, 1999; Vector Research, Inc., 1996).  
However, these findings were based on a small number of subjects (n = 10) from a 
military training facility. Further, the applicability of this data to prescribing 




been questioned (Robiner et al., 2002).  Nonetheless, proponents of the RxP movement 
have asserted that “hundreds of thousands” of prescriptions have been written by 
clinicians with prescriptive authority in New Mexico without any serious adverse effects 
(McGrath, 2010, p. 40).  
Research into the feasibility of psychologist postdoctoral psychopharmacology 
training programs has yielded mixed results. These inconsistencies may be linked to 
financial variables and assumptions about the extent to which additional psychotropic 
drug prescribers are needed (GAO, 1997, 1999; Vector Research, Inc., 1996). For 
example, the GAO studies, whose findings were less positive than the Vector Research 
Institute’s analysis, included start-up and program evaluation costs within their 
calculations while the latter study did not. Next, only the GAO studies assumed that the 
military possessed a sufficient number of psychiatrists—an assertion that has been 
challenged (McGrath, 2010).    
 At least four psychologist postdoctoral psychopharmacology training facilities 
have closed their doors or suspended enrollments since the inception of these programs in 
the 1980s. As of July, 2016, four programs were in operation (i.e., Alliant International 
University, Fairleigh Dickinson University, Prescribing Psychologists’ Register, and the 
University of Hawaii at Hilo).  The Southwestern Institute for the Advancement of 
Psychotherapy (2016) program at New Mexico University was temporarily closed to due 
to reorganization efforts. McGrath noted in 2010 that approximately 1,500 psychologists 
had completed civilian sector psychologist postdoctoral psychopharmacology training 




“For good or ill, then, the ‘truth’ of RxP will be determined politically: either it will win 
the legislatures or fade away” (p. 43).  
Psychologist postdoctoral psychopharmacology training curricula have undergone 
significant changes since the first iteration of this training was established by the United 
States military in 1989 (McGrath, 2010; Resnick et al., 2012). For example, the 
Department of Defence’s Pharmacology Demonstration Project (PDP), which ran from 
1991 to 1997, reduced its didactic requirements from 1365 credit hours to 660 credit 
hours during that period (McGrath, 2010; Sammons & Brown, 1997). These changes 
stemmed from a decision to omit content that was deemed to be outside the scope of 
training psychologists to prescribe psychotropic drugs. In comparing the American 
Psychological Association’s first recommended curriculum for training in 
psychopharmacology with the Department of Defense’s PDP curriculum, Dunivan and 
Orabona (1999 noted a “considerable reduction of hours (i.e., biochemistry, human 
anatomy, health assessment, clinical medicine)” (p. 516).  
 The American Psychological Association’s first Task Force on Prescription 
Privileges initially recommended training programs provide 300 hours of didactic 
coursework. More recently, this was increased to 400 credit hours (American 
Psychological Association, 1996, 2009a). At the same time, its recommendations for 
didactic training are still less than 70% of the PDPs maximum (1,365 credit hours) and 
roughly 40% less than the PDP program’s minimum (660 credit hours) didactic 
requirements (Sammons & Brown, 1997).  Current programs require that students 




 While the initial American Psychological AssociationTask Force on Prescription 
Privileges recommended that applicants demonstrate “knowledge of human biology, 
anatomy and physiology, biochemistry, neuroanatomy, and psychopharmacology” as “a 
necessary prerequisite” for postdoctoral prescription training, the Task Force did not 
specify what this entailed or how it would be regulated (1996, p. 2). To this end, Dr. 
Robert McGrath, Director for the Postdoctoral M.S. Program in Clinical 
Psychopharmacology at Fairleigh Dickinson University stated that there were “certain 
inconsistencies and impracticalities in the requirements of the curriculum,” and noted that 
“it was ambiguous whether certain elements of the practicum were required or 
voluntary . . . no program was able to comply with the guidelines exactly” (2010, p. 27).  
In an apparent effort to resolve these concerns, the APA Task Force on Prescription 
Privileges ultimately waved prerequisite courses and integrated them within the curricula 
of psychologist postdoctoral psychopharmacology training programs (American 
Psychological Association, 2009a; McGrath, 2010).    
By comparison, other disciplines have more rigorous enrolment requirements for 
prescription training. For example, the University of California’s Davis School of 
Medicine required that Physician Assistant Program applicants first complete classes in 
human anatomy (with lab), physiology (with lab), general chemistry (with lab), 
microbiology or bacteriology (with lab), in addition to mathematics and social science 
courses (University of California, 2015).   
Stricter yet were the University of New Mexico’s (2015) College of Pharmacy’s 
requirements for the Doctor of Pharmacy program which stipulated that applicants first 




(8 semester hours with labs), molecular cell biology (4 semester hours), genetics 
(4 semester hours), microbiology (4 semester hours with lab), anatomy and physiology 
(6 semester hours), and biochemistry (3 semester credit hours), in addition to classes in 
microeconomics, calculus, statistics, physics, communication, and critical thinking prior 
to enrollment. 
Internship requirements have also undergone changes since the PDP. For 
example, while all three iterations of the PDP required and the first RxP task force 
specifically recommended that students work with at least one hundred clients, this 
suggestion was dropped. Next, the American Psychological Association’s most recent 
Prescription Privilege Task Force (2009a) recommended that “the trainee gains 
supervised clinical experience with a sufficient range and number of patients in order to 
demonstrate threshold performance levels for each of the competency areas” (p. 10) 
without clarifying the number of clients this would entail.    
Clinical psychologist William Robiner and colleagues (2002) questioned the 
extent to which, “such condensed training overcomes current shortcomings to achieve 
knowledge and clinical proficiency equivalent to that of other prescribers, especially 
psychiatrists, and ensure competent prescribing that the public should reasonably expect 
of its doctors?”  (p. 235).  Similarly, Heiby (2002) noted that psychologist postdoctoral 
psychopharmacology curricula involved less formal training in hard sciences than other 
prescribing professions, including those which require ongoing supervision subsequent to 
licensure (i.e., nurse practitioners).  
Conversely, proponents of RxP noted that psychologist postdoctoral 




course work than physicians and nurse practitioners (Muse & McGrath, 2009). In 
response, Stuart and Heiby (2007) argued that educating physicians more effectively in 
psychopharmacology would be more cost effective than training psychologists to 
prescribe.      
 To date, psychologists with appropriate training and credentials can prescribe 
within New Mexico, Louisiana, Illinois, Iowa, and the territory of Guam (American 
Psychological Association, 2014, 2016).  Psychologists with prescription privileges can 
also prescribe within the Indian Health Services, United States Public Health Service, and 
the Department of Defence.  However, despite research into the prescriptive authority for 
psychologists movement’s legitimacy, the feasibility and safety of training psychologists 
to prescribe, and the composition of psychologist postdoctoral psychopharmacology 
curricula requirements, no studies have analyzed the extent to which these training 
materials are integrating relevant critical perspectives.  
 We do not know, for example, the extent to which psychologist postdoctoral 
psychopharmacology curricula are integrating critiques about neurobiologically based 
hypotheses of depression, or challenges to the empirical rigor of the DSM. Further, it is 
unclear whether or not these training materials are making efforts to address the 
implications that these critiques and associated risks of treatment errors have for the 
consumer/survivor/ex-patient (c/s/x) population and movement.  
Neurobiological Etiology of Depression  
Until recently, the monoamine hypothesis was the most commonly cited 
neurobiological hypothesis for depression (Stahl, 2013). The monoamine hypothesis 




specifically, the premise asserts that reduced levels of serotonin (5HT), noradrenalin 
(NE), and dopamine (DA) are implicated in depressive symptomatology. Despite initial 
optimism about this hypothesis, Stahl wrote in 2000 that “So far, there is no clear and 
convincing evidence that mono-amine deficiency accounts for depression; that is, there is 
no ‘real’ monoamine deficit” (p. 601).   
In Stahl’s Essential Pharmacology: Neuroscientific Basis and Practical 
Applications,  the author concluded that research in support of the monoamine hypothesis 
for depression has “unfortunately yielded mixed and sometimes confusing results” (Stahl, 
2013, p. 262; Stahl, 2008, p. 483).  Stahl (2013) also noted that studies have not 
consistently found deficiencies in serotonin (5HT), norepinephrine (NE), and dopamine 
(DA) metabolites. Additionally, there are concerns that neurotransmitter levels cannot be 
measured within the blood brain barrier of live human subjects (Lacasse & Gomory, 
2003).   
The neurotransmitter receptor hypothesis took the chemical imbalance premise a 
step further suggesting that depleted neurotransmitter levels trigger a homeostatic 
response involving the up-regulation of postsynaptic neurotransmitter receptors (Stahl, 
2013). Evidence for this hypothesis has been mixed. For example, consistent molecular 
lesions in monoamine receptors have not been found, leading Stahl (2013) to conclude 
that “There is no clear and convincing evidence that abnormalities in monoamine 
receptors account for depression” (p. 267). More compelling albeit, inconsistent findings, 
indicated that polymorphisms in the serotonin 1A receptor gene may be implicated in 
mood disorders (Albert, 2012; Fisher et al., 2013; Kishi et al., 2012).  Investigations into 




cellular plasticity (Krishnan & Nestler, 2008). Particular attention has been afforded to 
P11, a calcium binding protein that interacts with serotonin 5-HT1b. Using in-situ- 
hybridization, researchers found that P11 was down-regulated in depressed individuals’ 
cingulate cortex’s (Svenningsson et al., 2006). 
In addition, the role of transcription factor Cyclic-AMP-response-element-
binding-protein (CREB) has been studied. Findings with rodents suggest that stress 
activates CREB within the nucleus accumbens, triggering depression-like-responses 
(Pittinger & Duman, 2008).  Conversely, data has shown that antidepressants can 
precipitate an upregulation of CREB, indicating that changes in neuroplasticity may be 
site specific or mediated by some other mechanism (Krishnan & Nestler, 2008).  
More recently, research has focused on the means by which neurotrophins impact 
neuroplasticity and mood. This hypothesis stems from pre-clinical data which indicated 
that stress could inhibit brain-derived neurotrophic factor (BDNF) mediated signaling 
within the hippocampus, leading to atrophy and apoptosis (Krishnan & Nestler, 2008; 
Stahl, 2013).  Related research has shown that chronic antidepressant treatment can lead 
to increased BDNF signaling; an outcome that some interpret as further evidence in 
support of the neurotrophic hypothesis for depression (Duman & Monteggia, 2006; 
Krishnan & Nestler, 2008).  
There is also a substantial amount of research data which contradicts or fails to 
support these correlations between neurotrophins and mood (Krishnan & Nestler, 2008). 
For example, depression is not consistently induced by blocking BDNF or neurogenesis 
in the hippocampus (Airan et al., 2007; Santarelli et al., 2003).  Next, Dias and colleagues 




impacts to axon-specific BDNF transcription levels (Dias, Banerjee, Dunman, & Vaidya, 
2003).  Others have found that increased levels of serotonin in the hippocampus actually 
decreased levels of BDNF (Vaidya, Marek, Aghajanian, & Duman, 1997).  
In a review of the BDNF hypothesis for depression, Groves (2007) described the 
extant data as inconsistent and contradictory and asserted that “Like the monoamine 
hypothesis proposed over 40 years ago, we may have to accept that the role of BDNF lies 
more in the genesis of depressive symptoms than at the core of disease pathophysiology” 
(p. 1085).  
Further complicating these interpretations about the volume and density of neural 
matter within hippocampal and pre-frontal cortex regions are unresolved methodological 
problems pertaining to the research itself (i.e., co-morbid diagnoses and dissimilar 
medication histories across subjects) (Krishnan & Nestler, 2008). In addition, 
antidepressants are capable of iatrogenically altering brain matter. For example, 
researchers from Duke University found that antidepressant use, especially tricyclic’s, 
was associated with neuronal white matter degradation among elderly subjects (Steffens 
et al., 2008).  Thus, it is possible that antidepressants might cause some of the neuronal 
abnormalities observed within neuroimaging studies of depressed individuals’ brains, 
challenging conventional explanations for these results.      
 Links between mood and various neuroendocrine and neuroimmune mechanisms 
have also been linked to depression. For instance, chronic administrations of 
glucocorticoids in rodents have produced depressive-like behaviours (Gourley et al., 




excessively high concentrations of circulating cortisol in conjunction with depressive 
features and hippocampal atrophy (McEwen, 2007; Nestler et al., 2002).  
Interestingly, hypercortisolaemia has been associated with severe depressive 
symptomatology while hypocortisolaemia was linked to atypical depression. This 
indicates a potential relationship between glucocorticoid profiles and the severity of 
mood symptomatology.           
Neuromodulators of immunity known as cytokines have been implicated in 
depression’s etiology. In rodents, drug induced release of cytokines interferon-a, tumor 
necrosis factor-a, and IL-1B, were correlated with social withdrawal and reductions in 
exploratory and sexual behaviours (Dunn, Swiergiel, & de Beaurepaire, 2005). In the 
same vein, blocking pro-inflammatory cytokine-mediated signaling or targeted deletions 
of cytokine mediating genes, has yielded anti-depressant-like effects in rodents (Krishnan 
& Nestler, 2008). However, direct administrations of interferon-a and IL-1B have not 
been found to produce depression like symptoms (Dunn et al., 2005). Moreover, human 
studies have yielded inconsistent data surrounding any relationships between mood and 
serum cytokine concentrations (Dunn et al., 2005). Further, legitimate concerns have 
been raised about the validity of using results from animal models of psychological 
distress to explain the etiology of psychological distress in humans (Rose & Abi-Rached, 
2013).   
Estrogen has also been shown to have neurobiological impacts on mood levels. 
Stahl (2008) referred to the hormone as a trimonoaminergic modulator and described its 
capacity to mediate the activities of gamma-aminobutyricacid (GABA) and glutamate. 




feelings of relaxation and well-being (Julien et al., 2011). By proxy, estrogen tends to 
inhibit GABA activity. Next, age specific rates of depression have been positively 
correlated with the percentage of estrogen production over the course of a woman’s 
lifespan, with the highest rates for both occurring during childbearing years (Stahl, 2008).  
As a result of GABA being inhibited, pyramidal neurons become activated and 
release glutamate (Stahl, 2008).  Disturbances in glutamate metabolism and associated 
impacts on N‐methyl-D-aspartate (NMDA) receptors, as well as trophic changes, were 
linked to depressive symptomatology and suicidality (Paul & Skolnick, 2003).  In 
addition, it has been established that prolonged excitation of nerve cells can be toxic and 
atrophic (Julien et al., 2011).  
Estrogen also regulates gene production including brain-derived neurotrophic 
factor (BDNF) (Stahl, 2008). BDNF, as mentioned earlier, is thought to be critical for 
neurogenesis and preventing atrophy and apoptosis in areas of the brain like the 
hippocampus. Interestingly, administrations of estradiol (a type of naturally occurring 
estrogen) have been shown to reduce depressive-like-behaviours in older female mice 
(Walf & Frye, 2009). Conversely, human research has shown that estroidal was not an 
effective intervention for low mood in older postmenopausal women (Morrison et al., 
2003).            
 Support for an epigenetic etiology of depression includes the disorder’s high 
discordance rates among monozygotic twins, individual variations in depressive-like 
behaviors among inbred rodents and higher rates of depression among women (Krishnan 
& Nestler, 2008). Covalent change alterations of DNA (i.e., methylation), post-




silencing mechanisms such as micro RNAs have been noted too (Krishnan & Nestler, 
2008).  
In addition, epigenetic findings suggest that rats born to less attentive mothers 
(i.e., less maternal licking and grooming), are more likely to exhibit reduced expressions 
of glucocorticoid receptors and an associated increase in the methylation of cytosine, a 
glocorticoid receptor gene promoter (Tsankova, Renthal, Kumar, & Nestler, 2007). Thus, 
early neglect may contribute to genetic modifications and subsequent depressive 
symptomatology. These abnormalities were shown to arise within the first week of life 
and could, according to the researchers, be mediated by cross-fostering (Tsankova et al., 
2007).  
Trichostatin A, a histone deacetylase inhibitor (HDAC) has also been shown to 
reverse the course of methylation and HDAC inhibitors appeared to have antidepressant-
like effects on rodents that underwent trials using social defeat assays (Weaver et al., 
2004). Interestingly, mice that underwent complete eradications of HDAC5, showed an 
increased vulnerability to social defeat (Weaver et al., 2004). Also, while the 
antidepressant drug Imipramine can raise hippocampal HDAC5 levels, the drug also 
significantly reduces the expression of HDAC5 within the nucleus accumbens (Krishnan 
& Nestler, 2008). Such outcomes highlight the regional specificity of drug effects and the 
brain’s apparent leanings towards homeostasis.      
Additional insights about depression’s etiology have come from research into the 
neurobiological correlates of resiliency. For example, gene expression analyses of rodent 
brains provided distinct translational profiles consistent with overcoming adversity (i.e., 




2008). While these profiles suggest that resilience and disorders like depression may stem 
from specific neurobiological processes, the extent to which these results can be 
generalized to human beings is unclear.  
In an effort to link particular symptoms of depression to “inefficient information 
processing” within various regions of the brain, Stahl (2013) conceptualized the 
disorder’s symptomatology via a “symptoms and circuits” model (pp. 273–278). More 
specifically, Stahl tied the core symptoms of major depressive disorder (weight/appetite 
changes, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue, feelings 
of guilt or worthlessness, executive dysfunction, and suicidal ideation) to particular brain 
circuits within the prefrontal cortex, basal forebrain, striatum, nucleus accumbens, 
thalamus, hypothalamus, amygdale, hippocampus, brainstem, spinal cord, and 
cerebellum. Stahl (2013) also linked depressive symptoms to aminergic “dysfunction” 
(p. 278). 
In discussing the rationale for this hypothesis, Stahl asserted that “The trend is 
from categorical DSM diagnoses to dimensional symptoms matched to circuits in the 
RDoC [Research Domain Criteria] approach” (S. Stahl, personal communication, 
November 5, 2014). The National Institute of Mental Health (NIMH) 2008 Strategic Plan 
noted that  
RDoC attempts to bring the power of modern research approaches in genetics,  
neuroscience, and behavioral science to the problems of mental illness, studied  
independently from the classification systems by which patients are currently 
grouped. The approach provides a framework to develop hypotheses and evaluate 
results from studies that investigate the mechanisms of psychopathology. (NIMH, 





The NIMH Plan also stated that the “RDoC research starts with basic mechanisms 
and studies dysfunctions in these systems as a way to understand homogeneous symptom 
sets that cut across multiple disorders, rather than starting with clinical symptoms and 
working backwards” (2014, Abstract, para. Methods and Findings). The references to 
“mechanisms of psychopathology” and “dysfunctions” within the plan suggests that the 
“systems and circuits” approach to depression is based on certain etiological and 
epistemological assumptions about genetic and neurobiological correlates for 
psychological distress (2014). For example, decisions about what types of data to gather 
(i.e., neurobiological markers), how to accomplish this (i.e., neuroimaging), and how 
these results are interpreted (i.e., via the medical model).       
Genetic research for depression has also focused on a class of genes known as 
neuropeptides, which have been found to modulate neuronal communication. For 
example, neuropeptide nerve growth factor (VGF), which is transcribed by cAMP 
response element binding protein (CREB),  was shown to be down-regulated in the 
hippocampus of rodents undergoing stress inducing activities (learned helplessness and 
forced swim) (Thakker-Varia et al., 2007; Thakker-Varia & Alder, 2009).  Conversely, 
VGF was found to be upregulated in rodents given antidepressants or engaging in 
voluntary exercise opportunities (Thakker-varia & Alder, 2009; Thakker-Varia et al., 
2007).  
Another study investigated the relationship between neuropeptide Y (NPY) and 
responses to written words (Mickey et al., 2011).   These researchers used fMRI to 
measure how the emotional valence of words (negative or neutral) impacted brain activity 




(84% had an NPY genotype expression of low, intermediate, or high).  Findings indicated 
that healthy individuals were significantly more likely to exhibit activation of the frontal 
cortex during exposure to negatively valenced words and that this activity was negatively 
correlated with the strength of geno-type predicted NPY expression.  
The researchers hypothesized that “these genetically influenced neural response 
patterns” play a role in mitigating risk for certain types of major depressive disorder 
(Mickey et al., 2011).   Ultimately, this data may help to explain individual differences in 
resilience, emotional experience, and heterogeneous responses to pharmacological 
interventions for depression. At the same time, these findings are inconclusive and 
questions remain about the efficacy of using neuropeptides as an antidepressant agent 
(Thakker-Varia & Alder, 2009).   
The aforementioned findings represent a substantive body of research affording a 
variety of compelling and plausible neurobiologically based hypotheses for the etiology 
of depression. The advent of neuroimaging with pneumoencephalography in 1918 and 
subsequent developments with computerized axial tomography (CAT), single photon 
emission computerized tomography (SPECT), positron emission tomography (PET), 
magnetic resonance imaging (MRI) and functional magnetic resonance imaging (fMRI), 
have been critical to the acquisition of this knowledge.  
In 2008, Nikos Logothetis completed a database keyword search using the terms, 
“fMRI,” or “MRI,” or “functional magnetic imaging,” which yielded over 19,000 peer 
reviewed articles. Roughly two years later, the same search conducted by Rose and Abi-
Rached (2010) resulted in 53,662 papers. Neuroimaging technology has permitted 




hypotheses about cognitive-emotional experiences including mental illness and resilience 
(Satel & Lilienfeld, 2013).  Similarly, human brain injury studies and animal research 
have provided scientists with opportunities to uncover neural correlates that might 
predispose us towards mental health or psychiatric illness (Rose & Abi-Rached, 2010). 
This includes insights about neuroanatomy, neurotransmitters, neurotransmitter receptors, 
neurotrophins, the hypothalamic-pituitary-adrenal axis, neurogenesis, neuropeptides and 
the neuroendocrine system, immunological factors, genetics, glutamate, GABA, and 
enzymes’ role in behaviour and well-being.      
 Nonetheless, efforts to definitively establish which neural mechanisms play a 
causal role in depression and other psychological disorders have been unsuccessful. More 
than 15 years ago, Rockville (1999) stated within Mental Health: A Report From the 
Surgeon General, that “there is no definitive lesion, laboratory test, or abnormality in 
brain tissue that can identify the [mental] illness” (p. 44). This report also noted that the 
etiology for depression remains “unknown” (p. 49). Similarly, Krishnan and Nestler 
(2008) highlighted the “enormous gaps in the knowledge of depression and its treatment” 
(p. 901).  
 Additionally, legitimate concerns have been raised about the particular research 
methodologies upon which neurobiological hypotheses of depression have been based. 
For example, brain scan data used to support claims of irregular regional neural activity 
in disorders like AD/HD, bipolar disorder, depression, and schizophrenia has been 
criticized (Rosa & Abi-Rached, 2013).    
 In discussing the effects of brain lesions and the limits of neuroanatomical 




processes may be distinguished not by activity in specific regions but by patterns of 
activity across regions, there is reason for caution regarding many of the inferences that 
have been driven by highly modular approaches” (as cited in Rosa & Abi-Rached, 2013, 
p. 76).  
  Rose and Abi-Rached (2013) questioned whether scientists have ascertained the 
most appropriate scale for measuring mental processes with fMRI. Further, these authors 
posited that scanning facilities could impact neuroimaging results:  
The scanning facility is not a ‘non-place’ for those who are being scanned, it is a  
particular and rather unusual arrangement of space, persons, machinery, sounds, 
and sights, not to mention the experience of being in the scanner itself. What are 
the subjects thinking and doing when they are in the scanner? The scanned brain 
is in the human body, the body of a human being who is being paid to lie in the 
machine to perform a task that the brain will never be confronted with in the real 
world outside. . . . What is the salience of the image when it emerges from the 
secluded and simplified world of the  laboratory, and makes claims for its 
relevance to the understanding of conduct in the wild and messy world of 
ordinary life? (pp.76–77)   
 
 In their critical analysis of neuroimaging research, Satel and Lilienfeld (2013) 
noted that fMRI data represents correlative information about brain activity and prohibits 
causal conclusions about behaviours or psychological operations. These authors also 
noted the complexities involved in trying to deconstruct complex mental states and 
emotions into specific neural correlates—an effort that typically involves regional brain 
mapping or, more recently, pattern analysis. 
 Further, the correlation between blood flow and neurobiological activity is 
complicated by the delay (i.e., 2 to 5 seconds) between neural activation and subsequent 
increases in blood circulation to those neurons (Satel & Lilienfeld, 2013). Consequently, 




this undetected data, the technique has its own limitations. For example, EEG cannot 
effectively differentiate between the actions of excitatory and inhibitory neuronal 
impulses (Halgren & Pashler, as cited in Pashler, 2013).  
 Statistical methods used to examine neuroimaging findings can be problematic as 
well. For example, the task of interpreting neuroimaging data is highly complicated and 
analytic methods lack standardization. This can undermine the reproduction and 
comparison of neuroimaging studies. Further, when analyses run concurrent statistical 
tests on the same BOLD signals, the risk of false positive results increases (Satel & 
Lilienfeld, 2013). 
 In 2009, reflecting on the impacts that neuroimaging had on clinical practice over 
the past 20 years, Thomas Insel, Director of the NIMH, stated that: 
 what promise have we realized in the diagnosis and treatment of individuals with  
serious mental illness? In contrast to the steadily decreasing mortality rates of  
cardiovascular disease, stroke, and cancer, there is no evidence for reduced 
morbidity or mortality from any mental illness. (pp. 128–129) 
Insel (2009) also asserted that:   
Despite high expectations, neither genomics nor imaging has yet impacted the 
diagnosis or treatment of the 45 million Americans with serious or moderate 
mental illness each year. While we have seen profound progress in research (with 
molecular, cellular, and systems neuroscience revealing new, unexpected insights 
about the brain), the gap between the surge in basic biological knowledge and the 
state of mental health care in  this country has not narrowed and may be getting 
wider. (p. 128)  
 
 Behavioral neuroscientist Jacqueline Crawley (2007) expressed concerns about 
interpreting the data from animal models of human distress. In her textbook, What’s 
Wrong With My Mouse? Behavioral Phenotyping of Transgenic and Knockout Mice, 
Crawley (2007) recommended that researchers “Tread softly when approaching a mouse 




anthropomorphize! Emotions are personal, internal, and highly species specific. There is 
no way for a human investigator to know whether a mouse is feeling afraid, anxious, or 
depressed” (p. 261).       
 In addition, the validity of genetic findings for psychopathology has been 
challenged (Farber, 1981; Jackson, 1960; Joseph, 2002; Kamin, 1974; Leo, 2003; Leo & 
Joseph, 2002). For example, in discussing family research from the 1920s, Joseph (2002) 
asserted that “The ‘evidence’ of [psychiatrist] Myerson’s era consisted of family 
pedigrees, preconceived notions, and prejudice” (p. 72). Further, with regard to twin 
studies Joseph noted that:  
 Problems include the lack of an adequate and consistent definition of the trait 
under study, non-blinded diagnoses, inadequate or biased methods of zygosity 
determination  (i.e., the determination of whether the twins are MZ or DZ), the 
unnecessary use of age-correction factors, the use of non-representative sample 
populations, and the lack of adequate descriptions of the methods used in some of the 
studies. (Joseph, 2002, p.74) 
 Joseph (2002) has also challenged the “equal environment assumption” and 
posited that the environment of monozygotic twins was more similar than for fraternal 
twins (p. 73). For example, he stated that: 
The problem with the traditional EEA definition is that most people—including 
many prominent twin researchers (Bouchard, 1993; Gottesman, et al., 1972; 
Kendler et al., 1994; Morris-Yates et al., 1990; Rose, et al., 1990; Scarr, 1968; 
Scarr et al., 1979)—recognize that it is false since MZs are treated more similarly 
by their parents and by the social environment, spend more time together, and 





In addition, it was posited that the proband method of analysis can inflate twin 
concordance rates relative to using the pairwise method (Joseph, 2002; Leo, 2003).  
 In reviewing Caspi and colleagues’ suppositions about the implications of the 5-
HTT promoter polymorphism on one’s susceptibility for depression, Leo, noted that 
“68% of the population carries at least one copy of this allele . . . even people without the 
short form became depressed; serotonin processing has been implicated in numerous 
DSM-IV conditions; and this allele is most likely involved in many other traits—some of 
which might be considered beneficial” (Leo, 2003, p. 411). 
 Concerns also exist about the drug trial publication process (Dubovsky & 
Dubovsky, 2007; R. Smith, 2005; Turner, Knoepflmacher, & Shapley, 2012; Turner, 
Matthews, Linardatos, Tell, & Rosenthal, 2008). For example, Dubovsky and Dubovsky 
(2007) identified problems with ghost writing and the implications of journal articles 
attributing authorship to individuals who did not actually write the article and/or have any 
final say about its contents.  
 Richard Smith (2005), who was employed as an editor for the British Medical 
Journal for 25 years, noted that industry funded studies typically yielded results favoring 
the pharmaceutical company which funded them. For example, he described a 1994 study 
by Rochon and colleagues which analyzed 56 published studies on nonsteroidal anti-
inflammatory drugs for arthritis, and noted that none of the published results were 
unfavorable to the pharmaceutical company which funded the respective trials. 
 R. Smith (2005) was also concerned about editors’ reliance on authors for the 
provision of relevant studies in reviewing the literature. Further, editors may be faced 




to impact a journal’s financial viability. In a satirical paper, Sacket and Oxman listed 
tactics used to inflate drug trial results (i.e., using selective, non systematic reviews to 
bias support for proposals “invoking fallacious ‘placebo effects’ and ‘assay sensitivity’ 
arguments in order to avoid head to head comparisons,” manipulating data by selecting 
surrogate and composite end points that support desired results, adjusting the 
requirements for “superiority” and “non-superiority,” adding effective co-interventions to 
the drug being studied but not to the control group using the comparator treatment, 
unblinded outcome assessments that favor the drug treatment group, initiating sub-group  
analyses designed to establish statistically significant effects favoring the experimental 
drug, providing statistics for the relative but not absolute risk reduction and the number 
needed for treatment, and over interpreting the results of an indeterminate trial (Sackett & 
Oxman, 2003, p. 1443).    
 In a study investigating the publication of antidepressant drug trials, Turner (a 
medical reviewer at the US Food and Drug Administration from 1998 to 2001) and 
colleagues noted selective publishing of results and outcomes can inflate estimates of 
efficacy thereby impacting the risk-benefit ratio (Turner et al., 2008). In reviewing 74  
FDA-registered studies of 12 antidepressant drugs, involving 12,564 patients, these 
researchers found that 31% of the examined trials were not published. Conversely, of the 
37 studies viewed by the FDA as having positive results, only one did not get published. 
The article posited that “studies viewed by the FDA as having negative or questionable 
results were, with three exceptions, either not published (twenty-two studies) or 
published in a way that, in our opinion, conveyed a positive outcome (eleven studies)” 




 Turner and colleagues (2008) suggested a discrepancy between FDA analyses and 
the published literature on drug trials. For instance, these researchers noted that the FDA 
had concluded that 51% of antidepressant drug trials were positive while the published 
literature suggested that 94% of the conducted studies on antidepressant’s efficacy were 
positive (Turner et al., 2008). A more recent study by Turner et al. (2012) examined 
publication bias in antipsychotic drug trials and found that for the 20 published trials 
examined “the five that were not positive, according to the FDA, showed some evidence 
of outcome reporting bias” (2012, Abstract, Methods and Findings).  
 These researchers noted that the accuracy of their findings was limited by the 
small number of trials examined (Turner et al., 2012). However, Turner and colleagues 
(2012) also asserted that “Although the magnitude of the publication bias seen here is less 
than that seen in a similar study of antidepressant drugs, these findings show how the 
selective reporting of clinical data undermines the integrity of the evidence base and can 
deprive clinicians of accurate data on which to base their prescribing decisions” (Turner 
et al., 2012, Editor’s Summary, para. What Do These Findings Mean).   
 Gaps in the neuroscientific research on depression’s etiology mean that treatment 
errors are possible and that the limits of these research findings used to support 
neurobiological hypotheses for depression should be considered within the context of 
training psychologists to prescribe—particularly given the risks that treatment errors pose 
for patients and especially for marginalized groups like the c/s/x population. Potential 





Diagnostic and Statistical Manual of Mental Disorders 
This dissertation examined the extent to which psychologist psychopharmacology 
training materials were integrating critiques of the DSM’s empirical rigor because the 
manual plays such a central, albeit controversial role in contemporary mental health care 
services within the United States (American Psychiatric Association, 2000, 2013; 
Frances, 2013). The manual is used to determine the existence of a mental disorder, 
inform the selection of pharmacological interventions, and clarify treatment needs for 
insurers. In addition, the DSM aids in establishing prevalence rates for mental disorders 
and in the selection and assignment of research participants within drug trials. Kirk and 
Kutchins (1994) stated that the “DSM represents a major way of organizing psychiatric 
knowledge, research efforts, and treatment approaches” (p. 71). According to Jenkins and 
Vaida (2007) , the diagnosis of psychiatric conditions has “a significant impact on 
medication selection, dosing, and frequency” (p. 42).    
Members of the DSM-IV-TRs task force posited that “more than any other 
nomenclature of mental disorders, DSM-IV is grounded in empirical evidence” 
(American Psychiatric Association, 2000, p. xxiv). The DSM-IV-TR’s task force was 
made up of 27 members and integrated materials from 13 work groups. Each work group 
had five or more members whose reviews were evaluated by up to 100 advisers. 
Conferences, and workshops, external reviews of drafts, and liaisons with over 60 
organizations and associations, all aided in the development of the text’s methodological 
and conceptual frameworks (American Psychiatric Association, 2000). The manual stated 




(p. xxiv). The manual’s authors also described having made an effort to “extract, 
aggregate, and interpret [data] in a comprehensive and objective fashion” (p. xxvi).  
In addition, the task force solicited input from individuals who they anticipated 
would be critical of the literature reviews used to inform the manual’s content (American 
Psychiatric Association, 2000). Next, data reanalyses and field trials were used to address 
cases in which evidence was deemed to be insufficient. In total,12 field trials involving 
more than 70 sites with over 6,000 subjects were completed.  According to the DSM-IV-
TR’s authors, the primary goal of the text revision was to correct factual errors, reflect 
new information, enhance the document’s educational value, and better align the DSM-
IV-TR with the International Classification of Disease and Related Health Problems 
(ICD-10) manual (American Psychiatric Association, 2000).   
The DSM-IV-TR task force acknowledged the limitations of using a categorical 
classification system. For example, they identified problems with diagnosing “boundary 
cases” where the criteria for a particular disorder were just shy of being met (American 
Psychiatric Association, 2000, p. xxxi).  To address this, the DSM- IV-TR stressed that 
diagnosis required a thorough assessment by clinicians with sufficient training.   
The matrix of socio-cultural, environmental, biological, and psychological 
variables impacting mood complicates the creation of a fixed and universal diagnostic 
system. Critics have argued, for example, that the DSM’s nosology is based upon 
consensus versus objective scientific data (Valenstein, 1998; Whitaker, 2010). Nancy 
Andreasen, chair of the DSM-IV-TR work group for Schizophrenia, and co-author of 
Introductory Textbook of Psychiatry (3rd ed.) with Donald Black, stated that “The [DSM-




remain arbitrary as long as we are ignorant about pathophysiology and etiology” (2001, 
p. 35).   
Michael First, co-chair and editor of the DSM-IV-TR, reiterated Andreasen’s 
statement in positing that: 
DSM is a labeling system that is inherently superficial, and it is a convenient 
fiction  to suppose that patients’ problems can be broken down into discrete 
categories. We don’t  understand the etiology of mental illness and lab findings 
are practically never found that are diagnostically useful. (as cited in Lacasse & 
Gomory, 2003, p. 383)  
 
According to Caplan and Cosgrove (2004), diagnostic labels “are defined by 
whoever does the defining, and the power to make a definition stick usually resides in 
groups that have the most social, political, and/or economic power” (p. xx).  Similarly, in 
describing how various diagnostic decisions were made during the development of the 
DSM-III, Michael First stated that “A lot of what’s in the DSM [III] represents what Bob 
[Robert Spitzer] thinks is right . . . He really saw this as his book, and if he thought it was 
right he would push very hard to get it in that way” (as cited in Spiegel, 2005, p. 5).  
Spitzer and co-researcher Joseph Fleiss (1974) were influential in challenging the 
reliability of the DSM-II and stressed the importance of revising the manual to address 
this. In highlighting their concerns about the DSM-II’s reliability, Spitzer and Fleiss 
(1974) recomputed the findings of six prior reliability analyses of the DSM-II and 
concluded that:  
There are no diagnostic categories for which reliability is uniformly high. 
Reliability appears to be only satisfactory for three categories: mental deficiency, 
organic brain syndrome (but not its subtypes), and alcoholism. The level of 
reliability is no better than fair for psychosis and schizophrenia and is poor for the 





In an effort to promote greater reliability in the DSM-III, the revision task force 
initiated a number of field trials. When the DSM-III was published in 1980, and in 
reference to these field trial findings, the manual’s authors reported “far greater reliability 
than had previously been obtained with the DSM-II”, and noted that “reliability for most 
classes in both phases is quite good” (American Psychiatric Association, 1980, pp. 5, 
468). Roughly two years later, Hyler, Williams, and Spitzer (1982) asserted that “the 
reliability of the major diagnostic classes of DSM-III was extremely good” (p. 1276). 
Nonetheless, Kirk and Kutchins (1994) asserted that there was no evidence that 
any formal comparisons between the DSM-III and previous versions of the manual had 
been conducted. Further, in their own analysis of the DSM-III’s field trial data, Kirk and 
Kutchins (1994) asserted that reliability spanned “the entire spectrum from chance to 
perfect agreement” (para. 30). Further, the researchers concluded that the DSM-III’s 
kappa’s were “wildy uneven and unstable” (para. 33). These authors speculated that 
methodological problems precipitated these inconsistencies and noted that, of the 13 
kappas provided for children’s Axis I disorders, three were based on a single patient, one 
on two patients, and two kappas relied on four patients.  
Kirk and Kutchins (1994) also questioned the requirements on which the field 
trials’ kappas were based. For instance, in order to achieve a kappa of one (perfect 
agreement) the observers had only to agree that a mood disorder existed versus clarifying 
the particular type of mood disorder. Kirk and Kutchins suggested that it would have 
been more accurate for the DSM-III’s authors to refer to the field trial data as being 




Another study examined DSM-III-R’s reliability and documented similar 
problems with the manual’s rigor. This analysis was particularly noteworthy because a 
number of the study’s researchers played a significant role in the DSM-III’s development 
(Williams et al., 1992). The study was carried out at six sites in the United States and one 
in Germany and involved interviews of 390 psychiatric patients and 202 non-psychiatric 
participants. The diagnoses were conducted by experienced and specially trained mental 
health professionals utilizing:  
a finely tuned classification system (DSM-III-TR) developed over a ten year 
period by outstanding psychiatric researchers; specially behaviorally oriented 
diagnostic criteria, a carefully developed structured interview (SCID), careful 
selection and training of experienced professional interviewers, and the competent 
supervision research team that is perhaps the most experienced at conducting 
diagnostic studies in the world. (Kirk & Kutchins, 1994, para. 37) 
    
Data analysis of the study’s psychiatric patient sample yielded kappa scores 
ranging from .40 (fair agreement) to .86 (almost perfect agreement) with a weighted 
balance of .61 (substantial agreement), when aggregated across five of the sites (Williams 
et al., 1992). For the non-patient community sample, the kappa scores from two sites 
ranged from .19 (slight agreement) to .59 (moderate agreement) with an average of .37 
(fair agreement). Kirk and Kutchins (1994) asserted that, even with substantial efforts to 
maximize reliability, the results were uncompelling.  
Further, the authors posited that the reliability levels were likely higher than those 
which would have been expected from a more normative clinical setting (Kirk & 
Kutchins, 1994)—a conclusion reiterated by Robert Spitzer, who stated in reference to 




true . . . It’s been improved. But if you’re in a situation with a general clinician it’s 
certainly not very good” (as cited in Spiegel, 2005, p. 63).   
In 1974, Spitzer and Fleiss had posited that the DSM could not be valid if its 
classification system was unreliable. Roughly 27 years later, in reference to the DSM- 
IV-TR’s validity, Andreasen and Black (2001) asserted that “Biologically oriented 
psychiatrists have objected to the lack of validity in the DSM as well. In this instance 
they point to the arbitrary nature of the definitions, which are not rooted in information 
about biological causes” (pp. 35–36).  
Concerns surrounding the potential for the DSM-IV-TR to oppress marginalized 
populations have been raised by Caplan and Cosgrove (2004) who stated that “psychiatric 
diagnosis has been conceived of and applied in extremely biased ways and is surprisingly 
unwarranted by scientific research” (p. xix.). In addition, the authors asserted that the 
DSM-IV-TR’s biases are potentially dangerous because diagnostic labels can negatively 
impact employment, health insurance coverage, and legal proceedings (e.g., child 
custody).  
Eriksen and Kress (2008) argued that locating the source of psychological distress 
within the individual misdirects attention away from the socio-political determinants of 
psychological well-being.   In this way, forms of oppression like racism, sexism, 
homophobia, ageism, classism, ableism and mother-blaming, purportedly become 
embedded within diagnostic and treatment guidelines (Caplan & Cosgrove, 2004).   
Caplan and Cosgrove (2004) also noted the apparent absence of educational 
materials for psychotherapists that adequately address socio-cultural biases among 




Similarly, Ofer Zur, Director of the Zur Institute, an online continuing education resource 
for mental health clinicians, asserted that: 
 Most undergraduate, graduate, and post-graduate education neglects critical 
aspects of training in regard to the complex process of diagnosis. Few programs 
inform students that DSM diagnostic criteria generally lacks empirical support, 
that some criteria is the result of political or popularity ‘voting’, that scientific 
method and evidence has been largely disregarded in its development and that 
issues such as gender and cultural sensitivity are grossly underrepresented. (Zur & 
Nordmarken, 2010, p. 6)  
 
A paper co-authored by two members of the DSM-V task force made some 
predictions about the then unpublished DSM-V’s reliability tests.  This article stated that 
“To see a kappa for a DSM-V diagnosis above 0.8 would be almost miraculous; to see κ 
between 0.6 and 0.8 would be cause for celebration. A realistic goal is a kappa (κ) 
between 0.4 and 0.6, while a κ between 0.2 and 0.4 would be acceptable” (Kraemer, 
Kupfer, Clarke, Narrow, & Regier, 2012, p. 14). Further, in response to concerns 
surrounding the DSM-V’s rigor, Kraemer and colleagues (2012) asserted that: 
Many medical diagnoses go into common use without any evaluation, and many 
believe that the rates of reliability and validity of diagnoses in other areas of 
medicine are much higher than they are. Indeed, psychiatry is the exception in 
that we have paid considerable attention to the reliability of our diagnoses. It is 
important that our expectations of DSM-V diagnoses be viewed in the context of 
what is known about the reliability and validity of diagnoses throughout medicine 
and not be set unrealistically high, exceeding the standards that pertain to the rest 
of medicine. (p. 15) 
 
 The DSM-V was published in 2014. It is noteworthy that the DSM-V kappa 
guidelines used for establishing inter-rater agreement levels were adjusted relative to 
previous revisions of the manual (Carney, 2013; R. Cooper, 2014; Regier et al., 2013). In 
responding to this observation R. Cooper (2014) stated that:  
While many psychiatrists have become used to thinking of Spitzer’s threshold of 




lower benchmarks in the statistical literature. Influentially, Landis and Koch 
(1977) count 0.21-0.4 fair, 0.41-0.6 moderate, 0.61-0.8 substantial, and 0.81—
almost perfect. Altman (1991), condemns only kappas of less than 0.2 as poor, 
and considers anything above 0.61 as good. Fleiss, Levin and Cho Paik (2003) 
counts kappa’s below 0.4 poor, those Between 0.4 and 0.75 fair to good, and 
those above 0.75 excellent. Clearly there are no universally agreed standards for 
what would count as a “good” Cohen’s kappa. (para. 13)   
 
Based on these adjusted kappa levels, the DSM–V Task Force concluded that “most 
diagnoses adequately tested had good to very good reliability” (Regier et al., 2013, p. 59).   
 However, if one applies the older structure for establishing DSM kappa levels, 
there are some cases in which the inter-rater reliability for disorders has decreased 
relative to previous revisions of the manual. For example, inter-rater agreement for 
Schizophrenia was determined to have a kappa value of 0.81 in the DSM-III trial, and 
0.46 in the DSM-V trial (Regier et al., 2013). In this regard, major affective disorders 
have also seen a decrease from a kappa of 0.8 to a kappa of 0.28, respectively.  
Next, according to the previous measure of inter-rater reliability, the DSM-V’s 
kappa score for mixed anxiety-depressive disorder is negative (i.e., worse than chance 
alone)—meaning that clinicians would likely have achieved greater inter-rater agreement 
through guesswork (R. Cooper, 2014). In total, of the twenty diagnoses studied for the 
DSM-V field trials, three (15%) resulted in kappa scores that were greater than 0.6. 
According to the DSM-IV model for establishing inter-rater reliability, this meant that 17 
(85%) of the kappa scores had agreement levels at or below a moderate level of inter-
rater agreement (R. Cooper, 2014).  
The DSM has provided generations of clinicians across a variety of disciplines 
with a framework for evaluating the type and severity of mental distress. Similarly, the 




treatment (pharmacological and non-pharmacological) of psychological suffering. In 
addition, the DSM has helped to facilitate the provision of services, including financial 
support, for many individuals suffering with psychological distress.  
However, as noted herein, there are also well documented problems with the 
DSM’s validity and inter-rater reliability. Further, the implications of these shortcomings 
must be considered when it comes to training psychologists for prescriptive authority—
particularly since the DSM plays an integral role in determining which psychotropic 
drugs with potentially dangerous side effects, should be prescribed.     
C/S/X Movement  
 This study examined psychologist postdoctoral psychopharmacology training 
materials for c/s/x content because the c/s/x movement represents a population of 
marginalized individuals who are particularly vulnerable to the negative consequences of 
diagnostic and treatment errors resulting from unresolved issues pertaining to etiological 
hypotheses for depression and the rigor of the DSM (LeFrancois et al., 2013; Reaume, 
2002; Whitaker, 2010).  Further, integrating c/s/x voices within the context of training 
psychologists for prescriptive authority is consistent with both disciplines’ ethical 
guidelines, represents a valuable opportunity for shared advocacy, and has important 
ethical and legal implications within the context of obtaining informed consent from 
patients.       
 The c/s/x movement is an international patient-lead phenomenon comprised of 
diverse needs, experiences and perspectives reflected in the movement’s monikers; users, 
consumers, ex-patients, and survivors (Morrison, 2006). Through this lens, people who 




‘ex-patients’ are individuals who were treated, in some cases involuntarily, within 
psychiatric facilities. The term survivor refers to an identity based upon the concept of 
resilience and having endured previous psychiatric treatment, in some cases prior to 
deinstitutionalization. These nomenclatures have been criticized. For example, the term 
“consumer” has been challenged for its capitalist overtures and “survivor” because of its 
associations with the Holocaust (Reaume, 2002, p. 423).  
The c/s/x movement’s origins have been linked to the civil rights, gay liberation, 
feminist, and antipsychiatry movements of the 1960s and 1970s (Vogt, 2007). Vogt 
conceptualized the 1970s and early 1980s as a more radical period of mental health 
activism in which the majority of c/s/x initiatives excluded professionals and non-patients 
because they tended to “interfere in consciousness raising . . . and usually have mentalist1 
attitudes” (Chamberlin, 1978, p. 86).  However, some c/s/x organizations developed 
partnerships with mainstream mental health initiatives as a means to procure funding and 
sustainability (Chamberlin, 1978; Vogt, 2007). These collaborations were controversial 
among c/s/x activists. For example, Clay (2005) posited the risk of “‘co-option’ of a peer 
program’s basic principles and unique beliefs” by mainstream mental health providers 
who had their own agendas (p. 243). In addition, Clay suggested that the imposition of 
“external rules and procedures” by mainstream providers stifled the efficacy of some 
c/s/x programs (p. 242). 
 The c/s/x population has been characterized as being particularly vulnerable to 
negative outcomes from treatment errors because its members, in addition to being 
                                                 




stigmatized for mental distress, typically suffer from the impacts of low socioeconomic 
status. This includes stigmatization for being poor, difficulties securing employment and 
affordable housing, and access to post-secondary education and appropriate health care. 
Further, many c/s/x individuals face additional intersecting forms of marginalization such 
as racial discrimination, homophobia, and/or misogyny (LeFrancois et al., 2013). Next, as 
a result of being impoverished, access to more expensive non-pharmacological 
interventions (i.e., psychotherapy) may be restricted. In cases of generational poverty, 
financial support from immediate or extended family members may be limited too.  In 
this regard, Menzies, LeFrancois, and Reaume described “the critical need to examine 
psychiatric practices that mediate and amplify a host of crosscutting socio-economic and 
political forms of discrimination” (LeFrancois et al., 2013, p. 16).  
 In conceptualizing the c/s/x movement, Usar (2014) noted: 
Advocacy, choice, peer support, self-help, self-definition and self-determination, 
in particular claiming “voice” and talking from the standpoint of marginalized 
experience have been the guiding principles of the c/s/x movement since its 
inception in the second half of the 20th century. Rooted in broader struggles, for 
social justice these principles  have been successfully used by people who are 
labeled with mental illness to speak their truth, share their stories, voice their 
opinions, and challenge the psychiatric system and its knowledge. Collectively, 
people have organized to expose systemic discrimination and abuse they face 
within the psychiatric system and the larger society, disputed the bio-medical 
understanding of “mental illness”, and created self-help alternatives to coercive 
treatments. (p. 2) 
 
 The fight against coercive psychiatric practices has been an integral part of the 
c/s/x movement’s raison d’être, development and activism (Oaks as cited in Kallert, 
Mezzich, & Monahan, 2011). In the United States, forced drugging is primarily used for 
mitigating a person’s risk of harm to self and/or other(s) (Treatment Advocacy Center, 




assumptions that they lack the capacity to determine the best course of treatment 
(Treatment Advocacy Centre, 2016). Concerns have been raised, in some cases 
litigiously, about the constitutional legality of these practices which threaten liberty and 
dignity (Gottstein, 2008; Mendez, 2013; Oaks, 2011).  The recent United Nations report 
by the Special Rapporteur on Torture and other Cruel, Inhuman or Degrading Treatment 
or Punishment asserted: 
Despite the significant strides made in the development of norms for the abolition 
of forced psychiatric interventions on the basis of disability alone as a form of 
torture and ill-treatment and the authoritative guidance provided by the CRPD 
(Convention on the Rights of People with Disabilities), severe abuses continue to 
be committed in health-care settings where choices by people with disabilities are 
often overridden based on their supposed “best interests”, and where serious 
violations and discrimination against  persons with disabilities may be masked as 
“good intentions” of health-care professionals. (Mendez, 2013, p. 4) 
 
Similarly, psychologist and c/s/x activist Ronald Bassman (2005) asserted: 
Many of my peers, those of us who have been treated for serious mental illness, 
are not comforted by the popular belief that we have moved far beyond the days 
of frontal lobotomies, insulin shock, metrozal shock, electroshock, teeth 
extractions, and organ amputations. Though the sojourns of mental patients into 
community life freed them from confining institutions, if you listen you will hear 
stories of chemical lobotomies which have become their new prisons with 
invisible, yet substantial walls (Blanch, Fisher, Tucker, Walsh, and Chassman, 
1993; Ridgway, 2001; Chamberlin, 2002). (p. 492) 
 
 Another important issue pertaining to coercive prescription practices involves 
risks associated with psychotropic medications’ iatrogenic effects (Gottstein, 2008). For 
example, neuroleptics have been linked to degradation of the frontal cortex and 
antidepressants have been shown to negatively impact bone density and blood platelet 
characteristics, in addition to increasing the risk of stroke, suicidality, mortality, and 
complications during pregnancy (Andrews et al., 2011). The following body of research 




potential risks that this vulnerable population faces as a result of treatment errors 
pertaining to psychotropic interventions for depression. 
Pregnancy. Meta-analytical findings indicate an apparent link between SSRI 
exposure during the third trimester and pulmonary hypertension in newborns; a condition 
that is fatal for approximately 10% of babies who suffer from the illness (Ellfolk & 
Malm, 2010).  Other data suggested that antidepressants are correlated with preterm 
deliveries and low birth weight, although these findings currently lack sufficient evidence 
for any definitive conclusions (Ellfolk & Malm, 2010). Withdrawal symptoms correlated 
with maternal SSRI use have been observed in newborns, however, the associated risks 
and long-term implications, are unclear (Ellfolk & Malm, 2010; Moret, Isaac, & Briley, 
2009).  
In-vitro studies suggest that SSRIs paroxetine and, potentially, fluoxetine and 
citalopram have teratogenic potential (Sloot, Bowdeb, & Yih, 2009). Additional animal 
research using mice indicated that permanent neurobehavioral alterations subsequent to 
in-utero exposure to these medications can and do occur (Ansorge, Morelli, & Gingrich, 
2008; Holmes, Murphy, & Crawley, 2003). Nonetheless, human data surrounding long-
term developmental risks associated with maternal SSRI use during pregnancy remains 
inconclusive (Ellfolk & Malm, 2010).  
For example, a meta-analysis of seven studies (n = 1774) by Einarson and 
Einarson (2005) did not find increased risk of birth complications from antidepressants.  
These conclusions are limited by the study’s methodology which involved using a 
number of different antidepressants that impacted a variety of different pathways. Also, 




potential for bias in the selection, presentation, and interpretation of data. Finally, the 
review did not investigate the potential for any long-term neurobehavioral effects for 
babies whose mothers were using SSRIs or other antidepressants.  
Electrolytes and bone density. Another health risk correlated with SSRIs is 
hyponatremia, a condition which can increase the chances of falls due to dizziness 
associated with electrolyte imbalances. A number of reviewers outlined how this can be 
problematic for older individuals, particularly when it comes to compounded effects from 
polypharmacy (e.g., diuretics) (Andrews et al., 2011; Jacob & Spinler, 2006; Moret et al., 
2009).  There is also evidence that SSRIs degrade bone mineral density which could 
conceivably increase the likelihood of bone fractures, particularly among the aged (Moret 
et al., 2009).  
A randomly selected prospective cohort study involving 5,008 community 
dwelling adults (50 years old or older) found that daily SSRI use (n = 137) was 
associated with a two-fold increased risk of fractures (J. Richards et al., 2007).  However, 
limitations of this study included the fact that the duration of participants’ daily SSRI use 
was unknown. Hence, it was not possible to link the extent of SSRI use with fractures. 
Also, depression was diagnosed by questionnaires and not via an interview with a 
psychiatrist. Other reviewers have suggested that the sympathetic nervous system 
activity, glucocorticoids, and inflammatory cytokines associated with depression, may 
underlie decreases in bone density (Chau, Atkinson, & Taylor, 2012; Yirmiya & Bab, 
2009). 
Internal bleeding. A number of studies indicated that SSRI users were more likely 




non-antidepressant users (Meijer et al., 2004; van Haelst et al., 2010). A study which 
analyzed data from a cohort of 64,000 new antidepressant users found 196 cases with 
abnormal bleeding and a positive correlation between this problem and SSRI use (Meijer 
et al., 2004). Limitations of the study included the relatively small number of cases and 
the fact that hospital records were used for diagnosis. Also, instances of bleeding where 
hospitalization did not occur would have been missed meaning there was a possibility 
that risk levels were underestimated.    
SSRI use has also been linked to upper gastrointestinal bleeding—a risk that 
appears to be amplified by concurrent prescriptions for anti-thrombotic pharmaceuticals 
like non-steroidal anti-inflammatory drugs (NSAIDs) (Dall, De Muckadell, Lassen, 
Hansen, & Hallas, 2009). Dall and colleagues compared data from 3,652 individuals 
diagnosed with serious upper gastrointestinal bleeding (USB) to 36,502 controls matched 
for age and gender. The researchers found that SSRI use was associated with USB and 
noted that the results were consistent with antiplatelet effects already associated with this 
class of drug. These results may have been skewed by selection and information biases, 
however. For example, the researchers noted that their database did not include 
information about potential confounds like alcohol use, smoking, physical frailty, or the 
consumption of non-prescription ulcerogenic drugs.    
Stroke. SSRIs have been associated with increased risk for ischemic and 
hemorrhagic stroke (Trifiro, Dieleman, Sen, Gambassi, & Sturkenboom, 2010). Trifiro 
and colleagues identified 996 cases of ischemic stroke from a primary care database.  In 
comparison with controls matched for age (65 years and older), sex, and index date, SSRI 




This was an observational study, however, and the researchers lacked confirmation about 
whether prescriptions were actually filled and taken. Thus, it is possible that poor 
compliance confounded results.  
   Other findings indicated that antidepressant use may actually improve survival 
rates in stroke patients (Jorge, Robinson, Arndt, & Starkstein, 2003). Nonetheless, even if 
SSRIs can offer anticoagulant benefits for such patients, this upshot may be offset by the 
harmful anti-clotting effects mentioned earlier (Andrews et al., 2011).  
Behaviour. Behavioral inhibition problems, attentional deficits, increased suicidal 
behaviours, and higher mortality rates have been linked to antidepressants. For example, 
a review noted that SSRIs and tricyclic antidepressants were correlated with difficulty 
inhibiting socially appropriate behaviours. Other research has shown a positive 
correlation between motor vehicle accidents (MVAs) and antidepressants use (Chang et 
al., 2013; Gibson et al., 2009). However, these findings should be viewed cautiously 
given that compliance with medications use and unmeasured environmental stressors 
could ostensibly have impacted the rate of MVAs.   
Suicidality. Large scale meta-analytic studies supported claims surrounding the 
existence of age-dependent risk for suicidal behaviours among SSRI users (Fergusson, 
Doucette, & Cranley-Glass, 2005; Stone et al., 2009). The meta-analysis by Stone and 
colleagues (2009) found that antidepressant use in children, adolescents, and young 
adults (< 25 years old) was associated with increased risk of suicidality, but that this risk 
declined with age. Indeed, for patients over the age of 65, suicidal ideation appeared to 
decrease with SSRI use. It should also be noted that, for younger patients, the harmful 




those who were being treated for disorders other than depression. Conversely, among 
older individuals, the beneficial outcomes were associated with their being treated for 
major depressive disorder (Stone et al., 2009). Thus, suicidality risks linked to 
antidepressants may be age and disease dependent. Stone and colleagues noted the 
primary limitation of their meta-analysis was that it failed to sufficiently address the 
differing types of patients and variety of circumstances for which antidepressants may be 
prescribed. In particular, they asserted that patients exhibiting a high risk for suicide 
would probably not have been enrolled in a placebo controlled study for ethical reasons. 
Also, most of the examined studies involved the treatment of acute versus chronic 
conditions. Finally, there was a sparse amount of relevant data since few suicides 
occurred during the studies. 
Proponents of antidepressants have argued that, left untreated, depression itself 
can result in suicide (Julien et al., 2011; Stahl, 2008). However, a meta-analysis of 19 
epidemiological studies on depression and suicide risk showed that there was little 
evidence to support the hypotheses that suicide risk could be reduced or increased via 
antidepressant use (Baldessarini et al., 2007). 
Mortality. Adding to the controversy surrounding suicidality and notwithstanding 
the potentially favorable effects of SSRIs in this regard for elderly patients, are findings 
linking antidepressants to an overall increase in mortality rates. The recent Woman’s 
Health Initiative study, for instance, showed that antidepressant use was associated with 
being one and a half times more likely to die, even if the participants did not meet the 




of participants’ deaths were attributed to suicide, suggesting that the mortality rate for 
this sample was primarily based on physical health issues.     
The complexity of empirical literature on antidepressant related suicide and 
mortality makes it difficult to draw more definitive conclusions about the associated risks 
that these drugs pose (Baldessarini et al., 2007; Reeves & Ladner, 2010). Methodology 
wise, it is impossible to control for the sheer number of variables that can ultimately lead 
to an untimely death or health problem. For example, it is conceivable that environmental 
teratogens may play a role in accounting for the adverse health symptoms experienced by 
babies whose mothers happened to be using antidepressants during the child’s neonatal 
development (Ellfolk & Malm, 2010). Further, the data was correlative and findings from 
animal studies may not be applicable to human beings.   
These health and safety concerns should also be considered in light of the 
unprecedented numbers of people being prescribed antidepressants. For example, in 
2010, more than 250 million prescriptions for antidepressants were dispensed in the 
United States alone (IMS Institute for Healthcare Informatics, 2011). In Canada, 19% of 
British Columbian women—roughly one in five—received a prescription for an SSRI 
during a 12 month period between 2002 and 2003 (Currie, 2005).   
Consequently, it warrants considering the potentially negative implications of 
these risks on vulnerable groups like the c/s/x population. A population, for whom the 
health and safety risks of antidepressants (prescribed amidst unresolved etiological and 
diagnostic questions) have the potential to compound existing hardships born from 
poverty and other forms or marginalization. In the same vein, and also in line with the 




students about the c/s/x movement, are the disciplines’ (psychology and prescribing 
psychology) ethical guidelines. Guidelines which assert the importance of addressing the 
strengths and weaknesses of evidence used to justify interventions, when obtaining 
informed consent from patients.   
 For example, the American Psychological Association’s Ethical Principles of 








	 Similarly,	the	Practice Guidelines for Psychologists’ Involvement in 
Psychopharmacological Issues states:	
Rationale. The APA (2002b) Ethics Code requires psychologists to obtain 
informed consent before any professional interaction whenever possible. The 
decision to prescribe medication for a patient optimally results from collaboration 
between that patient and the psychologist, rather than from a unilateral decision 
by the prescriber. A collaborative decision depends upon appropriate education of 
the patient about alternative treatments and full informed consent. (American 
Psychological Association, 2011, p. 844) 
 
In addressing the implications of informed consent with regard to forced and voluntary 
use of psychotropic medications the same guidelines state: 
Psychologists in forensic settings may work with individuals who are unable or 
unwilling to provide informed consent. In these circumstances, it is incumbent 
upon the psychologist to be aware of both institutional rules and regulations and 
APA ethical expectations for how to handle the administration of medications in 
the absence of  consent. Despite differences in the context of the treatment, the 
psychologist endeavors to provide the same level of education and disclosure 
about medication and its efficacy, iatrogenic effects, and medication procedures 




 The use of medication increases the universe of topics to be addressed as 
part of the informed consent process. (American Psychological Association, 2011, 
p. 844) 
 
	 Based on both of the aforementioned guidelines for informed consent the 
prescribing psychologist would presumably need to convey that the etiology of 
depression has not been established and that there are considerable limits to the rigor of 
DSM diagnoses used to inform psychiatric interventions and decisions about forced and 
voluntary drugging. The ability to relay this information as a prescribing psychologist 
would arguably require that it had been addressed with sufficient breadth during clinical 
training and within the materials used to accomplish this. Further, failure to address these 
issues within the scope of obtaining informed consent could present ethical and legal 
problems in cases where treatment errors occur.  	
 Consider the American Psychological Association’s (2011) Practice Guidelines	
Regarding	Psychologists’ Involvement in Pharmacological Issues here: 
Guideline 2. Psychologists are urged to evaluate their own feelings and attitudes 
about the role of medication in the treatment of psychological disorders, as these 
feelings and attitudes can potentially affect communications with patients. 
Rationale: There is some evidence to suggest the clinician's faith in the treatment 
can be  an important predictor of treatment response (Jacobson & Hollon, 1996). 
Unfortunately, treatment with medication has at times been associated with both 
excessive optimism and skepticism (e.g.,, Kramer, 1993; Valenstein, 1998), and 
both positions have been exaggerated by media attention. Psychologists will 
inevitably form their own opinions about medications. These opinions can in turn 
affect patients' decisions about taking a prescribed medication, and even 
medication effectiveness, if they are not addressed openly in the process of 
discussing psychopharmacological interventions. 
 Implications: Psychologists who are aware of their attitudes and feelings 
towards medications, and who openly accept the possible validity of alternative 
viewpoints, are in the best position to discuss the potential risks and benefits of 
using medication in a balanced manner. Psychologists are encouraged to explore 
their own feelings about medication, and to consider the possible role of those 










The patient’s right of self-decision can be effectively exercised only if the patient 
possesses enough information to enable an informed choice. The patient should 
make his or her own determination about treatment. The physician's obligation is 
to present the medical facts accurately to the patient or to the individual 
responsible for the patient’s care and to make recommendations for management 
in accordance with good medical practice. The physician has an ethical obligation 
to help the patient make choices from among the therapeutic alternatives 
consistent with good medical practice. Informed consent is a basic policy in both 
ethics and law that physicians must honor, unless the patient is unconscious or 
otherwise incapable of consenting and harm from failure to treat is imminent.  
(AMA, 2006, Opinion 8.08 – Informed Consent para. 1) 		
 
 In this regard, Oaks has written about “coercion by misinformation” and noted: 
One could argue that in coerced psychiatric procedures, some of the most 
powerful individuals in our society have authority over some of the most 
disenfranchised, and discredited citizens. Because of this power imbalance, the 
veracity of claims by mental  health professionals ought to be held to the highest 
academic standards, because an error may destroy what many of us hold most 
precious: our liberty. (as cited in Kallert et al., 2011, p. 189) 
 
 Another ethical reason for integrating information about the c/s/x movement 
within psychologist postdoctoral psychopharmacology training materials is that the 
discipline of psychology’s ethical principles and code of conduct and the practice 
guidelines for prescribing psychologists both uphold the importance of cultural 
sensitivity. It warrants noting here that the c/s/x movement has its own cultural mores 
reflected in the movement’s history, distinctive beliefs, unique forms of artistic 




Principle E: Respect for People's Rights and Dignity from the American 
Psychological Association’s Ethical Principles of Psychologists and Code of 
Conduct states: 
 
Psychologists are aware of and respect cultural, individual and role differences, 
including those based on age, gender, gender identity, race, ethnicity, culture, 
national origin, religion, sexual orientation, disability, language and 
socioeconomic status and consider these factors when working with members of 
such groups. (American Psychological Association, 2010, p. 4) 
 
 Next the third tenet of the Practice Guidelines for Psychologists’ Involvement in 
Psychopharmacological Issues states: 
When clinicians work with patients or clients from different linguistic, ethnic, or 
cultural groups, clinicians recognize that the presentation or description of the 
clinical syndrome may reflect culturally-specific referents and may not conform 
to those of the dominant group. (American Psychological Association, 2011, 
p. 840) 
 
 This is reiterated in the guidelines’ ninth tenet which notes that “Psychologists are 
encouraged to explore issues surrounding patient adherence and feelings about 
medication” and the tenth guideline, which states that “Psychologists are urged to 
develop a relationship that will allow the populations they serve to feel comfortable 
exploring issues surrounding medication use” (American Psychological Association, 
2011, pp. 842–843).  	 
Opportunities for shared advocacy efforts also dictate that psychologist 
postdoctoral psychopharmacology training materials should integrate information about 
the c/s/x movement.  For example, there are already professional allies (e.g., various 
psychiatrists, psychologists, physicians, and social workers) and clinician activists, who 
have identified the importance of considering the c/s/x movement’s history, mission, and 
needs when it comes to the provision and reformation of mental health care practices 




 Additionally, prescribing psychologists have identified the importance of 
considering the c/s/x movement within the context of advocacy efforts. For example, 
Campbell and Gardner noted in Prescriptive Authority for Psychologists: A History and 
Guide that: 
The story of psychology’s consumer and professional alliances in the pursuit of 
prescriptive authority cannot adequately be told without a candid and personalized 
view of the journey taken by the pioneers and advocates in the struggle with 
mental illness and with the systems that have determined their course. 
Psychologists’ alliances with  consumers, families, and mental health 
professionals grow from mutual and intersecting goals for better legislation, 
improved mental health systems, and the underlying power of advocacy as the 
vehicle of change.” (as cited in Sammons et al., 2003, p. 159) 
 
 At the same time Campbell and Gardner asserted:  
Until recently, psychologists had a mixed record regarding involvement in the 
consumer mental health movement. Consumer’s very negative view of mental 
health professionals is largely leveled at psychiatry as the professional force that 
directed patients into involuntary hospitalization and forced medication. On the 
other hand, consumers and families ask “Where are the psychologists and where 
were they then? (as cited in Sammons et al., 2003, pp.164–165) 
  
 In considering the opportunity for rectifying this, Campbell and Gardner posited 
that “The importance of capturing this bird’s eye view of the consumer’s experience 
within the mental health system is that the practices that cause dissatisfaction with 
psychiatric services invite change and movement into the psychosocial realm of 
psychological treatment” (as cited in Sammons et al., 2003, p.162). Similarly, the authors 
asserted “As psychologists adopt the role of mental health professionals with prescriptive 
authority, they are skilled and prepared to offer a psychosocial model of comprehensive 
treatment that corresponds to the long-standing needs and preferences of the consumer’s 




The value of teaching psychologists within postdoctoral psychopharmacology 
programs about c/s/x self-help initiatives also has implications for advocacy efforts. For 
example, c/s/x self-help offerings have the potential to provide valuable mental health 
resources, particularly for marginalized individuals who do not possess insurance for 
mental health support (i.e., counseling). Research by Nelson, Ochocka, Janzen, and 
Trainor (2006a, 2006b, 2006c, 2006d) identified the benefits of c/s/x initiatives on 
members’ levels of community integration, psychiatric symptom reduction, reductions in 
the use of traditional mental health care services, and improvements in quality of life. A 
study by Chassot and Mendes (2014) examined how active participation (i.e., activism) 
within the British “user/survivor movement” impacted subjects’ ability to conceptualize 
their experiences through positive reframing, increased self-esteem and afforded 
opportunities for acceptance and connections with fellow users/survivors difficult to 
achieve within social networks outside of that context. 
Chassot and Mendes (2014) also noted diversity in terms of the types of support 
being offered by “user/survivor” organizations:   
Although alternative models of understanding mental distress are important to 
some members, we also found that other participants valued access to mainstream 
psychiatric information through service user/survivor groups, which they used to 
better understand their conditions and to negotiate care with practitioners. (p. 9)   
 
A large SAMHSA funded study of consumer operated service programs from 
1998 to 2002 found that the examined drop-in programs provided a variety of services 
that typically paralleled traditional mental health and social services offerings (i.e., 
activity and support groups, telephone access, laundry facilities, computer use, and 




Teague, & Herr, 2005). The researchers also reported that both of the examined peer 
support programs “have a systematic approach consistent with the principles of 
empowerment and recovery” (Johnsen et al., 2005, pp. 232–233). Next, the study 
concluded that peer support initiatives provided additional assistance with managing 
personal concerns (i.e., employment issues, housing and health, recreation, and 
maintenance of personal relationships). By contrast, the educational programs focussed 
attention on helping consumers gain an “accurate and comprehensive knowledge about 
mental illness and psychiatric services” (Johnsen et al., 2005, p. 232).   
There is a history of collaborative advocacy efforts between c/s/x organizations 
and mainstream institutions. For example, MindFreedomInternational has collaborated 
with the World Health Organization (Mezzich, 2007) and the United Nations (2006). In 
discussing their alliance with MindFreedomInternational’s efforts to protect human rights 
within the context of mental health care, Dr. Benedetto Saraceno, former Director of the 
World Health Organization’s Department of Mental Health and Substance Abuse 
asserted: 
MindFeedom is doing remarkable work nationally and internationally to promote 
the protection of human rights in mental health. In my experience, MindFeedom 
has been a fair, transparent interlocutor. WHO has different views from 
MindFeedom in some areas, such as the definition of mental disorders or mental 
disability, or the assessment of the advantages and disadvantages of psychotropic 
medicines, but WHO also shares many common views with MindFeedom 
concerning the right of choice about treatment and, above all, the need of 
addressing the global emergency about the violation of human rights. On several 
occasions, MindFeedom’s Director David Oaks has expressed the same concerns 
as WHO and I think it is possible to build up a fair collaboration on those  
issues on which we agree, more than having no collaboration based on issues on 





There are also examples of instances in which the c/s/x movement has been 
addressed within university curricula (Ryerson University, 2015; Trent University, 2015; 
York University, 2014). Similarly, in 2008, Simon Fraser University hosted the Madness 
Citizenship & Social Justice Conference. The conference’s brochure noted: 
Psychiatric users and survivors have become increasingly visible and proactive on 
various political fronts, organizing and aligning themselves with community 
groups, legal advocates and other constituencies in their collective struggles for 
adequate medical care, housing, education, employment, and legal and civil 
protections. By recruiting participants from these various constituencies, this 
conference will provide a sharp counterpoint to the prototypical meetings of 
clinical, professional and academic associations concerned with issues related to 
‘mental illness’ and psychiatry. This event will be unique in offering a venue for 
the advancement of multi-vocal, progressive and counter-hegemonic perspectives 
on these critical topics and issues. The intention is to establish a context of mutual 
knowledge-sharing and empowerment, and to develop longer-term strategies that 
will permit activists, survivors, scholars and other participants to interact, share 
experiences, develop connections and engage in problem-solving praxis. (Simon 
Fraser University, 2008, p.1)    
	 
 Integrating c/s/x perspectives into the materials used to train psychologists for 
prescriptive authority is also important because information about the population and its 
movement is so widely available online.  For example, Usar (2014) has described how 
increasing numbers of c/s/x groups have developed websites in recent years to “publicize 
their work, as well as expand their outreach and advocacy activities” and for the purpose 
of providing “instant access to vital information, establishing links with various 
survivor/consumer groups and for keeping the advocacy momentum alive (Morrison, 
2005, pp. 88–89)” (p. 21).  Consequently, training for prescriptive authority which 
includes information on the c/s/x movement would ostensibly support prescribing 
psychologists in addressing questions and concerns that might result from clients’ 




 In concluding their chapter on Alliances with Consumer Groups and other 
Associations within Prescriptive Authority for Psychologists: A History and Guide, 
Campbell and Gardner ended with a quote from Catherine Acuff who asserted that:  
By creating collaborative partnerships with those in the c/s/x movement, by truly 
listening to their voices, by recognizing the individuality of those with whom we 
work, by rejecting pejorative labels and going beyond pathology based models, by 
being open to alternative therapies and self-help approaches, and by training our 
students and ourselves about the true hope of recovery, we can create a profession 
that is prepared for the future and the promise it holds (Acuff, 2000, p.1464). (as 
cited in Sammons et al., 2003, p. 175) 
   
Further, it is conceivable that members of the c/s/x movement will seek out 
prescribing psychologists to explore alternatives to drug therapy, titrate medications, 
and/or combine the use of psychotropics with provisions for psychotherapy under a single 
provider (McGrath, 2010). Ultimately, if affiliations between prescribing psychologists 
and the c/s/x movement are weak or non-existent, opportunities for collaboration, shared 
learning, research, advocacy, and treatment could be missed.  
 Legitimate concerns surrounding the consequences of abolishing forced 
psychotropic interventions and forced hospitalization have also been raised. These 
arguments point to the ethical and legal complexities of maintaining the safety of patients 
and community members. Further, faced with dwindling community resources, 
compounded in some cases by addiction and poverty, there may be limited alternatives 
available for mental health practitioners, including prescribing psychologists, when it 
comes to mitigating risk.  In the same vein, psychiatrists like Torrey (1997) and Satel 
(2000) have posited concerns about the potential for c/s/x organizations to dissuade 
individuals in need of psychiatric care from voluntarily receiving such services thereby 




To this end, Torrey and Satel have actively lobbied against government funding 
for c/s/x groups (McLean, 2003). Further, they have alleged that c/s/x organizations 
frequently represent extremist views whose arguments lack scientific support, and whose 
messaging amounts to misinformation about electro-convulsive-therapy, involuntary 
commitment, and psychotropic prescription drugs (Rissmiller & Rissmiller, 2006).  The 
Treatment Advocacy Center which Torrey founded suggested that c/s/x initiatives aimed 
at individuals with mental distress increase the latter’s risk of homelessness, 
imprisonment, and violence towards others (Treatment Advocacy Centre, 2011a). 
Similarly, former American Psychiatric Association medical Director, John Scully, called 
MindFreedomInternational’s activism “ill-considered” and invited the group to 
reconsider its position and “join NAMI to help improve the care of our fellow citizens 
who suffer from serious mental illnesses” (MindFreedomInternational, 2003, p.1).  
Critiques of the c/s/x movement have also been levied by its own members. For example, 
Estroff (2004) noted that the movement’s “exaggerated claims of agency may pose as 
many problems as erasure of agency for people with schizophrenia—and both are 
probably inaccurate” (p. 300).   
 The fact that the c/s/x movement is controversial does not negate the importance 
of addressing the phenomenon within the context of the materials used to train 
psychologists to prescribe. Rather, being exposed to information about this marginalized 
population would require that prescribers grapple with the history, perspectives and needs 
of a diverse, complex, and marginalized population that is, by virtue of its members’ 




Research Question                                                                                                                           
To clarify the extent to which current psychologist postdoctoral 
psychopharmacology training materials are integrating critical perspectives and 
considering their implications for treating a marginalized population, this study sought to 
understand:  (a) To what extent do psychologist postdoctoral psychopharmacology 
training materials critique neurobiologically based hypotheses for the etiology of 
depression, (b) challenge the DSM’s empirical rigor, and (c) integrate information about 




Chapter II: Method 
Operational Definitions 
 The following operational definitions were used within the study’s content 
analysis.  
 Measures— Neurobiological Hypotheses of Depression refers to any brain 
based hypothesis or theory about the cause of depression.  
 Measures—DSM. The Diagnostic and Statistics Manual of Mental Disorders 
(DSM) is published by the American Psychiatric Association. There are five 
editions of the DSM, plus two formal revisions (I, II, III, III-R, IV, IV-TR, 
and V).  Operationally, the DSM must be explicitly mentioned or cited in 
order for content to be assigned to a particular coding category for this topic. 
However, provisions were also made to document relevant content falling 
outside of the coding framework’s requirements (i.e., content about the DSM 
that did not include any explicit mentions of the manual).     
 Measures—C/S/X Movement. This operational definition pertained to any 
mentions of the consumer/survivor/ex-patient movement. The Encyclopedia 
Britannica (2016) defined social movement as a “loosely organized but 
sustained campaign in support of a social goal, typically either the 
implementation or the prevention of a change in society’s structure or values.” 
For the purposes of this study, the c/s/x movement has been conceptualized as 
an organized and sustained movement challenging the medicalization of 
mental distress including practices like forced drugging, forced 




problems with obtaining informed consent. Materials or statements by and 
about individuals who identified or were deemed to have identified as c/s/x 
activists were also included within this operational definition. In this regard, 
the term activist has been characterized within the Oxford Dictionary (2016) 
as a “person who campaigns to bring about political or social change.” 
Consequently, for the purposes of this study, “c/s/x activist” is defined as an 
individual who campaigns for social change within the context of supporting 
the c/s/x movement as outlined above. The terms “consumer(s).” 
“survivor(s),” or “ex-patient(s)” on their own did not meet the criteria for this 
operational definition unless the statement(s) in which they were embedded 
clearly referred to the c/s/x movement.   
 Measures—Citations/References. Citations within an examined reading or 
video were documented in two scenarios. First, the researcher identified 
citations from the following list of critics: Joseph Glenmullen, Marcia Angell, 
Peter Breggin, David Cohen, David Healy, Joanna Moncrieff, Irving Kirsch, 
Robert Whitaker, Glen Spielmans, Jeffery Lacasse, Jonathan Leo, Jay Joseph, 
David Antonuccio, and Brett Deacon . The citation could be documented via 
APA format or the critic could be referenced by name. This list of critics was 
developed through consultation with a number of the experts and critical 
perspective holders identified within the dissertation’s acknowledgements 
section.  Second, this study sought to determine whether or not any articles or 




 Measures—Critiques. A “critique” was operationally defined as any statement 
that highlighted the limitations of a neurobiologically based hypothesis or 
theory for depression’s etiology, or content which was critical of the DSM in 
any way. For example, any content which identified problems with the DSM’s 
inter-rater reliability and construct validity, or limitations of using the manual 
(e.g.,, requires considerable training) or controversy (e.g.,, disagreements 
about a category based approach), was documented as a critique. A critique of 
the c/s/x movement was operationally defined as any content which 
challenged the legitimacy of the movement and its organizations. Similarly, a 
critique of this aforementioned content was operationally defined as any 
challenge levied against a negative appraisal of the c/s/x movement’s 
legitimacy.  
 Measures—Construct Validity for DSM. In this context, construct validity 
pertained to whether or not DSM diagnoses actually measure what they are 
purported to by the manual.  
 Measures—Inter-rater Reliability for DSM. In this context, inter-rater 
reliability was operationally defined as the likelihood that different clinicians 
or coders would obtain similar diagnostic results when using the DSM to 
diagnose the same patient.   
 Measures—Statistics on Inter-Rater Reliability or the Construct Validity of 
the DSM. The operational definition for this measure pertained to the 




scores) for DSM diagnoses and/or the manual’s construct validity (e.g.,, 
concordance rates between the DSM and the ICD-10).  
 Measures—Coding Categories.  Coding categories were developed for each of 
the three topics to identify and categorize information pertaining to a 
neurobiological etiology of depression, the DSM, and the c/s/x movement. For 
operational definitions pertaining to each of the topic’s coding categories, see 
Appendices A (neurobiological etiology’s of depression), B (the DSM), and C 
(the c/s/x movement).   
Methodology   
General description of content analysis. According to social psychologist 
Steven Stemler (2001), content analysis is “a systematic, reliable technique for 
compressing many words of text [or video] into fewer content categories based on 
explicit rules for coding” (p. 1.). Neuendorf (2002) asserted that the researcher must 
initially determine what content will be examined and clarify the rationale behind the 
proposed analysis. This includes ascertaining which theories or perspectives justify the 
value of the proposed study. Following this, the researcher should select the research 
question(s) or hypotheses and conceptualize the variables to be studied. Next, the 
researcher must clarify the coding process including the establishment of operational 
definitions, known as coding schemes (Neuendorf, 2002). The researcher should also 
determine whether a complete census of the materials is viable.    
In content analysis, an identifiable message or component of a message within the 
coding scheme is called a unit (Neuendorf, 2002). The unit helps identify which variables 




analyses frequently involve word counts, other forms of data can be used. For instance, 
Lacasse and Gomory’s (2003) study examined the extent to which critics’ works were 
being incorporated into social work syllabi.  
According to Krippendorf (2004), the researcher must clarify the parameters of 
the variables being studied.  In this way, operational definitions are used to dictate which 
of the written passages in books or spoken segments of video materials, will be analyzed.   
The two primary means of organizing data via content analysis are a-priori and 
emergent coding (Stemler, 2001). With a-priori coding, a particular theory is used to 
establish categories prior to the main analysis. In emergent coding, categories are 
developed and refined throughout the analysis of data.  The specificity of coding 
categories has important implications for data collection. For example, if the categories 
are too broad the researcher may face challenges in developing complex impressions 
about the data set. Conversely, if the categories are highly specific, the researcher may 
have difficulty formulating general impressions.   
Inevitably, some relevant content will fall outside of the coding categories and the 
researcher must determine what to do with this information. Miles and Huberman (1994) 
noted, 
Data reduction is not something separate from analysis. It is part of analysis. The 
researcher’s decisions—which data chunks to code and which to pull out, which 
evolving story to tell—are all analytic choices. Data reduction is a form of 
analysis that sharpens, sorts, focuses, discards, and organizes data in such a way 
that “final” conclusions can be drawn and verified. (as cited in Namey, Guest, 
Thairu, & Johnson 2008, p. 139)   
 
 If the researcher concludes that the omission of relevant data that cannot be categorized 




developed for this purpose (Namey et al.., 2008). At the same time, Namey and 
colleagues (2008) asserted that “There is no single “right” way to approach analysis of a 
large qualitative data set and often an assortment of complementary approaches, building 
one upon another and triangulating findings, is preferable” (p. 158).  
 One or more additional coders must be enrolled in the study, prior to utilizing the 
emergent or a-priori coding method, in order to establish that there is sufficient inter-rater 
reliability to proceed with the main analysis.  This includes training the additional coder 
or coders and check inter-rater reliability via a preliminary analysis (Neuendorf, 2002).  
If the level of reliability is insufficient (i.e., below the minimal level set by the 
researcher) the coding framework may need to be revised and/or the second coder(s) 
retrained. Once a sufficient level of reliability has been established within the preliminary 
examination, it is time to proceed with the main analysis. The main analysis will also 
require periodic inter-rater reliability checks to confirm that adequate the required level 
of inter-rater agreement is maintained.        
Method 
 This study employed content analysis to examine the Division 55 Prescription 
Exam for Psychologists Review DVD as well the syllabi, and a selection of the required 
and recommended readings, and two videos from one psychologist postdoctoral 
psychopharmacology program. These materials were chosen based on the assumption 
that the program’s syllabi and associated readings accurately reflected the most pertinent 
aspects of training psychologists to prescribe psychotropic medications. Further, given 
that a significant portion of this content was purportedly based on the PEP exam’s 




about psychologist postdoctoral psychopharmacology training materials. For example, 
the PEP exam is said to “Measure credibly the knowledge-base competency necessary to 
prescribe” (Sammons et al., 2003, pp. 179–180).    
Through examining these resources the researcher sought to obtain a clearer 
picture about the extent to which psychologist postdoctoral psychopharmacology training 
materials were integrating critiques of neurobiological hypotheses of depression, 
challenging the rigor of the DSM, and addressing the c/s/x movement. In line with 
Neuendorf’s (2002) recommendations, the rational for this study’s methodology stemmed 
from dialogues with experts in the field, an extensive literature review, and a preliminary 
analysis of the syllabi and two pharmacology textbooks (required readings) from a 
psychologist  psychopharmacology program’s 2012/2013 curriculum (this curriculum 
was posted online). In developing the study’s prospectus the researcher communicated 
with a variety of experts identified within the manuscript’s Acknowledgements section, 
for their support with selecting the three topics of analysis, addressing methodological 
considerations, and in overcoming initial obstacles associated with the controversial 
nature of the topic.  
 Categories for each of the study’s three coding frameworks (i.e., for the DSM, 
neurobiological etiology of depression, and the c/s/x movement) were developed through 
reading a variety of written materials from within and outside of the examined 
psychologist  postdoctoral psychopharmacology program’s curriculum. Some examples 
of non-program materials examined during the formation of coding categories included 
the Clinical Handbook of Psychopharmacology (2008); Principles and Practices of 




New Drugs; Elliot Valenstein’s (1998)  Blaming the Brain; David Healy’s (2008) Mania; 
Joanna Moncrieff’s (2009) The Myth of the Chemical Cure; Thomas Szasz’s (2008) 
Psychiatry: The Science of Lies); Judi Chamberlin’s (1978) On Our Own: Patient-
Controlled Alternatives to the Mental Health System; and Mad Matters: A Critical 
Reader in Canadian Mad Studies, edited by Brenda LeFrancois et al. (2013). 
Additionally, journal articles from the literature review, and an analysis of c/s/x 
organizations’ websites including but not limited to, 
www.MindFreedomInternational.org, www.theicarusproject.net, www.mhselfhelp.org, 
and www.psychrights.org, were helpful in this regard. Further, the researcher attended 
two talks by c/s/x activists at the Unitarian Church in Vancouver, British Columbia, and 
spoke with these and other individuals who identified as c/s/x activists.   
 The coding framework for the neurobiological etiology of depression was 
comprised of 12 different hypotheses. In some cases, the researcher elected to combine 
hypotheses with overlapping mechanisms. For example, neurotrophins, proteins, and 
second messenger hypotheses were combined into one neurobiologically based theory for 
the etiology of depression as were the Neuroendocrine and Neuropeptides hypotheses. 
Similarly, all neurotransmitter hypotheses for depression were combined into one theory 
as were the neuroanatomical and circuit based hypotheses.  
 Differences in the nomenclature and approaches used to describe 
neurobiologically based hypotheses for the etiology of depression made the formation of 
coding categories more challenging. For example, in Principles and Practices of 
Psychopharmacology, the authors discussed a variety of “interactional theories of 




psychopharmacology program’s readings (Janicak, Marder, & Pavuluri, 2011).  Next, in 
discussing the neurobiology of depression, Janicak et al.’s (2011) text referred to the 
“Permissive Hypothesis,” “Adrenergic-Cholinergic Balance Hypothesis,” and 
“Bidimensional Model Hypothesis,” which were not identified as such within any of the 
other readings (pp. 206–207). Similarly, Julien and colleagues (2011) text, A Primer of 
Drug Action, was the only analyzed text whose examined readings referred to the 
“Neurogenic Theory”—a term that Stahl was unfamiliar with (S. Stahl, personal 
communication, November 5, 2014).  
 Next, while Stahl noted the role that various facets of the neurogenesis hypothesis 
(i.e., glutamate, apoptosis, neurotrophins, the neuroendocrine system and the HPA-axis) 
played in the etiology of depression, he did not explicitly reference the hypothesis within 
his chapter on depression. Ultimately, however, the researcher chose to interpret this 
content as implicit references to the neurogenesis hypothesis of depression and coded it 
accordingly. It is possible that Stahl would disagree with this decision. For example, he 
might assert that the content pertains to the disorder’s pathophysiology versus its causes.    
 In the process of developing the DSM coding categories, the researcher found 
associated content ranging from general descriptions of the manual to information about 
its history/development, strengths/benefits, and criticisms/limitations/controversies. For 
the c/s/x movement, relevant content tended to focus on the movement’s history, 
organizations, campaigns/events/activism, challenges to the legitimacy of the c/s/x 
movement, and personal stories of c/s/x activists.   
 The development of categories continued iteratively during the main analysis such 




analyses. This meant that the researcher periodically returned to previously analyzed 
materials and revise them based upon updated coding categories. Ultimately, the 
researcher stopped adding or changing categories when it appeared that a sufficient level 
of saturation had been reached (i.e., the coding categories managed to capture the primary 
content on the each of the three topics of analysis within each of the successively 
examined materials).  
The researcher gathered data that was relevant to the topics of analysis, albeit 
falling outside of their respective coding frameworks, within a ‘comments’ section of the 
excel spreadsheets used for data collection. The researcher ultimately consolidated this 
information within a narrative summary which provided an overview of that content and 
the extent to which the information differed from the coded findings.  
 For additional thoroughness, and upon completion of the main analysis, the 
researcher searched the examined books’ indices for the following terms:  
 ADHD 
 Attention Deficit Hyperactivity Disorder  
 ADD  
 Attention Deficit Disorder  
 Affective Disorders  
 Anxiety, Bipolar, Consumer  
 Depression  
 Ex-Patient  
 Major Depressive Disorder  




 Mood Disorders  
 DSM  
 Diagnostic and Statistics Manual of Mental Disorders  
 Psychosis  
 Psychotic Episode  
 Psychotic Disorder  
 PTSD  
 Post Traumatic Stress Disorder  
 OCD  
 Obsessive Compulsive Disorder  
 Personality Disorders  
 Schizophrenia 
 Survivor  
Next, the researcher reread each of the examined psychologist postdoctoral 
psychopharmacology program’s non-textbook articles. In addition, both of the examined 
videos were viewed four times.    
Sampling  
The researcher initially telephoned the Directors of all four psychologist 
postdoctoral psychopharmacology programs in addition to sending them an email and 
registered letter (see Appendix D). Three of the programs responded—two agreed to 
participate in sharing their syllabi and all three Directors were willing to take part in the 
interview. The Director who was not agreeable to providing syllabi noted that this would 




7, 2014). However, this Director did send a number of articles and a PowerPoint in 
response to the researcher’s request for program materials that provided nonconventional 
perspectives pertaining to the three topics of analysis (personal communication on 
February 7, 2014).  
In reviewing the two psychologist postdoctoral psychopharmacology programs 
which had expressed a willingness to fully participate within the study, the researcher 
determined that there was insufficient time to analyze them both. Further, it was noted 
that only one of the program’s curriculums contained any readings from critics of 
conventional psychopharmacology. Additionally, this curriculum contained substantially 
more primary source articles. Consequently, the latter program was selected because it 
seemed more likely to have integrated critiques of conventional perspectives.  
 Required book readings were selected based on the relevance of their titles, and a 
brief examination of the texts’ contents section and indices. The researcher ultimately 
analyzed ten of the 14 required Non-Semester Project (NSP) books, six of the ten 
recommended texts, and all six of the semester project books. In addition, all fifty-seven 
of the non-textbook readings were examined (see Appendices E, F, G, H, I, J, K).    
 Four of the required NSP book readings and four of the recommended textbook 
readings were omitted from the analysis for the following reasons (see Appendix L). 
Here, the researcher assumed that the required Physical Examination and Health 
Assessment (Jarvis, 2011a), Clinician’s Pocket Drug Reference (Gomella, Haist, & 
Adams, 2009) and Stahl’s Prescriber’s Guide (Stahl, 2011), were unlikely to contain 
information about the etiology of depression, the DSM, or the c/s/x movement. One 




Psychiatry (3rd ed) was excluded because the researcher was unable to obtain a copy of 
the book and was later informed by the examined program’s Director that the reading was 
no longer part of the curriculum. 
 Taber’s Cyclopaedic Medical Dictionary (Venes, 2013) and the Pocket 
Companion for Physical Examination & Health Assessment (Jarvis, 2011b) were omitted 
because their respective subject areas were deemed to be outside of the study’s analysis. 
Next, the researcher omitted the recommended Clinical Handbook of Psychotropic Drugs 
for Children and Adolescents (Bezchlibnyk-Butler & Virani, 2007) because an 
examination of the required version of this text for the prescription consideration 
pertaining to adults (i.e., Clinical Handbook of Psychotropic Drugs by Virani, 
Bezchlibnyk-Butler, Jeffries, & Procyshyn, 2011) did not address etiological or 
diagnostic considerations pertaining to the DSM, nor provide any information about the 
csx movement.   
 Next, while students were encouraged to read the Carlat Report 
(www.thecarlatreport.com), Journal of Clinical Psychiatry, and review current literature 
on the National Library of Medicine’s PubMed website 
(www.ncbi.nlm.nih.gov/pubmed/) this body of information was too large to analyze for 
this study.  It is possible that students would have accessed critical discourse about a 
neurobiological etiology of depression, challenges to the rigor of the DSM, and 
information about the c/s/x movement therein. However, a number of factors point to the 
unlikelihood of this. First, research on reading compliance suggests that only 50% of 
students actually complete reading assignments prior to a lecture (B. Cooper, 2015). An 




Association accredited doctoral programs found that that only half of clinical psychology 
students completed assigned readings. Second, work and family demands can limit the 
amount of time available for reading (McMinn, Tabor, Trihub, Taylor, & Dominguez, 
2009)—a consideration that seems particularly relevant to the population of psychologists 
returning to complete  psychopharmacology training for prescriptive authority.  Third, 
these reading were recommended and non-specific, meaning that students were not 
required to read these materials and they were not being guided to any specific articles. 
Consequently, students would need to search as well as read recommended articles with 
content that they may not be tested on.  
In most cases, when the required chapters for a selected book were specified, only 
those portions of the reading were analyzed. However, in some cases an additional 
chapter or chapters was/were examined to inform the discussion. These latter cases were 
not tallied during data analysis. The book was read in its entirety when no specific 
chapters were identified within the syllabi (i.e., the recommended textbooks). All of the 
non-textbook readings were examined in their entirety.  
Tabulation and Reporting 
Syllabi. Descriptive statistics were used to identify the types of materials being 
analyzed (i.e., books, journal articles, primary source studies, reports, guidelines, 
handbooks, newsletters, videos, magazines, and journals).  In addition, the number of 
referenced works from the researcher’s listed critics of conventional 
psychopharmacology beliefs and practices were tallied.  
Books/Articles. Descriptive statistics for the examined books and non-textbook 




were discussed and critiqued. Further, to establish which aspects of the DSM were 
addressed and whether or not this included any information and critiques about the 
manual’s inter-rater reliability and construct validity.  Descriptive statistics were also 
used to document (a) the extent to which the researcher’s listed critics were cited, (b) 
aspects of the c/s/x movement were discussed, (c) works from c/s/x-identified individuals 
were included, and (d) critiques of the c/s/x movement were challenged.   
PEP DVD & PEP practice questions. Descriptive statistics for the PEP Review 
DVD were  calculated by analyzing the PowerPoint’s, the PEP Review DVD’s 
supplemental required and recommended readings, as well as the 162 PEP Practice 
Questions from Dr. Marlin Hoover, for content on the study’s three topics of analysis. 
Psychologist postdoctoral psychopharmacology program videos. Two video 
presentations from the Treatment Issues in Psychopharmacology: Affective Disorders 
class were analyzed by the researcher. This included the Biological Basis of Depression 
and Pharmacotherapy for Depressive Disorders. The researcher used time as a measure 
for documenting the location and breadth of coded content within the videos.  
Inter-Rater Reliability  
A second coder was enrolled to establish inter-rater agreement.  Requirements for 
their participation included enrollment within the PsyD Program at Antioch University 
Seattle and completion of the program’s psychopharmacology (PSYCH723) class. In 
total, the second coder required thirteen hours to train – this included the eight hours of 
preliminary (pilot) coding to establish sufficient inter-rater reliability (i.e., Cohen’s 
Kappa ≥ .41) prior to proceeding with the main analysis. The main analysis took the 




The researcher randomly selected 30% (n = 7) of the examined books and 30% 
(n = 11) of the examined articles for the second coder’s analysis. By chance, the random 
selection of texts included two of the Semester Project books.  The researcher also chose 
to include Robert Whitaker’s book Anatomy of an Epidemic to measure inter-rater 
agreement for c/s/x content because it was the only training material to address the 
movement in a substantive manner.  In addition, the second coder was provided with a 
PowerPoint from Marlin Hoover (developer of the PEP Training DVD), which contained 
a set of 162 Practice Questions for the Psychopharmacology Exam for Psychologists. The 
second coder was asked to determine whether these questions addressed the study’s three 
topics of analysis.  
In total, the second coder examined 25 pages of text for the practice analysis, 214 
pages for the main analysis, and all 162 of the aforementioned Practice Questions for the 
PEP.  The textbooks analyzed for the practice analysis included, Neuroscience: Exploring 
the Brain (2006), Stahl’s Essential Psychopharmacology: Neuroscientific Basis and 
Practical Applications (2013), The Myth of the Chemical Cure (2009), Prescriptive 
Authority for Psychologists (2003), and The Handbook of Clinical Psychopharmacology 
(2008). The second coder was provided with a coding framework and algorithm for each 
of the three topics and for identifying references and citations (see Appendices A, B, C, 
D, M, N, O, P).  
The researcher omitted the syllabi from the second coder’s analysis because there 
was little indication that any of the study’s topics were being addressed within this 
particular aspect of the curriculum. Consequently, it was determined that the second 




syllabi. The second coder did not analyze two of the program’s examined videos because 
both presentations were obtained after the inter-rater reliability process had been 
completed.  Additionally, the second coder did not analyze the PEP Training DVD 
because the researcher’s own analysis of did not find substantive content pertaining to 
any of the three topics of analysis within these materials.  Further, feedback from the 
DVD’s developer, Marlin Hoover, confirmed the researcher’s findings in this regard (M. 
Hoover, personal communications, November 23, and December 10, 2015). Next, it was 
assumed that the practice test questions— for which inter-rater reliability was 
examined—would be exemplars of the PEP Training DVD content and, most 
importantly, represent the knowledge required for psychologists to safely and effectively 
prescribe.  
 Inter-rater reliability was determined through calculating Cohen’s Kappa via 
SPSS software. Agreements required that the researcher and second coder selected the 
same coding categories, critiques, and listed critics. Further, that both coders agreed upon 
whether the inter-rater reliability/construct validity of the DSM, neurobiological 
hypotheses of depression, and legitimacy of the c/s/x movement, had been critiqued.  
A number of different scales have been developed for interpreting kappa scores. 
For example, Cohen (1960) asserted that Kappa  values of less than zero were indicative 
of no agreement while values of 0.01– 0.20 represented none to slight agreement, kappas 
of 0.21–0.40 suggested a fair level of agreement, 0.41– 0.60 moderate agreement, 0.61– 
0.80 substantial consensus, and kappas of 0.81–1.00 reflected almost perfect concurrence. 
Fleiss (1981) consolidated these agreements in recommending that a kappa less that .40 




while any kappa over .75 suggested an excellent level of consensus.  Altman (1991) 
subsequently readjusted the kappa scale to include more levels of agreement such that 
any kappa scores under .20 were described as poor, .21-.40 as fair, .41-.60, as moderate, 
.61-.80 as good, and .81-1.00 as indicative of very good inter-rater agreement.  
 This researcher elected to follow Altman’s scale for establishing inter-rater 
reliability levels because it provided more detail than Fleiss’ approach. In this regard, at 
least a moderate level of agreement (k = .41) had to be achieved for each of the examined 
materials during the practice analysis in order that the second coder could proceed with 
the main analysis.    
The researcher initiated the inter-rater reliability process by reviewing the three 
coding frameworks with the second coder. Next, with support from the researcher, the 
second coder applied these coding frameworks to a variety of pharmacology textbooks.  
Once the second coder appeared to understand the coding frameworks the practice 
analysis was initiated. After establishing that sufficient kappa had been reach in the 
practice analysis, the second coder proceeded with the main analysis. 
Inter-rater reliability checks were also conducted during the main analysis, after 
each of the materials had been examined, to establish whether sufficient reliability was 
maintained. The researcher informed the second coder when they had made 
administrative errors (i.e., if she missed a paragraph’s heading that explicitly indentified a 
particular neurobiological hypothesis for depression, or overlooked a citation for a critic 
or an explicit mention of the DSM). However, these administrative errors were included 




Random Selection of the Second Coder’s Materials   
The second coder’s materials were randomly selected by taking a sheet of paper 
with the readings’ titles and cutting each of these titles into a symmetrically shaped piece 
of paper.  These pieces of paper were subsequently placed within the appropriate envelop 
(i.e., for book readings or non-textbook articles). The second coder then removed 30% of 
these pieces of paper from each of the two large envelopes. During this process, the 
second coder selected the Study Guide to Psychiatry: A Companion to the American 
Psychiatric Publishing Textbook of Psychiatry (2009). The researcher chose to omit this 
reading from the analysis of inter-rater agreement because the second coder had already 
selected the American Publishing Textbook of Psychiatry (2009).  Consequently, the 
second coder randomly selected another title (i.e., A Primer of Drug Action, 2011) from 
the same envelope. The researcher did not include the four American Academy of Child 
and Adolescent Psychiatry Practice Parameters within the random selection process 
because they were missed during his initial review of the syllabi.  
An App was used to generate random page numbers (Random, 2012). These page 
numbers were only selected if they fell within the parameters of the required or 
recommended chapters/pages. The random number app was developed and operated by 
Dr. Mads Haahr, from the School of Computer Science and Statistics at Trinity College 
in Dublin, Ireland (Random, 2012).  
Materials for the second coder were printed, photocopied, or supplied in the 
original book format. The researcher made sure that there was no highlighting, 
underlining, or notes from his own analysis within any of the materials being examined 




algorithm for each of the coding frameworks as well as an excel spreadsheet for data 
collection. For instances in which the second coder had questions about a particular 
section of text, the researcher directed them back to the coding frameworks and 
algorithms (see Appendices A, B, C, M, N, O, P). 
Ethical Considerations 
 The study had the potential to result in negative perceptions about the 
participating psychologist postdoctoral psychopharmacology program and its director 
depending on the findings and peoples’ perceptions thereof. To address this potentiality, 
the study protected the program and its director’s anonymity by not mentioning their 
names or the names of the presenters from the analyzed videos. Additionally, program 
syllabi were kept in a locked filing cabinet in the researcher’s office where they will be 




Chapter III: Results 
Findings 
Inter-rater reliability. Inter-rater reliability scores were calculated for the 
randomly selected materials. This included readings from the analyzed program’s 
required and recommended Non-Semester Project textbooks and Semester Project books. 
A number of the Non-Textbook readings and all of Hoover’s 162 PEP review questions 
were examined by a second coder to establish inter-rater reliability, as well.     
 Practice analysis. Texts used for the practice analysis included the Handbook of 
Clinical Psychopharmacology for Therapists (2008), Prescriptive Authority for 
Psychologists: A History and Guide (2003), Myth of the Chemical Cure (2009), 
Neuroscience: Exploring the Brain (2006), and Essential Psychopharmacology: 
Neuroscientific Basis and Practical Applications (2013).  Stahl’s (2013) book was the 
only text from the examined psychologist postdoctoral psychopharmacology program’s 
readings list that was used for practice coding—note that the text was not randomly 
selected for the main inter-rater reliability analysis. The researcher selected the 
aforementioned texts to mitigate any practice effects that might have resulted from 
having the second coder interact with the same books being used for the main analysis.    
During the practice and main analyses, the researcher reviewed inter-rater 
agreement levels subsequent to the completion of each of the materials examined by the 
second coder. The purpose of evaluating the second coder’s assessments was to confirm 
whether or not sufficient levels of inter-rater agreement had been achieved to warrant the 




 For the practice analysis, Kappa scores were “good” for the etiology of 
depression: κ = .782, p < .0005 and “very good” for content on the DSM: κ = .888, 
p < .0005 (when agreements for no content were included). To address the possibility that 
inter-rater agreements for no content might be skewing reliability levels the researcher re-
calculated kappas   subsequent to omitting this data. This resulted in a “good” level of 
agreement for content on neurobiological hypotheses of depression (κ = .677, p <  .0005), 
and “good” agreement for DSM content (κ = .708, p <  .0005).  
 Kappa scores for c/s/x content were in the “good” range when agreements for no 
content were included (κ = .773, p <  .0005). However, given that the researcher and 
second coder only documented three and four instances of c/s/x content, respectively, a 
recalculation of kappa minus no-content-agreements was not completed.   
 Levels of inter-rater reliability were also calculated within the practice materials 
for agreements surrounding critiques of neurobiologically based hypotheses of 
depression, the rigor of the DSM, and the c/s/x movement. Here, levels of agreement 
were all in the “very good” range with consensus for critiques of neurobiologically based 
hypotheses of depression yielding a kappa of κ = .851 (p <  .0005). Challenges to the 
DSM’s rigor (κ = 1.00, p < .0005), and critiques of the c/s/x movement (κ = 1.00, 
p < .0005) both showed perfect agreement.  Agreement for critiques of the DSM which 
had not focused on its rigor also yielded a kappa of κ = 1.00 (p < .0005). There were no 
critiques of the c/s/x movement within any of the practice materials. Consequently a 
kappa score for this variable was not calculated.  
 There was complete agreement between the researcher and second coder for the 




the three topics of analysis. In addition, there was full agreement for listed critics whose 
works were cited on topics outside of the study’s analysis (i.e., three listed critics in 
Prescriptive Authority for Psychologists: A History and Guide (2003) and one in The 
Myth of a Chemical Cure (2009)). Both coders identified the same two listed critics 
whose works were cited on one of the two reference pages examined for the practice 
analysis.     
 There were four occasions during the practice coding exercise in which the 
second coder made an administrative error. In two instances, the mistake occurred 
because the second coder missed a heading which identified the primary etiology for 
depression that was discussed. In another case, the second coder interpreted content about 
Kraepelin as pertaining to the DSM’s development. While Kraepelin is inextricably 
linked to the DSM’s origins, this study only focused on content specifically related to 
development of the DSM itself (as outlined within the DSM coding framework).  The 
second coder’s fourth administrative error involved the omission of a listed critic. The 
administrative errors were treated like any other disagreements within the context of 
calculating kappas.  
 Main analysis.  After completing the practice analysis the second coder moved 
on to the main analysis. Each reading was analyzed by the researcher in order to confirm 
that a sufficiently high level of inter-rater agreement had been reached prior to 
proceeding with the examination of additional randomly selected readings.  During this 
process, the researcher informed the second coder about seven administrative errors the 




reference to the neurogenesis hypothesis of depression in a reading from A Primer of 
Drug Action (2011),    
Additionally, in analyzing Essential Evidence Based Psychopharmacology 
(2012), the second coder was informed that she had incorrectly attributed a comment 
about the analeptic agent Modafinil’s mechanism of action, to the etiology of depression.  
Next, in analyzing the American Psychiatric Publishing Textbook of 
Psychopharmacology (2009), the second coder missed a neurobiological hypothesis of 
depression that was explicitly mentioned. There were also two cases within this latter 
textbook and one case within Moynihan and Cassels (2006) text, Selling Sickness, where 
the second coder overlooked an explicit mention of the DSM. The researcher informed 
the second coder about these mistakes and treated the errors like any other disagreements 
when calculating kappas.       
Finally, during the coding of Anatomy of an Epidemic (2011), the researcher 
informed the second coder that she had mistakenly identified the Depression and Bi-Polar 
Support Alliance (DBSA) as a c/s/x organization. The DBSA is not considered a c/s/x 
organization because it receives up to half of its funding from industry contributions and 
the majority of this amount has been linked to pharmaceutical companies (Mark, Levit, & 
Buck, 2009).  
Kappa scores for inter-rater agreements within the main analysis were as follows. 
There was a “good” level of agreement for content on neurobiological etiology’s of 
depression (κ = .741, p < .0005), and a “moderate” level of inter-rater agreements when 
concurrences of no content were excluded (i.e., κ = .555, p < .0005). Inter-rater 




inter-rater agreements for no-content were omitted the kappa dropped to “moderate” 
(κ = .599, p < .0005).  
 Explicit references to the manual were automatically coded within the 
general/applications/guidelines coding category for DSM content. Consequently, it was 
conceivable that agreements for this particular grouping might have been easier to 
achieve than for the other categories (i.e., development, benefits/merits, or 
criticisms/limitations/controversies—including challenges to the manual’s rigor). This 
may have inflated inter-rater reliability levels for DSM content. Consequently, to address 
this, inter-rater agreements for DSM content were recalculated subsequent to removing 
all instances in which both coders concurred about coding for the 
general/applications/guidelines category. This resulted in a “moderate” level (κ = .455, 
p < .0005) of inter-rater agreement for DSM content. 
 Next, both coders agreed that Whitaker’s (2010) book Anatomy of an Epidemic 
was the only randomly selected set of readings to contain information about the c/s/x 
movement. Here, inter-rater agreement for c/s/x content that met the coding category 
requirements for this topic were in the “good” range (κ = .635, p < .0005) unless 
agreements for no c/s/x content were excluded. In this case the kappa dropped to 
“moderate” (κ = .529, p < .0005).     
 When the comparisons of critiques were based upon the same neurobiological 
hypotheses of depression that both raters had identified, there was a “good” level of inter-
rater agreement for these critiques (κ = .625, p < .0005). However, if all theories were 
tallied (i.e., including those where only one rater identified a particular hypothesis) and 




inter-rater reliability dropped to fair (κ = .367, p < .0005). Nonetheless, consensus about 
the lack of a critique is arguably still an agreement regardless of whether or not the 
researchers concurred about the inclusion or exclusion of a particular neurobiological 
hypothesis of depression within that particular portion of the text.     
 Similarly, it made sense to include instances in which there was consensus about a 
critique regardless of whether both coders agreed upon the hypothesis that it represented. 
In this case, the researcher tallied three instances in which a critique was identified for a 
neurobiological hypothesis of depression that only one had coder identified. When these 
three disagreements were included within the analysis of critiques for hypotheses 
identified by both raters, the level of inter-rater reliability remained at a “good” level 
(κ = .719, p < .0005).   
 Inter-rater agreement for critiques of the DSM was in the “very good” range 
(κ = .852, p < .0005). In total, the researcher coded seven pages on which the DSM was 
critiqued, and these critiques were found within two of the 18 materials with content on 
this topic that met coding framework requirements. By comparison, the second coder 
found eight pages in which the DSM had been critiqued within the same two readings. 
The researcher and second coder agreed that the DSM’s construct validity had been 
critiqued on six pages of Selling Sickness (2006). The researcher and second coder also 
agreed that the inter-rater reliability of the DSM had been challenged on one page within 
the paper by Reeves and colleagues (2011). 
 In another case, both coders agreed that the DSM had been critiqued but only the 
researcher characterized this critique as having explicitly challenged the manual’s 




a critique of the DSM—this critique was not characterized as having challenged the 
manual’s rigor.  
 Neither the researcher nor the second coder found critiques of the c/s/x movement 
within the examined materials’ randomly selected readings (including the randomly 
selected pages of Whitaker’s (201) Anatomy of an Epidemic. Both coders agreed on the 
three instances in which a c/s/x activist’s work was cited within Whitaker’s book. This 
included two interviews (one with David Oakes and another with Jim Gottstein) and a 
reference to John Modrow’s (2003) book How to Become a Schizophrenic.  
 In terms of critics, both coders identified David Healy in two works that critiqued 
the neurotransmitter hypothesis of depression’s etiology. Next, the researcher identified 
five materials (four books and one article) whereas the second coder found four materials 
(three books and one article), in which listed critics were cited for issues outside of the 
study’s three topics of analysis. The researcher and second coder were in agreement 
about the names of these listed critics in all cases but one. In this latter instance, only the 
second coder identified content from Peter Breggin as being related to the c/s/x 
movement. Next, six reference pages were analyzed for inter-rater agreement and neither 
coder found any of the listed critics therein.  
Examined Psychologist Postdoctoral Psychopharmacology Program  
 The examined psychologist  psychopharmacology program’s 2013/2014 
curriculum was comprised of 10 classes:   
1. Biological Foundations of Psychopharmacological Practice I 





4. Neuropharmacology  
5. Clinical Pharmacology  
6. Professional Issues and Practice Management  
7. Treatment Issues in Psychopharmacology: Affective Disorders   
8. Treatment Issues in Psychopharmacology: Psychotic Disorders  
9. Anxiety Disorders 
10. Other Disorders   
There was a combined syllabus for the Neuroscience and Neuropharmacology classes 
and for the Biological Foundations of Psychopharmacological Practice I and II courses.  
 The program’s syllabi identified a total of 14 required textbook readings, ten 
recommended books, and a semester project that had students select one of six books. 
The curriculum also included 57 required non-textbooks readings, 26 of which were 
journal articles (see Appendices E, F, G, H, I, J, K). Nine of these journal articles were 
primary source studies—three focused on county-level estimates of coverage by mental 
health professionals, one included a comparison between psychotherapy and 
psychopharmacology, and another focused on the efficacy of psychotherapy. Next, two of 
the journal articles were studies on the efficacy of antidepressants, and two investigated 
the effectiveness of neuroleptics.  
 Of the remaining 17 journal articles, three focused on safe prescribing habits, one 
provided a critique of the pharmaceutical industry, and two papers discussed the 
implications of genetic research and testing on psychopathology and diagnosis. There 
was also a journal article on lab values, another on Warfarin, two journal articles in 




guideline for prescribing psychologists. In addition, there were two journal articles in 
support of prescriptive authority, one on interpreting health statistics, two on the 
pharmacological management of agitated patients, and an article on the use of 
neuroleptics to treat schizophrenia.   
 Next, there were four practice parameters from the American Academy of Child 
and Adolescent Psychiatry (i.e., on ADHD, bipolar disorder, depressive disorders, 
anxiety disorders, respectively),  one practice guideline on PTSD from the Department of 
Defense Veterans Affairs, seven prescription algorithms, five papers with safety 
recommendations for avoiding prescription related medical errors, two assessment 
templates, one template for documenting a treatment plan, a template for clinical notes, 
one prescription template, a measurement conversion chart, and two reports (one on 
mental health surveillance in the US and another on prescribing psychologists’ 
integration of psychotherapy and psychopharmacology). 
 The non-textbook reading materials also included a list of resources for drug 
references, an unpublished “Fact Sheet for Psychologists Prescribing Psychotropic 
Medications,” an unpublished article on Monoamine Oxidase Inhibitors, a newsletter 
focusing on Serotonin Syndrome, and one magazine article on prescribing. Additionally, 
there was a TedTalk video (its transcription was used for this study) which discussed how 
unreported negative findings from drug trials could limit physicians’ knowledge about 
medications and, by proxy, negatively impact a doctor’s prescribing habits. There were 





 For this study, the researcher analyzed ten of the 14 required Non-Semester 
Project (NSP) books, six of the ten recommended texts, all six of the Semester Project 
(SP) books and each of the 57 required non-textbook readings. Four of the required 
readings were omitted from the analysis because the researcher assumed that the required 
Physical Examination and Health Assessment (2012), Clinician’s Pocket Drug Reference 
(2009) and Stahl’s Prescriber’s Guide (2011) were unlikely to contain information about 
the etiology of depression, the DSM, or the c/s/x movement. Next, a required reading on 
ADHD by Joseph Biederman within Lewis’ (2002) textbook, Childhood and Adolescent 
Psychiatry (3rd ed) was excluded because the researcher was unable to obtain a copy of 
the book. Further, the researcher was informed by the examined program’s Director that 
this particular reading had been removed from the curriculum. 
 In terms of the recommended readings, Taber’s Cyclopaedic Medical Dictionary 
(2009) and the Pocket Companion for Physical Examination & Health Assessment (2011) 
were omitted from the analysis because their respective subject areas were outside of the 
study’s topics of focus. Next, the Clinical Handbook of Psychotropic Drugs for Children 
and Adolescents (2007) was excluded from the examination because the researcher’s 
analysis of the Clinical Handbook of Psychotropic Drugs (2011) did not yield any 
substantive findings pertaining to a neurobiological etiology of depression, the DSM, or 
the c/s/x movement. Robert Whitaker, David Healy, and Daniel Carlat, each authored a 
text within the list of six recommended Semester Project books. 
 Finally, the researcher reviewed two of the Program’s 56 videos (i.e., Biology of 
Affective Disorders and Neuropharmacology of Antidepressants and Mood Stabilizers 




50 seconds long, respectively. The researcher did not review the other 54 videos due to 
time constraints and the assumption that these presentations were unlikely to contain any 
substantive information about the three topics of analysis.   
Syllabi 
 Neurobiological etiology of depression.  The combined syllabus for Biological 
Foundations of Psychopharmacological Practice I & II, noted within the course 
description that “The goals of these two courses are to enhance the student’s recognition 
of signs and symptoms of medical conditions requiring collaboration with and referral to 
other health professionals and to provide knowledge about the psychological, biological, 
and medical correlates of disease” (Psychologist Postdoctoral Psychopharmacology 
Program Syllabus, 2014a, p. 4). There were no specific references to depression within 
this syllabus. 
 No references to the etiology of depression were identified within the combined 
Neuroscience and Neuropharmacology syllabus. However, the table of contents included 
a Module on Neurobiology and Pathophysiology (Psychologist Postdoctoral 
Psychopharmacology Program Syllabus, 2013a). Further, the combined Neuroscience 
and Neuropharmacology course description stated that  “Knowledge of principles of 
neuroanatomy, neurophysiology, neurochemistry and neuropathology will serve as the 
foundation for understanding of neurotransmitter systems and their role in the etiology 
and treatment of mental and neurodegenerative disorders” (p. 4). Next, the course 
objectives for this syllabus noted that students would learn to “Identify gross anatomical 




each structure, identify associated function, major dysfunction, and associated pathology” 
(p. 4).  
 The combined Neuroscience and Neuropharmacology syllabus also indicated that 
students would “Describe and correlate the major neurochemical systems associated with 
mental disorders, and psychotropic medications” (Psychologist Postdoctoral 
Psychopharmacology Program Syllabus, 2013a, p. 4).  Next, the objectives for Module 7 
(Neuropharmacology) stated that “Neuropeptides as neurotransmitters and/or 
neuromodulators” would be addressed (2013a, p. 26). In addition, the directed study 
questions for Module 7 queried students about the HPA-Axis and the mechanism by 
which Peptides A and B regulate levels of intracellular cAMP (2013a, pp. 26–27).  
 The Clinical Pharmacology syllabus outlined a “Semester Project”—an 
assignment that “was designed in light of the theme for this semester, which is the 
creation of your personal identity as a critical user of pharmacology in clinical practice” 
(Psychologist Postdoctoral Psychopharmacology Program Syllabus, 2013b, p. 8).  For 
this assignment, students were instructed to “critically evaluate the case made by the 
author” and to conduct “A critical analysis of central arguments” (p. 8). While there were 
no specific references to the etiology of depression within this syllabus, the semester 
project contained the titles of six books (students were required to select one) indicative 
of works that might provide critical perspectives on neurobiological hypotheses for 
depression. The syllabus also noted that “[The semester] project is meant to be fun! Don’t 
be too concerned about grading. The intent here is to get you thinking about how you 
think pharmacotherapy should be integrated into psychology, where standard practice 




 Next, the syllabus for Professional Issues and Practice Management noted within 
its course description that “genetic factors in psychopathophysiology” would be 
addressed (Psychologist Postdoctoral Psychopharmacology Program Syllabus, 2013c, 
p. 3). A description for the Semester Project was also included within this syllabus. The 
Treatment Issues in Psychopharmacology: Affective Disorders syllabus indicated that the 
“Biological Basis for Affective Disorders” would be covered within Module 1 (2014b, 
p. 2). The course description noted that “Biological models of the disorders are reviewed, 
as are classes of medications appropriate to the treatment of mood dysfunction” (2014b, 
p. 3).  
 Course objectives for this class noted that students would learn to “Describe both 
current and recently popular models used to explain the etiology of affective disorders 
from a biological perspective” (Psychologist Postdoctoral Psychopharmacology Program 
Syllabus, 2014b, p. 1).  The syllabus’ learning objectives for Module 1: Biological Basis 
of Affective Disorders stated that the course would “Describe the proposed theories of the 
biochemical basis of depression” (p. 12). In addition, Module 1 and Module 2 for this 
course required that students watch a video on the Biological Basis of Affective Disorders 
and the Pharmacotherapy of Depression, respectively (p. 4). The researcher did not find 
content pertaining to a neurobiological etiology of depression within the Psychotic 
Disorders (Psychologist Postdoctoral Psychopharmacology Program Syllabus, 2014c), 
Anxiety Disorders (Psychologist Psychopharmacology Program Syllabus, 2013d), or 
Other Disorders (Psychologist Postdoctoral Psychopharmacology Program Syllabus, 
2013e) syllabi.   




 DSM.  There were no explicit mentions of the DSM within the combined syllabus 
for Biological Foundations of Psychopharmacological Practice I & II. However, the 
syllabus for this course included an assessment template for documenting a client’s 
“History and Physical Format.” This document also included a section for recording 
“Past Psychiatric History” (Psychologist  Postdoctoral Psychopharmacology Program 
Syllabus, 2014a, p. 12). In addition, this combined syllabus contained an assignment 
titled “History and Physical Evaluation”, which included a section for documenting a 
client’s psychiatric history. These documents were also included within the combined 
syllabi for the Neuroscience and Neuropharmacology classes (Psychologist Postdoctoral 
Psychopharmacology Program Syllabus, 2013a).  
 As noted earlier, the Clinical Pharmacology (Psychologist Postdoctoral 
Psychopharmacology Program Syllabus, 2013b) and the Professional Issues and Practice 
Management (Psychologist Postdoctoral Psychopharmacology Program Syllabus, 2013c) 
syllabi both contained identical descriptions of the Semester Project. While none of the 
Semester Project readings explicitly referred to the DSM or psychopathology, the books’ 
titles were indicative of works that might address diagnostic issues and provide non-
conventional perspectives about the manual.  
 A course description for the Treatment Issues in Psychopharmacology: Affective 
Disorders syllabus stated that “The course assumes a working knowledge of the 
Diagnostic and Statistical Manual criteria for affective disorders, as well as presentation, 
manifestations, and differential diagnosis of these categories” (Psychologist Postdoctoral 




document titled “Case Presentation Format (Mood Disorder)”, which had a section 
allocated for identifying “DSM Diagnosis: Axis I-III” (p. 10).  
 The Treatment Issues in Psychopharmacology: Psychotic Disorders syllabus 
reiterated the expectation that students already possess skills in utilizing the DSM 
(Psychologist Postdoctoral Psychopharmacology Program Syllabus, 2014c, p. 3). In 
addition, the syllabus contained the “Case Presentation Format” template mentioned 
within the previous paragraph (p. 11). The learning objectives for this class’ third Module 
(Antipsychotic Medications) noted that students would “Review symptomatology and 
pathophysiology of psychosis” (p. 15).   
 The Anxiety Disorders syllabus reiterated the aforementioned “Case Presentation 
Format” document and the stipulated expectation surrounding prior experience with using 
the DSM (Psychologist Postdoctoral Psychopharmacology Program Syllabus, 2013d, 
pp. 10–11). In addition, the learning objectives for Module 1: Anxiety Disorders 
Overview noted that students “Should fully understand and be able to discuss each of the 
following: . . . diagnostic classification and prevalence of anxiety disorders: Evolution of 
standardized classification systems (i.e., ICD and/or DSM) and implications for 
neurobiology” (p.13).  Next, the learning objectives for this course’s third Module: 
Special Populations and Genomics stated that students would have opportunities to 
“Discuss population differences that can affect diagnosis and treatment of anxiety 
disorders” (Psychologist Postdoctoral Psychopharmacology Program Syllabus, 2013d, 
p. 16). In Module 4: Confounding Drugs and Disease States, the syllabus noted that “the 
physical work-up and differential diagnosis for general medical conditions and substance 




 The syllabus for the Other Disorders class repeated the expectations that students 
be familiar with the DSM and the course also included the “Case Presentation Format” 
(previously document herein) with space for identifying DSM diagnoses (Psychologist 
Postdoctoral Psychopharmacology Program Syllabus, 2013e, pp. 9–10).   
 C/S/X. There were no explicit references to the c/s/x movement, its organizations, 
or works by c/s/x activists within the syllabi. However, it was plausible that the topic 
might be broached within one or more of the Semester Project’s books based on their 
respective titles and authors. Next, Module 5 for the Professional Issues and Practice 
Management class noted within its learning objectives that students would “Address 
issues of diversity as they impact on our knowledge and practice of pharmacotherapy” —
a comment that could be interpreted as indicative of c/s/x content despite the fact that it 
did not meet the coding category frameworks for this topic (Psychologist Postdoctoral 
Psychopharmacology Program Syllabus, 2013c, p. 17).      
Non-Semester Project Textbooks 
 Etiology of depression. The 16 Non-Semester Project (NSP) textbooks 
collectively addressed twelve different neurobiologically based hypotheses for the 
etiology of depression (i.e.,  neurotransmitters, neuroanatomy/circuits, neuroendocrine 
system/neuropeptides, genetics, neurotransmitter receptors, glutamate, neurotrophins, 
neurogenesis, circadian rhythms, immunological-cytokines, enzymes, and GABA).   For 
a visual representation of the number of neurobiological hypotheses addressed within 





Figure 1. Number of neurobiological hypotheses for the etiology of depression addressed 
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Pathophysiology: The Biological Basis for Disease, 6th ed. (2010) (23 chapters) 
A Primer of Drug Action, 12th ed. (2011) (11chapters) 
Essential Psychopharmacology: Neuroscientific Basis & Practical Applications, 4th ed. (2013) (9 
chapters) 
The American Psychiatric Publishing Textbook of Psychopharmacology (2009) (16 chapters) 
Neurosciences, 5th ed. (2012) (7 chapters; 8 pages from 3 other chapters; Appendix and Atlas) 
Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12th ed. (2010) (38 chapters; 
Appendix 1) 
Pharmacotherapy for Psychologists (2010) (5 chapters) 
Case Studies: Essential Psychopharmacology (2011) (10 chapters)  
Essential Evidence Based Psychopharmacology, 2nd ed. (2012) (3 chapters) 
Clinical Handbook of Psychotropic Drugs 19th ed. (2011) (Entire Book Examined) 
Manual of Clinical Psychopharmacology for Nurses (2013) (Entire Book Examined)* 
Pharmacotherapy: A Pathophysiological Approach, 8th ed. (2011) (2 chapters) * 
Seeley’s Anatomy & Physiology, 9th ed. (2011) (Entire Book Examined)* 
Atlas of Functional Neuroanatomy, 2nd ed. (2005). (Entire Book Examined)* 
Neuroanatomy Through clinical cases, 2nd ed. (2010). (Entire Book Examined)* 
Study guide to Clinical Psychopharmacology: A Companion (2009). (16 chapters)*  





 There was some variability in the extent to which each of the neurobiological 
hypotheses of depression was discussed across the NSP books (see Figure 2). For 
example, the neurotransmitter hypothesis was collectively addressed on 44 pages of these 
texts in a manner that met the coding framework requirements for this topic.  By contrast 
the neuroendocrine/neuropeptides hypothesis was discussed on 28 pages, genetics 
(19 pg’s), neurogenesis (21 pg’s), neuroanatomical/circuits (11 pg’s), neurotransmitter 
receptors (13 pg’s), neurotrophins (7 pg’s), glutamate (8 pg’s), circadian rhythms 
(6 pg’s), immunological-cytokines (1 pg.), enzymes (1 pg.), and GABA hypothesis on 
one page of text, in a manner that met the coding framework requirements.  
 
Figure 2. Total number of pages for neurobiological hypotheses of depression content 
that met coding category requirements within examined non-semester project books.  
 
 Eleven of the 16 examined NSP textbooks addressed one or more neurobiological 




of the neurobiological hypotheses for depression discussed. Pathophysiology: The 
Biological Basis for Disease in Adults and Children (2010) was the only NSP textbook to 
critique all four of the neurobiological hypotheses of depression addressed therein—these 
hypotheses and critiques were all focused on Pre-Menstrual Dysphoric Disorder. See 
Figure 3 for a visual representation of the number of hypotheses discussed and critiqued 
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Figure 3.Number of neurobiological hypotheses for the etiology of depression addressed 
and critiqued within examined non-semester project books, and meeting coding category 
requirements.  
 
Pathophysiology: The Biological Basis for Disease, 6th ed. (2010) (23 chapters) 
A Primer of Drug Action, 12th ed. (2011) (11chapters) 
Essential Psychopharmacology: Neuroscientific Basis & Practical Applications, 4th ed. (2013) (9 chapters) 
The American Psychiatric Publishing Textbook of Psychopharmacology (2009) (16 chapters) 
Neurosciences, 5th ed. (2012) (7 chapters; 8 pages from 3 other chapters; Appendix and Atlas) 
Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12th ed. (2010) (38 chapters; App. 1 
examined) 
Pharmacotherapy for Psychologists (2010) (5 chapters examined) 
Case Studies: Essential Psychopharmacology (2011) (10 chapters examined)  
Essential Evidence Based Psychopharmacology, 2nd ed. (2012) (3 chapters) 
Clinical Handbook of Psychotropic Drugs 19th ed. (2011) (Entire Book Examined) 
Manual of Clinical Psychopharmacology for Nurses (2013) (Entire Book Examined)* 
Pharmacotherapy: A Pathophysiological Approach, 8th ed. (2011) (2 chapters) * 
Seeley’s Anatomy & Physiology, 9th ed. (2011) (Entire Book Examined)* 
Atlas of Functional Neuroanatomy, 2nd ed. (2005). (Entire Book Examined)* 
Neuroanatomy Through Clinical Cases, 2nd ed. (2010). (Entire Book Examined)* 
Study guide to Clinical Psychopharmacology: A Companion (2009). (16 chapters examined)*  





 Examined Non-Semester Project books with analyzed required readings that 
discussed one or more neurobiologically based hypotheses for the etiology of depression 
included, Pathophysiology: The Biological Basis for Disease, Neurosciences (2010), 
Primer of Drug Action (2011), Goodman & Gilman's: The Pharmacological Basis of 
Therapeutics (2010), Stahl’s Essential Psychopharmacology (2013), Neurosciences 
(2012), Essential Evidence Based Psychopharmacology (2012), Case Studies: Essential 
Psychopharmacology (2011), American and the Psychiatric Publishing Textbook of 
Psychopharmacology (2009). Recommended books with readings that discussed one or 
more neurobiologically based hypotheses for the etiology of depression included the 
Manual of Clinical Psychopharmacology  for Nurses (2013), Neuroanatomy Through 
Clinical Cases (2010) and the Study Guide for Psychopharmacology (2009)—the former 
two of these three books were read in their entirety. The researcher did not find content 
on a neurobiological etiology of depression within the examined chapters of the required 
Pharmacotherapy for Psychologists (2011) or within Pharmacotherapy: A 
Pathophysiologic Approach (2011), Clinical Handbook of Psychotropic Drugs (2011), 
Seeley’s Anatomy and Physiology (2011) and, the Atlas of Neuroanatomy (2005)—all 
three of these latter books were examined in their entirety.   
 The ratio of hypotheses to critiques for the examined chapters of the six NSP 
textbooks that incorporated challenges for neurobiologically based hypotheses of 
depression were as follows: Pathophysiology: The Biological Basis for Disease = 4:4, 
A Primer of Drug Action = 8:2, Essential Psychopharmacology: Neuroscientific Basis & 
Practical Applications = 10:3, American Psychiatric Publishing Textbook of 




Therapeutics = 3:1, and the Manual of Clinical Psychopharmacology  for Nurses = 3:2 
(see Figure 3).    
 Heterogeneity was also reflected in the number of pages containing information 
and critiques for neurobiological hypotheses of depression within the analyzed NSP 
textbook readings (see Figure 3). For example, a neurotransmitter hypothesis of 
depression was absent in some texts but addressed with varying degrees of depth on up to 
18 pages in other books. Further, neurobiological based hypotheses of depression were 
critiqued on one to three pages of the six NSP books that provided challenges for these 
hypotheses. The following paragraphs will discuss each of the six NSP books that 
contained one or more neurobiological hypothesis of depression and at least one critique 
of one or more of these hypotheses. 
 In Pathophysiology: The Biological Basis for Disease, four neurobiological 
hypotheses for premenstrual disorders were discussed (i.e., neurotransmitters, 
neuroendocrine, genetics, GABA) (McCance, Huether, Brashers, & Rote, 2010).  The 
authors critiqued each of these hypotheses with one summative statement (i.e., “the 
mechanisms involved are not known”) (Latendresse, McCance, & Morgan, as cited in 
McCance et al., 2010, p. 826). In a discussion about fibromyalgia, the textbook also noted 
the “major role for neuroendocrine and stress response alterations” in mood disorders, 
and stated that “Altered circadian activity of several neuroendocrine axes and ANS 
dysfunction have been reported (Martinez-Lavin, 2007)” (Crowther-Radulewicz & 
McCance, as cited in McCance et al., 2010, p. 1607).  This latter comment about a 




 In A Primer of Drug Action, Julien and colleagues (2011) discussed eight 
neurobiological hypotheses for depression and challenged two (i.e., the neurotransmitter 
and neurotransmitter receptor hypotheses). The neurotransmitter hypothesis was critiqued 
on two of the four pages in which it was discussed (i.e., pp. 142, 150). Here, the authors 
noted that the lag time in antidepressants’ effects was “a weakness of this model” 
(p. 142), and stated that the “[chemical imbalance] interpretation is much too simplistic” 
(p. 150). The neurotransmitter receptor hypothesis was also critiqued via the latter 
sentence.   
 In Essential Psychopharmacology: Neuroscientific Basis and Practical 
Applications (2013), ten neurobiological hypotheses for the etiology of depression were 
identified. This included the neurotransmitter hypotheses of depression which were 
discussed to varying degrees on 18 pages—three of these pages contained a critique of 
this hypothesis. For example, Stahl (2013) noted that the initial conceptualization of the 
monoamine hypothesis was “rather simplistic” and stated that definitive evidence in 
support of the hypothesis was “still largely lacking” (p. 262).  
 In addition, Stahl (2013) noted that efforts to uncover monoamine deficiencies in 
depression had “yielded mixed and sometimes confusing results” (p. 262), and that there 
was “no clear and convincing evidence that monoamine deficiency accounts for 
depression—i.e., there is no ‘real’ monoamine deficit” (p. 266). In addition, the textbook 
posited that the lag time for antidepressants’ results presented a “problem” for this 
hypothesis (p. 290).  
 Next, Stahl (2013) addressed the neurotransmitter receptor hypothesis of 




generally lacking” (p. 266). In addition, the text noted inconsistencies and replication 
issues with neuroimaging data used to support this hypothesis (p. 266). A genetic source 
for depression was challenged on three of the 13 pages in which this particular premise 
was discussed. Each of these critiques acknowledged that a single gene for depression 
had not been identified. More specifically, it was noted that the specific genotype for 
SERT “accounts for only a small amount of the variance” of the disorder’s etiology 
(p. 272). The text also posited that genetics might predispose a person towards 
depression, particularly with the addition of environmental stressors. Additionally, Stahl 
discussed glutamate, neuroendocrine/neuropeptide, neurogenesis, circadian rhythm, and 
enzyme hypotheses for the etiology of depression, but without critiques.      
 In the examined sections of Schatzberg and Nemeroff’s (2009), American 
Psychiatric Publishing Textbook of Psychopharmacology, four of the seven 
neurobiological hypotheses of depression discussed were also critiqued (i.e., the 
neurotransmitter receptor, genetic, glutamate, and neurogenesis theories of depression 
were challenged).  Critiques were integrated within one of the three pages addressing the 
neurotransmitter receptor hypothesis, one of four pages that discussed a genetic 
neurobiological etiology for depression, one of three pages which outlined the glutamate 
hypothesis for depression, and within two of four pages examining the neurogenesis 
hypothesis.  
 Next, a critique of the neurotransmitter receptor hypothesis stated that “In regions 
postsynaptic to ascending raphe neurons such as prefrontal cortex, altered levels of 
5-HT1A receptor binding have been found in the prefrontal cortex of depressed suicide 




Cheetham et al., 1990)” (Robinson, Rickels, & Yocca, as cited in Schatzberg & 
Nemeroff, 2009, p. 488).  
 Genetic correlates for depression were discussed within four pages and critiqued 
on one page of the examined chapters from American Psychiatric Publishing Textbook of 
Psychopharmacology (2009). The critique occurred within a discussion linking the 
disorder to mutated gene coding for the purinergic receptor P2X7. Here, the textbook 
posited that “The function of the P2X7 receptors in the context of depression is not clear” 
(Holsboer, as cited in Schatzberg & Nemeroff, 2009, p. 521). The glutamate hypothesis 
for the disorder was addressed within three pages of text (i.e., pp. 25, 513, 514) and 
critiqued on one of these pages. In this instance, the textbook noted that “Although not 
always conclusive, in vivo magnetic resonance imaging (fMRI) studies have revealed 
altered glutamate levels in various brain areas (Auer et al., 2000; Sanacora et al., 2004) as 
well as in the CSF (Frye et al., 2007) of depressed patients” (p. 513).  
 Next, the author addressed the proposed role of neurogenesis in depression to 
varying degrees on four pages of the examined portions of The American Psychiatric 
Publishing Textbook of Psychopharmacology (Holsboer as cited in Schatzberg & 
Nemeroff, 2009) (i.e., pp. 493, 519, 520, 521). In this case, critiques for the hypothesis 
were provided on two pages. For example, the text posited that “altered plasma BDNF 
concentrations were reported in affective disorders (Machado-Vierira et al., 2007; 
Shimizu et al., 2003), although the source of this neurotrophin in blood remains to be 
elucidated” (Schartzberg & Nemeroff, 2009, p. 519). Further, in a discussion about 




individuals, but it is not entirely clear from where this neurotrophic factor derives” 
(p. 521).  
 In the Goodman and Gilman’s: The Pharmacological Basis of Therapeutics 
readings, three neurobiological hypotheses of depression were discussed (i.e., 
neurotransmitter, genetics, and neuroendocrine/neuropeptides) (Brunton, Chabner, & 
Knollman, 2010). The neuroendocrine/neuropeptides hypothesis was critiqued within one 
of two pages on which the hypothesis was addressed. Here, the textbook stated that “the 
physiological/ pathophysiological relevance of these findings is controversial, and some 
actions of vasopressin on memory and learned behavior may be due to visceral 
autonomic effects” (p. 708).    
 The Manual of Clinical Psychopharmacology for Nurses (2013) (a recommended 
reading examined in its entirety) addressed three hypotheses (i.e., neurotransmitters, 
neuroanatomical/circuits, neuroendocrine/ neuropeptides) on five, two, and two pages, 
respectively (Leahy & Kohler, 2013). This textbook critiqued two of the three hypotheses 
presented. For example, in addressing the neurotransmitter and neuroendocrine 
hypotheses for Pre-Menstrual Dysphoric Disorder, the textbook noted that:  
it has long been believed that PMDD is caused by a complex set of interactions 
between the woman’s reproductive hormones (progesterone and estrogen) and the 
brain’s neurotransmitters, especially serotonin. Because the selective serotonin 
reuptake inhibitor (SSRI) antidepressants have been used to treat PMDD and have 
shown efficacy, this would seem to hold true; however, this interaction is not yet 
fully understood. (Josey & Neidert, as cited in Leahy & Kohler, 2013, p. 66)  
 
The neuroanatomy/circuits hypothesis for PMDD (i.e., abnormalities in the orbitofrontal 




 DSM.  Findings for the number of pages with DSM content that met coding 
requirements within the analyzed Non-Semester Project textbooks’ examined readings 
are as follows (also see Appendix R). Eleven of the 16 NSP textbooks contained 
information about the DSM. This information was disseminated on 121 pages of text and 
focused primarily on discussing the manual in general terms, as well as describing its 
guidelines, and applications. The development of the manual was discussed to varying 
degrees on 26 pages and its benefits and strengths were identified on three pages.  
 There were 13 pages on which criticisms, limitations and/or, controversies about 
the manual were found (see Figure 4).  Six of these pages identified problems with the 
manual’s construct validity. The researcher found one instance in which the DSM’s 
reliability was challenged. The researcher did not find critiques of the manual’s inter-
rater reliability and there were no examples of statistics pertaining to the DSM’s 
empirical rigor. No references were made to the researcher’s listed critics within the 





 = Number of pages with content critiquing the DSM’s construct validity (CV) 
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Figure 4. Number of examined non-semester project textbooks’ analyzed pages that 
contained challenges to the dsm’s construct validity or inter-rater reliability, that met 
coding category requirements.  
 
Pathophysiology: The Biological Basis for Disease, 6th ed. (2010) (23 chapters) 
A Primer of Drug Action, 12th ed. (2011) (11chapters) 
Essential Psychopharmacology: Neuroscientific Basis & Practical Applications, 4th ed. (2013) (9 chapters) 
The American Psychiatric Publishing Textbook of Psychopharmacology (2009) (16 chapters) 
Neurosciences, 5th ed. (2012) (7 chapters; 8 pages from 3 other chapters; Appendix and Atlas) 
Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12th ed. (2010) (38 chapters; Appendix 
1) 
Pharmacotherapy for Psychologists (2010) (5 chapters) 
Case Studies: Essential Psychopharmacology (2011) (10 chapters)  
Essential Evidence Based Psychopharmacology, 2nd ed. (2012) (3 chapters) 
Clinical Handbook of Psychotropic Drugs 19th ed. (2011) (Entire Book Examined) 
Manual of Clinical Psychopharmacology for Nurses (2013) (Entire Book Examined)* 
Pharmacotherapy: A Pathophysiological Approach, 8th ed. (2011) (2 chapters) * 
Seeley’s Anatomy & Physiology, 9th ed. (2011) (Entire Book Examined)* 
Atlas of Functional Neuroanatomy, 2nd ed. (2005). (Entire Book Examined)* 
Neuroanatomy Through clinical cases, 2nd ed. (2010). (Entire Book Examined)* 
Study guide to Clinical Psychopharmacology: A Companion (2009). (16 chapters)*  





 In examining the 23 required chapters of Pathophysiology: The Biological Basis 
for Disease (2010), the researcher found four pages with DSM content. Two of these 
pages addressed the DSM-IV’s diagnostic criteria for Premenstrual Dysphoric Disorder 
(PDD) and identified problems associated with PDD’s construct validity. For example, 
the textbook noted that “inconsistent and overlapping use of terminology and criteria are 
used to describe these syndromes.” (Latendresse, McCance, & Morgan, as cited in 
McCance et al., 2010, p. 826).  In addition the authors asserted, “many women with 
clinically relevant premenstrual syndrome/premenstrual Dysphoric disorder 
(PMS/PMDD) symptoms do not meet the full criteria of the DSM-IV” (p. 827). The other 
two pages of DSM content within this textbook focused on the diagnostic criteria for 
anorexia nervosa, albeit without any critiques (McCance et al., 2010).  
 The DSM was addressed within four pages of the eleven examined chapters from 
A Primer of Drug Action (2011). This included two pages which discussed the diagnostic 
criteria of a major depressive episode, and one page on which differences in the 
diagnostic category for anxiety prior to the DSM-III were noted. The fourth page 
identified the manual in a discussion about prescriptive authority, which the authors 
noted could add to psychologists’ “armamentarium of treatment modalities for DSM-IV 
diagnoses” (Julien et al., 2011, p. 682). One page (i.e., p.128) within the Neurosciences 
(2012) readings referred to the DSM’s definition of addiction. Next, in discussing the 
“Diagnosis Phase” of a “psychobiosocial” approach, Pharmacotherapy for Psychologists 
identified the DSM on two pages of text within the five chapters examined for this study 
(McGrath & Moore, 2010, p. 110). The manual was both critiqued and supported via the 




Additionally, the authors asserted that “A critical analysis of these diagnostic systems is 
tangential to the substance of this chapter” (p. 110).  
 Stahl’s Essential Psychopharmacology: Neuroscientific Basis & Practical 
Applications (2013), addressed the DSM in a manner consistent with the study’s coding 
framework requirements, on 12 pages of the nine chapters analyzed.  For example, Stahl 
referred to the manual in discussions about “The Symptom Dimensions of 
Schizophrenia” (p. 79), “The Bipolar Spectrum” (pp. 247–249), in distinguishing 
unipolar depression from bipolar depression (i.e., p. 250), in identifying the “Mixed states 
of mania and depression” (p. 253), in proposing the “Symptoms and circuits” of 
depression and mania (pp. 273, 277, 278, 279) and in presenting a “Symptoms Based 
Algorithm for Antidepressants” (pp. 355, 356).  There were two pages in which Stahl 
challenged the DSM’s construct validity. Here, the text discussed instances in which a 
patient experienced a manic or hypomanic episode while taking an antidepressant. For 
example, Stahl (2013) noted that:   
Patients who develop a manic or hypomanic episode on antidepressants are 
sometimes called bipolar III. According to formal diagnostic criteria, however, 
when an antidepressant causes mania or hypomania, the diagnosis in not bipolar 
disorder, but rather, ‘substance induced mood disorder.’ Many experts disagree 
with this designation and feel that patients who have a hypomanic or manic 
response to an antidepressant do so because they have a bipolar spectrum 
disorder, and can be more appropriately diagnosed as bipolar III disorder. (p. 247)  
 
 Next Stahl (2013) referenced the manual within the context of discussing the 
Research Domain Criteria (RDoC) which the author described as the “future of 
psychiatry” and an improvement over the DSM which describes “categorical syndromes 
that mix together many symptoms” (p. 474). There were two pages within the ten 




content about the DSM which met the study’s coding requirements for this topic (Stahl, 
2011a). The first was a case in which a pharmacological intervention was being proposed 
for an individual who “probably has never reached the threshold of experiencing 
unequivocal hypomania as defined by DSM-IV or ICD-10” (p. 72). In the second 
reference to the manual, Stahl questioned the DSM’s construct validity with respect to its 
conceptualization of antidepressant induced mania. Here, the author queried whether 
“Despite DSM-IV is Substance Induced Mood Disorder a form of bipolar disorder that 
should be treated as such?” (p. 352).  
 Content about the DSM meeting coding framework criteria within the 17 
analyzed chapters of The American Psychiatric Publishing Textbook of 
Psychopharmacology, focused on a variety of topics (Schatzberg & Nemeroff, 2009). For 
example, the text referred to the manual’s definition of “substance (drug) dependence” 
(Sheehan & Raj, as cited in Schatzberg & Nemeroff, 2009, p. 474) and provided the 
criteria for the DSM’s substance dependence disorder (i.e., p. 475). The DSM was also 
briefly referenced within discussions about research on psychotropic prescription drug 
abuse and the efficacy of benzodiazepines, antidepressants, and stimulants. Here, the 
DSM-II, DSM-III, DSM-III-R, and DSM-IV were cited in discussions about studies’ 
methodologies (i.e., pp. 475, 476, 489, 1182, 1185, 1186, 1322, 1418). 
 For example, the text referred to the DSM-II and DSM-III-R within the context of 
citing research that investigated the efficacy of anxiolytic’s for anxiety and depression 
(Schatzberg & Nemeroff, 2009, pp. 491, 496). Next, the manual was referenced in 
discussing OCD and its categorization as an anxiety disorder. The authors for this chapter 




distinct or representative of “subtle variations of a shared etiology?” (Amiel, Mathew, 
Garakani, Neumeister, & Charney, as cited in Schatzberg & Nemeroff, 2009, p. 979).      
 In chapter 49 (Neurobiology of Substance Abuse and Addiction), Kennedy and 
Kilts briefly mention the DSM-IV-TR in discussing drug addiction (as cited in 
Schatzberg & Nemeroff, 2009, p. 1007).  Next, the manual was cited in a discussion 
about research on the prevalence and population estimates of individuals diagnosed with 
psychiatric disorders (p.1020). In chapter 51 (Neurobiology of Personality Disorders), 
Lee and Coccaro addressed the characteristics of personality disorders represented within 
the DSM-IV-TR and ICD-10 (as cited in Schatzberg & Nemeroff, 2009, p. 1045).   In 
chapter 55, Treatment of Schizophrenia, the criteria for the disorder and some aspects of 
its Kraepelinian and post-Kraepelinian evolution were described (i.e., p. 1137).  
 The first of two critiques of the DSM (that met the study’s coding criteria) 
occurred within the context of discussing the psychopharmacological treatment of general 
anxiety disorder (Schatzberg & Nemeroff, 2009). Here, in addressing the evolution of 
GAD’s diagnostic criteria, Davidson, Connor, and Zhang questioned the disorder’s 
construct validity noting that:  
A degree of uncertainty still hangs over the most appropriate way to classify GAD 
[General Anxiety Disorder]. Even as DSM-IV was being crafted debate centered 
around the extent to which GAD could be separated from mood disorders, such as 
dysthymia and major depression. This question has never been well resolved, and 
it is possible that with so much in common between GAD and depressive 
disorders, its classification primarily  as an anxiety disorder may change in DSM-
V. (as cited in Schatzberg & Nemeroff, 2009, p. 1182) 
  
This chapter also mentioned the inclusion of Acute Stress Disorder within the context of 




  Additionally, The American Psychiatric Publishing Textbook of 
Psychopharmacology briefly referred to the DSM-IV-TR in a discussion about incidence 
rates for Nicotine use (i.e., p. 1215) and in mentioning the manual’s “course specifier ‘on 
agonist therapy’” within the context of discussing the use of methadone or buprenorphine 
for maintenance treatment of opioid dependence (O’Brien & Dackis, as cited in 
Schatzberg & Nemeroff, 2009, p. 1221).  The text also noted the manual’s diagnostic 
criteria for primary insomnia (i.e., pp. 1254, 1255, 1256). 
 The second and last critique of the DSM within the examined readings for this 
textbook was located within the chapter, Treatment of Childhood and Adolescent 
Disorders (Wagner & Pliszka, as cited in Schatzberg & Nemeroff, 2009). Here it was 
posited that “Although DSM-IV-TR criteria are used to diagnose bipolar disorder in 
youths, the clinical features in children may differ from those in adolescents and adults” 
(Wagner & Pliszka, as cited in Schatzberg & Nemeroff, 2009, p. 1315). This chapter also 
referenced the DSM in discussing obsessive compulsive disorder, general anxiety 
disorder, social anxiety disorder, separation anxiety disorder, post-traumatic stress 
disorder, oppositional defiance disorder, Tourette’s, schizophrenia, autistic disorders and 
other pervasive developmental disorders in children (i.e., pp. 1319, 1320, 1322, 1323, 
1324, 1330, 1335, 1340, 1341). 
 The researcher found 57 pages of text within the Manual of Clinical 
Psychopharmacology for Nurses (2013) that addressed the DSM in a manner consistent 
with coding criteria for this topic. This book was examined in its entirety. The text’s 
forward noted that “In particular, contents of each chapter focus on diagnostic criteria and 




diagnostic criteria for anxiety disorders, depressive disorders, bipolar disorders, psychotic 
disorders, attention deficit/hyperactivity and autism spectrum disorders, substance use 
disorders, sleep wake disorders, Post-Traumatic Stress Disorder, and delirium, to varying 
degrees on 55 pages.   
 The book also discussed the DSM-IV-TR’s Outline for Cultural Formulation and 
Glossary of Culture-Bound Syndromes, (i.e., pp. 390, 391, 394) (Leahy & Kohler, 2013). 
Next, the manual was cited in discussing psychiatric emergencies (i.e., pp. 310, 317, 320, 
321). In this context, the text identified the DSM criteria for substance intoxication, 
withdrawal and delirium, and in defining personality disorders. The manual was also 
cited within instructions for the Adult ADHD Self-Report Scale (i.e., p. 455).  
 There were six instances in which content met the study’s coding criteria for the 
DSM’s “development” category (i.e., pp. 85, 130, 131, 156, 236, 237) (Leahy & Kohler, 
2013). In one of these instances the text noted that “In recent years, many developments 
in diagnosing and treating bipolar disorder have emerged” (Knight, as cited in Leahy & 
Kohler, 2013, p. 85). Here, Knight acknowledged that questions remained about whether 
the concept of bipolar illness was best conceptualized as a discrete category or a spectrum 
disorder. In addition, the book’s chapter on Psychotic Disorders posited that changes in 
the DSM diagnostic criteria for delusional disorders had complicated attempts to compare 
research results across time (i.e., p. 130).  Finally, the manual’s development was 
discussed within the context of addressing the evolving diagnostic criteria for attention 
deficit hyperactive disorder (i.e., p. 156), post-traumatic stress disorders (i.e., p. 236, 




 The researcher found four critiques of the DSM within the Manual of Clinical 
Psychopharmacology for Nurses (2013). For example, Knight noted that the question of 
whether or not a categorical approach to diagnosing bipolar disorder was preferable to a 
dimensional method “had been the subject of considerable debate” (as cited in Leahy & 
Kohler, 2013, p. 89). Further, the potential benefits and pitfalls of expanding the 
definition to include bipolar spectrum disorder were considered.  
 One of the four critiques of the DSM within this text could be interpreted as a 
challenge to the manual’s construct validity and inter-rater reliability (Leahy & Kohler, 
2013). For example, in the chapter on Bipolar Disorders Knight posited that “About 69% 
of all patients with bipolar disorder are inaccurately diagnosed” (as cited in Leahy & 
Kohler, 2013, p. 89). However, the text did not clarify what the source of the inaccurate 
diagnosis was (i.e., a problem with the manual or insufficient training of the clinician). 
Next, in discussing ADHD, the textbook noted that “ADHD has been a diagnosis fraught 
with much controversy” (Varley & Leahy, as cited in Leahy & Kohler, 2013, p. 156).  At 
the same time, Varley and Leahy asserted that “Today we know that the symptoms 
related to ADHD are neurodevelopmental in origin. Despite the controversies, the core 
symptoms of the disorder—reduced attention span, distractibility, difficulty focusing, and 
hyperactivity—have remained throughout” (as cited in Leahy & Kohler, 2013, p. 156).   
 The researcher found three pages of text with content that met the coding criteria 
for the DSM within one of the two chapters examined in Pharmacotherapy: A 
Pathophysiologic Approach (2011). In the chapter, Evaluation of Psychiatric Illness, 
Schneiderhan, Nelson, and Munro provided an overview of the manual’s origins and 




cited in Dipiro et al., 2011, p. 1077, 1078). Additionally, it was noted that “The DSM-IV-
TR contains many components that provide a comprehensive understanding of specific 
mental illnesses and assist in making an accurate diagnosis” (Schneiderhan et al., as cited 
in Dipiro et al., 2011, p. 1078). 
 In the 17 chapters and six pages examined within the Study guide to Clinical 
Psychopharmacology: A Companion, the researcher found that the DSM-III, DSM-III-R, 
and DSM-IV were cited on page 350 within the context of discussing drug trials for 
PTSD. 
 C/S/X. The researcher did not find content about the c/s/x movement within the 
analyzed Program’s examined Non-Semester Project textbook readings. 
Semester Project Textbooks 
 Etiology of depression.  One of the six Semester Project (SP) books presented six 
neurobiological hypotheses for depression’s etiology, while another examined two 
hypotheses, and four of the SP books discussed one hypothesis. There was one case in 
which a SP textbook did not critique a hypothesis (i.e., genetic) that was discussed (i.e., 
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Figure 5. Number of neurobiological hypotheses for the etiology of depression and 




Number of Pages With Content on a Neurobiological Etiology of Depression and 
Critiques for These Hypotheses (in brackets) Meeting Coding Category Requirements 
within Semester Project Books 
 
SP Book Title NT NTRE NTROP N/C GEN GABA GLUT NE/NP NGEN IMM CR ENZ
Unhinged 10(9) 0 1(1) 2(2) 2(2) 0 1(1) 1(1) 0 0 0 0
Medicalizatio
n of Society
0 0 0 0 1 0 0 0 0 0 0 0
Selling Sicknes 5(5) 0 0 0 0 0 0 0 0 0 0 0
Let Them Eat 
Prozac
20(13) 0 0 0 1 0 0 0 0 0 0 0
Psychotropic 
RX Guide
1(1) 0 0 0 0 0 0 0 0 0 0 0
Anatomy of 
an Epidemic
21(15) 0 0 0 0 0 0 0 0 0 0 0
 
Note. Number of pages with critiques of each hypothesis identified within brackets ( ). NT: 
Neurotransmitter; NTREC: Neurotransmitter Receptor; NTROP: Neurotrophins/Proteins; N/C: 
Neuroanatomy/Circuits; GEN: Genetics; GABA; GLUT: Glutamate; NE/NP: 
Neuroendocrine/Neuropeptides; NGEN: Neurogenesis; IMM: Neuromodulators/Inflammation/Neuro-
immunological; CR: Circadian Rhythm; EN: Enzymes; AD: Adrenergic-Cholinergic Balance Hypothesis; 




 The number of pages with content on a neurobiological hypothesis for depression 
within the Semester Project books ranged from zero to 21 (see Table 1). Critiques for 
these hypotheses were disseminated on between 65% (i.e., 13/20) and 100% of the pages 
on which they premises were addressed. The neurotransmitter hypothesis was covered by 
five of these books and it was also the most commonly discussed neurobiological 
hypothesis therein (i.e., the neurotransmitter hypothesis of depression was discussed to 
varying degrees on 57 pages of these books). Additionally, the chemical imbalance 
hypothesis was critiqued on nine of the ten pages which addressed the hypothesis within 
Unhinged (Carlat, 2010).  In Selling Sickness (Moynihan & Cassels, 2006) all five of the 
pages addressing this hypothesis included a critique. Thirteen of 20 pages addressing the 
chemical imbalance hypothesis of depression in Let Them Eat Prozac also contained a 
critique (Healy, 2003). Next, the neurotransmitter hypothesis of depression was 
mentioned and challenged on one page within the Psychotropic Drug Prescriber’s 
Survival Guide (Dubovsky & Dubovsky, 2007), and on 15 of 21 pages within Anatomy of 
an Epidemic (Whitaker, 2010).  
 Carlat’s (2010) book also dealt with the neurotrophic (i.e., 1 page), 
neuroanatomy/circuits (i.e., 2 pages), genetics (i.e., 2 pages), glutamate (i.e., 1 page), and 
neuroendocrine/neuropeptides (i.e., 1 page) hypotheses of depression. In all but one case 
(i.e., one of the ten pages on which the neurotransmitter hypothesis was discussed) Carlat 
critiqued the neurobiological hypotheses for depression’s etiology that were addressed.  
 For example, in challenging the neurotransmitter hypothesis of depression the text 
stated that “we are still far away from a true understanding of the biological causes of 




regard” (p. 6). Carlat also quoted the American Psychiatric Association Publishing 
Textbook of Psychopharmacology (2009) as having asserted that the “central question of 
what variables drive the pathophysiology of mood disorders remains unanswered” (as 
cited in Carlat, 2010, p. 6). Next, in referencing the chemical imbalance hypothesis, 
Carlat asserted that “direct evidence of such a deficiency is lacking” (p. 7).  
 Similarly, Carlat (2010) challenged the veracity of neuroimaging findings 
typically used to support neurobiological hypotheses of depression.  Unhinged also 
discussed the methodological limitations of measuring neurotransmitter levels within 
body fluids and the use of this data to support neurobiological hypotheses of depression. 
Next, Carlat posited a colleague’s supposition that longstanding maladaptive behaviors 
were more likely to be the source of depression than any “chemical imbalance” (p. 29).   
 In further critiquing the monoamine hypothesis of depression (i.e., pp. 74, 75, 76, 
77, 78, 82) Carlat (2010) pointed to “increasingly elaborate theories about ‘downstream’ 
effects of antidepressants, in which neurotransmitters set into motion a cascade of 
biochemical events that eventually cause genes to be activated” (p. 78). In addition, 
Carlat noted that delays in antidepressants’ effects effectively undermine hypotheses that 
are based upon the existence of chemical imbalances.    
  In one of the two pages within Unhinged that addressed a 
neuroanatomical/circuits hypothesis of depression, Carlat (2010) questioned the 
relevance of various research findings that have been linked to the disorder (i.e., 
“decreased activity in the frontal lobe, a shrunken hippocampus, an oversized amygdalae, 
disrupted circuits around the basal ganglia, and miscellaneous abnormalities in the 




neuroanatomical/circuits hypothesis for the disorder, Carlat deconstructed an outdated 
hypothesis about the purported connection between depression and “temporal lobe 
epilepsy” (p. 40).       
 Next, genetic correlates for a neurobiological hypothesis of depression were 
discussed on two pages of Unhinged, with Carlat (2010) asserting that genes undoubtedly 
play a role in mental disorders. However, the text also posited that research findings 
linking specific genotypes to the disorder have been inconsistent (i.e., pp. 80, 81). The 
glutamate, neuroendocrine, neurotrophin and neurotransmitter hypotheses of depression 
were supported and critiqued within the summative statement that “Researchers have 
found evidence of abnormalities in serotonin, norepinephrine, dopamine, cortisol, 
thyroid, growth hormone, glutamate, and brain derived neurotrophic factor—yet no 
specific defect has been identified” (p. 6).  
 In Selling Sickness, Moynihan and Cassels (2005) discussed and critiqued the 
neurotransmitter hypothesis for depression to varying degrees on five pages of text. For 
example, the authors stated that:  
As specialists in mental illness remind us, the idea that depression is caused by a 
deficiency of the brain chemical serotonin is in fact just one scientific view 
among many— and a simplistic and outdated one at that. But it is a theory kept 
very much alive by the massive marketing machinery that starts with the morning 
deliveries of pharmaceutical  company sales representatives. (p. 23) 
  
 In the same vein, Moynihan and Cassels (2005) cited Healy in their assertion that 
“early theories suggesting that a serotonin imbalance cause’s depression have not been 
verified by later research” (p. 27). The authors also posited that pharmaceutical 
companies had a vested interest in disseminating this hypothesis to promote the sale of 




depression, there is much scientific uncertainty about whether these difficulties are 
primarily due to biological and chemical problems in the brain, or are the result of a 
complex interplay of physical, social, cultural, or economic factors” (p.64).    
 In Let Them Eat Prozac, Healy (2003) referred to the neurotransmitter hypothesis 
for depression to varying degrees on 20 pages of text and challenged the hypothesis on 13 
of these pages. For two of these critiques, Healy (2003) cited his own work (2000, 2001). 
In challenging the neurotransmitter hypothesis of depression Healy stated that: 
This mass creation of depression affects even those who are not depressed. It is 
now widely assumed that our serotonin levels fall when we feel low, and that this 
lowering is thought to have consequences for everything from diet to criminality. 
But there is no evidence for any of this, nor has there ever been. The huge gap 
between what is scientifically demonstrable and what people believe points to a 
cultural fact that lies well beyond the ‘medicalization’ so worrying to sociologists 
and bio-ethicists. (p. 13)   
  
 In discussing the origins of the chemical imbalance hypothesis, Healy (2003) 
acknowledged that the premise made sense in principle, based upon SSRI’s purported 
mechanism of action. However, the text also reiterated that a reduction in serotonin levels 
among depressed individuals was unconfirmed. Further, in describing the concept of low 
norepinephrine levels linked to depression, Healy stated that this hypothesis “could be 
supported by some but not all the evidence” (p. 46).  
 In addition, Healy (2003) challenged the chemical imbalance hypothesis by 
positing how “By 1970, Ashcroft had concluded that whatever was wrong in depression, 
it was not lowered serotonin. More sensitive studies had shown no lowering of serotonin 
in depression. Indeed, no abnormality of serotonin metabolism in depression has ever 
been demonstrated” (2003, p. 47). The book also posited that historic research 




neurotransmitter hypothesis early on since the medication has no connection to 
monoamines.  
 Further, Healy (2003) noted that reducing serotonin appeared to as effective as 
increasing the neurotransmitter for treating the disorder. Next, Healy (2003) posited that 
“If Prozac was a better serotonin reuptake inhibitor than older antidepressants and if 
serotonin was lowered in depression, why wasn’t Prozac bringing about recoveries in 
hospital depressions quicker than older drugs?” (p. 129). Moreover, Healy stated that 
“The mythologies underpinning Prozac cast it as an antibiotic of the mind raising lowered 
serotonin levels to normal, when its use is in fact more like treating mild hypertension” 
(p. 379). 
 Let Them Eat Prozac also referred to the “modern rhetoric of depression” and 
contrasted the high degree of evidence supporting the use of pharmacological 
interventions for bacterial infections versus the treatment of depression with 
antidepressants (Healy, 2003, p. 326). In addition, the book documented the role that 
British popular media had played in propagating this information without sufficient 
critiques. For example, Healy stated that “In a way unimaginable, ten years ago, popular 
culture takes it for granted that serotonin is low in depressed people” (p. 374).  Finally, in 
describing the evolution of depression as a disorder, Healy briefly introduced the concept 
of an “endogenous depression” and noted that this “implied a genetic depression” (p. 25). 
However, the researcher could not find any explicit critiques within Let Them Eat Prozac 
for a genetic based neurobiological etiology of depression.  
 In, Medicalization of Society, Conrad (2007) discussed a genetic based 




Medicalization can obscure the social forces that influence well-being. For 
example, by focusing completely on the neurobiological features of depression, 
this condition is viewed increasingly as being genetic, and it is treated 
predominantly with antidepressants, while the social environments that frequently 
feed depression are not altered. (Horwitz, 2002, p. 152) 
  
 While the book did not explicitly challenge the rigor of a genetic hypothesis for 
depression, Conrad did note the implications of viewing the disorder exclusively through 
this lens. For example, the text posited that “The focus on the individual has reinforced 
the proclivity of treating complex societal problems with technological fixes (e.g., a 
medical, surgical, or pharmaceutical intervention) rather than by changing the social 
structure” (p. 153).   
 Psychotropic Drug Prescriber’s Survival Guide contained content on the 
neurotransmitter hypothesis for the etiology of depression on one page and challenged 
this premise by noting mixed results from early Reserpine trials. For example, the text 
indicated that this medication had been shown to cause as well as treat depression 
(Dubovsky & Dubovsky, 2007). The authors also described how the French tricyclic 
antidepressant tianeptine was thought to work by decreasing the amount of serotonin in 
the brain, thereby challenging traditional assumptions about the nature of chemical 
imbalances and SSRI’s mechanism of action. Next, Healy, a listed critic, was cited in  
critiquing the neurotransmitter hypothesis (i.e., “The rapid ascendance of a theory that 
had mixed empirical support emerged from a single observed action of a few medications 
and ‘an emerging eclipse of clinical observation by laboratory based world-views’” 
(Healy,1999, as cited in Dubovsky & Dubovsky, 2007, p. 6).       
 In Anatomy of an Epidemic, Whitaker (2010) addressed one neurobiological 




book’s pages. Critiques for the hypothesis were discussed to varying degrees on 15 of 
these pages. Whitaker (2010) introduced the concept of a neurobiological based etiology 
of depression by noting the origins of the chemical imbalance hypothesis (i.e., in the 
1950s with Brodie and Carlson’s research on reserpine and Joseph Schildkraut’s 
conceptualization of their work in 1965). The hypothesis was challenged with a quote by 
Schildkraut who asserted that the premise was “at best a reductionistic oversimplification 
of a very complex biological state” (as cited in Whitaker, 2010, p. 63).   
 Whitaker (2010) began the fifth chapter, The Hunt for Chemical Imbalances, with 
a quote by Thomas Huxley: “The great tragedy of science—the slaying of a beautiful 
hypothesis by an ugly fact” (Whitaker, p.77, chapter five).  Anatomy of an Epidemic went 
on to discuss the complexity of the human brain and noted the limitations of research 
investigating neurotransmitter levels within the cerebrospinal fluid of depressed 
individuals. This included a description of Mendels and Frazer’s work in 1974 which had 
reviewed and critiqued Schildekraut’s hypothesis.   
 Here, Whitaker quoted Mendels (1974) in stating that “the depletion of brain 
norepinephrine, dopamine or serotonin is in itself not sufficient to account for the 
development of the clinical syndrome of depression” (as cited in Whitaker, 2010, p. 72). 
The text also described how a similar conclusion about serotonin was reached in 1984 by 
NIMH researchers investigating the plausibility of 5-HIAA levels being linked to 
amitriptyline’s mechanism of action.  Later in the book, works by listed critics Lacasse, 
Healy, and Glenmullen were cited in the process of challenging the monoamine 
hypothesis (Lacasse, 2005; and Healy, 2002, 2005; and Glenmullen, 2000, as cited in 




 The researcher did not find content about the neurotransmitter receptor, GABA, 
neurogenesis, circadian rhythm, immunological-cytokines, and enzymes/cofactors 
hypotheses within any of the Non-Semester Project books.    
 DSM.  In total, the six Semester Project textbooks contained 107 pages on which 
the DSM was explicitly mentioned—this included general information about the manual, 
its guidelines, and applications (see Appendix S). Sixty-eight of these pages contained 
information about the DSM’s development, and 21 pages included content about the 
manual’s merits. Fifty-four of the 107 contained criticisms, limitations and/or information 
about controversies surrounding the manual. Forty-six pages integrated critiques 
surrounding the manual’s construct validity and there were two pages in which the 





 = Number of Pages on which the DSM’s Construct Validity was Critiqued  
 = Number of Pages on which the DSM’s Inter-rater Reliability was Critiqued   
 
Figure 6. Number of pages in which the DSM’s construct validity and inter-rater 
reliability were critiqued within semester project books. 
  
The researcher did not find statistical information about the DSM’s rigor within the 
Semester Project books.  Two critics (i.e., Peter Breggin and David Healy) from the 
researcher’s list of critics were cited within Anatomy of an Epidemic with regard to 
challenging conventional perspectives about the DSM (Whitaker, 2010).  The researcher 
did not find any additional instances in which a listed critic was cited for this topic within 
the other five SP books.  
 In Unhinged (2010), there were 37 pages containing content that met the study’s 
coding framework criteria for the DSM. This content discussed the manual in general 




these pages contained content concerning the manual’s development including its origins, 
structure and content, its revision process including the upcoming DSM-V, and the 
manual’s role in the evolution of psychotropic drug trials and marketing of 
pharmaceuticals.  There were 11 pages on which the manual’s merits were discussed. 
Here, the text noted that the DSM could be helpful with organizing information in a 
manner that reassured patients “who often improve markedly just by hearing that they 
have a condition that is well-recognized and treatable” (Carlat, 2010, pp.44, 61).  
 Carlat (2010) also noted how the DSM had been useful in formulating medication 
decisions (i.e., pp. 46, 61), establishing more precise descriptions of psychological 
disorders (i.e., pp. 47, 62), raising money for the American Psychiatric Association 
through its sales (i.e., p. 55), supporting other assessment tools for determining the 
existence of psychopathology (i.e., p. 57), and in accurately reflecting the debilitating 
effects of disorders like social phobia (i.e., p. 58) and pre-menstrual dysphoric disorder 
(i.e., p. 59). Further, Carlat (2010) noted that “while the diagnostic labels may sound 
spurious, there are plenty of people out there who are genuinely suffering from the 
conditions they describe” (p. 59).  
 Unhinged also posited that the pending DSM-V’s diagnostic label for mild 
cognitive impairment might help patients “make better sense of their prognosis” (Carlat, 
2010, p. 66). In addition, Carlat asserted that the DSM had been helpful in catalyzing 
pharmaceutical research and development (i.e., p. 67). Further, the text noted that “The 
writers of the DSM-IV tried to safeguard against ADHD being too easily diagnosed in 
adults by adding a requirement that patients had some symptoms before age seven” 




 There were 22 pages within Unhinged that critiqued the DSM. General criticisms 
of the DSM included Carlat’s (2010) opinion that the manual’s categorical approach to 
diagnosis had undermined “psychological curiosity” since the process was more focused 
on determining what disorder a person had versus trying to ascertain why they were 
suffering (p. 45). The text also suggested that the DSM had “drained the color out of the 
way that we understand and treat our patients” (pp. 59–60). Next, Carlat described Robert 
Spitzer’s failed efforts to obtain copies of the minutes from the DSM-V’s committee 
meetings and the APA’s justification for their response to Spitzer’s request.  
 Of the 19 pages critiquing the DSM’s empirical rigor, all contained content which 
challenged the manual’s construct validity and one of these pages also critiqued the 
DSM’s inter-rater reliability (Carlat, 2010). For example, the DSM’s construct validity 
was disseminated by the statement that “psychiatric diagnosis continues to lag far behind 
medicine” (Carlat, 2010, p. 14). Further, via the author’s assertion that “new diagnoses 
are based on votes of committees of psychiatrists, rather than neurobiological testing” 
(p.14) Carlat went on to state that “we commonly think of diseases as collections of 
symptoms with clear biological origins. Psychiatric diseases are similar but different. 
They are indeed collections of symptoms but without any clear biological cause” (p. 44).  
 Next, Unhinged noted that the DSM had been criticized for its “collection of 
arbitrary labels based on shaky science” (Carlat, 2010, p. 47, also see pp. 54–55), “poor 
diagnostic reliability” (p. 52), pathologization of “outdated cultural mores” (p. 53), the 
medicalization of “normal human emotion” (p. 56, also see p. 57), and issues with 
comorbidity (i.e., pp. 60–61). The coverage of diagnostic reliability on page 52 included 




which the limits of DSM-I and II’s inter-rater reliability levels were reviewed (as cited in 
Carlat, 2010).  
 In discussing critiques of the DSM-V work groups’ summaries, Carlat quoted 
Alan France’s “scathing editorial” within the New York Times which noted that the 
manual was being developed upon “remarkably weak methodology” (as cited in Carlat 
2010, p. 64) and that the supportive evidence for new diagnoses was “slim” (p. 65). 
Unhinged also referred to Frances’ concerns about new disorders such as mild cognitive 
impairment (MCI) leading to overdiagnosis (i.e., p. 66) and the possibility that bipolar 
disorder was being used as an “umbrella term” for symptoms reflecting sociological 
problems versus neurobiological pathology (2010, p. 146). Additionally, issues 
surrounding the conceptualization and diagnosis of ADHD in adults were addressed (i.e., 
p.150), and concerns were raised about the subjective nature of the interview process 
from which the diagnoses were formulated (i.e., p. 151).  
 Conrad’s (2007) Medicalization of Society contained information on 27 pages that 
met the coding framework’s criteria for DSM content (Conrad, 2007). The text discussed 
the manual in general terms as well as specifics surrounding its guidelines and 
applications. On 21 of these pages Conrad integrated information about the manual’s 
development including: the origins and evolution of the DSM, the origins and evolution 
of social anxiety disorder, generalized anxiety disorder, and adult attention deficit 
hyperactivity disorder. Additionally, the text described the pharmaceutical industry and 
medical profession’s involvement in the expansion of diagnostic criteria, the manual’s 
historic references to homosexuality as a form of psychopathology, the evolution of 




revision of the manual (i.e., pp. 17, 48–49, 51–52, 57–58, 68, 99–102, 104, 112–113, 
118–119, 156–157, 166–167).  
 There were three pages of Medicalization of Society (2007) in which the manual’s 
merits were discussed. Here, the text noted that diagnosis with gender identity disorder 
could help facilitate reimbursement for sexual reassignment surgery (i.e., pp. 103, 112). 
Next, it was posited that “DSM-III, the third revision, aimed for more rigorous 
diagnoses” (Conrad, 2007, p. 166). The DSM was critiqued to varying degrees on 12 
pages of text. Four of these pages identified general controversy surrounding the 
medicalization of homosexuality and gender identity disorder, and eight of these pages 
integrated critiques of the DSM’s empirical rigor. These critiques included challenges to 
the construct validity of social anxiety disorder “because of its loosely defined 
boundaries” (p. 18), and the author’s assertion that the DSM “is not a scientific 
document” (p. 48). Conrad also noted that the DSM II included the diagnosis of ADHD 
despite the lack of “solid evidence of biological causation” for the disorder (p. 49). 
 Next, Conrad (2007) discussed problems with the DSM’s construct validity in 
terms of its historic treatment of homosexuality as a disorder and, more recently, for 
gender identity disorder (i.e., pp. 99, 100, 102, 103). In addition, the book identified 
concerns with the increasing numbers of diagnoses that followed each revision of the 
manual. Within this context, Kirk (2005) was quoted in referencing a list of DSM-V 
disorders: “If you don’t find yourself on that [DSM-V] list, don’t fret, more are in the 
works for the next edition of the DSM” (as cited in Conrad, 2007, p. 118).  
 Finally, within the Notes section of Medicalization of Society, Conrad quoted the 




diagnostic” for psychological disorders (American Psychiatric Association, 2000, as cited 
in Conrad, 2007, p. 167). The researcher did not find information about the manual’s 
inter-rater reliability within Conrad’s text. 
 In Selling Sickness (2005), there were 20 pages containing content that met the 
study’s coding framework’s criteria for the DSM. This content discussed the manual in 
general terms in addition to addressing specifics about its guidelines and applications. 
Twelve of these pages were concerned with the manual’s development, including 
discussions about changes to the definitions of ADHD and social phobia, the evolution of 
pre-menstrual dysphoric disorder, the increasing number of psychological disorders, and 
the DSM committee’s selection process for determining which disorders are included or 
omitted through the revision process. The text also discussed the development of the 
DSM within the context of addressing the manual’s conceptualizations of “female sexual 
dysfunction” (Cassels & Moynihan, 2005, p. 182).   
 There were five pages on which the manual’s merits were discussed. Here, the 
text noted that, according to the organization Children and Adults with Attention Deficit 
Hyperactivity Disorder (CHADD), a diagnosis with Attention Deficit Disorder “can bring 
special help at school, and nowadays, for adults, special help in the workplace” (as cited 
in Cassels & Moynihan, 2005, p. 77). Similarly, the text addressed Jean Endicott’s 
viewpoint that a diagnosis with PMDD could facilitate appropriate treatment (i.e., p. 100) 
and that the medicalization of premenstrual symptoms could legitimize menstrual related 
suffering for some women (i.e., p. 108). Cassels and Moynihan (2005) also presented the 
perspective that including PMDD within the DSM had the potential to catalyze etiology 




with PMDD afforded financial coverage of associated prescription medications by 
insurers.  
 The text contained challenges to the DSM on ten pages and there were critiques of 
the manual’s construct validity, to varying degrees, on each of these pages (Cassels & 
Moynihan, 2005). For example, Cassels and Moynihan raised concerns “that ordinary 
kids might be ending up with a medical label” (p. 78). Further, the book discussed Paula 
Caplan’s critiques of PMDD and her perspective that “the condition has essentially been 
invented” (as cited in Cassels & Moynihan, 2005, p. 99).  Moreover, that “using a 
medical label to explain away the sever distress some women experience in the lead-up to 
their period runs the risk of masking the underlying causes of their suffering” (Caplan, 
2002, as cited in Cassels & Moynihan, 2005, p. 100).   
 In challenging the validity of the DSM, Cassels and Moynihan quoted Joan 
Crisler and Paula Caplan (2002) as having stated that “The concept of PMS is so vague 
and so elastic that almost every woman can see something of her own experience within 
it” (as cited in Cassels & Moynihan, 2005,pp. 107–108).  The text also described 
concerns that Spitzer and other members of the DSM revision committee had expressed 
via their statements that “so little was known about [PMDD’s] causes, or how to treat it” 
and, “the danger that psychiatrists were going to label aspects of ordinary life as a mental 
disorder” (as cited in Cassels & Moynihan, 2005, p. 109). 
 Additionally, the text noted that PMDD was placed within the manual’s appendix 
because of disagreements surrounding its validity (Cassels & Moynihan, 2005, p. 110). 
For example, psychiatrist Sally Severino, who sat on the DSM committee tasked with 




existed as a valid diagnosis” (as cited in Cassels & Moynihan, 2005, p. 111).  In the same 
vein, Caplan’s concerns were noted with regard to the potential for a PMDD diagnosis to 
overlook sociological factors. For example, she was quoted as having asserted that “a 
history of violent relationships, stressful life circumstances, poverty, or harassment—
[are] problems that cannot clearly be fixed by a pill” (as cited in Cassels & Moynihan, 
2005, p. 115).  
 In addressing international perspectives about PMDD, the text quoted a European 
Agency for the Evaluation of Medicinal Products panel as having stated that “PMDD is 
not a well established disease entity across Europe. It is not listed in the International 
Classification of Diseases and remains only a research diagnosis in DSM-IV” (as cited in 
Cassels & Moynihan, 2005, pp. 115–116). In addition, Cassels and Moynihan (2005) 
noted that the aforementioned panel had raised concerns about the possibility of false 
positive diagnoses and the inappropriate prescription of fluoxetine to treat pre-menstrual 
symptoms that fell below the diagnostic boundary for PMDD (i.e., p. 116). Finally, the 
text indicated that PMDD research efforts were confounded by disagreements 
surrounding how best to define and measure female sexual dysfunction (FSD) (i.e., 
p. 181).        
 Healy’s (2003), Let Them Eat Prozac, contained three pages with content that met 
the study’s coding framework’s criteria for the DSM. This included general information 
about the manual as well as specifics surrounding its guidelines and applications. Two of 
these pages addressed the manual’s development within the context of discussing the 




“therapeutic drug dependence” (Healy, 2003, p. 42; see also p. 77). The researcher did 
not find content on the manual’s merits within this book. 
 The DSM’s construct validity was challenged to varying degrees on two pages of 
this text and both of these pages contained critiques of the manual’s construct validity 
(Healy, 2003). In the first case, Healy noted that the antipsychiatry movement had 
questioned “the legitimacy of psychiatric diagnoses and practices” (p. 42). In the second 
case—as mentioned within the preceding paragraph—Healy noted that neither the 
DSM—III nor the DSM-IV recognized the possibility of therapeutic drug dependence 
(p. 77).   
 One page within The Psychotropic Drug Prescriber’s Guide (2007) contained 
information that was consistent with the study’s coding framework for the DSM. This 
content briefly touched upon the manual’s general criteria for diagnosis (i.e., that 
symptoms cause distress or interfere with normal functioning), and noted that this 
dimension “is not considered at all in most studies” (Dubovsky & Dubovsky, 2007, 
p. 99).  The researcher did not find content that discussed the DSM’s development or 
merits within this book and there were no statistics or critiques pertaining to the manual’s 
rigor.  
 In Anatomy of an Epidemic (2010) there were 19 pages with content that met the 
study’s DSM coding framework. This content discussed the manual in general terms and 
addressed specifics surrounding the DSM’s guidelines and applications. Fifteen of these 
pages dealt with the manual’s development and evolution (i.e., p. 10, 128, 177–178, 218–




p. 10). The DSM’s development was also addressed within the context of discussing its 
integration within the medical model (i.e., pp. 269–272, 316).  
 There were three pages of Whitaker’s (2010) book on which the DSM’s merits 
were identified including the manual’s role in facilitating services associated with the 
Disabilities Act (i.e., p. 220). The book also quoted Spitzer’s assertion that the inter-rater 
reliability of DSM-III’s disorders was “so much better than we had expected (Kirk, 
1992)” (as cited in Whitaker, 2010, p. 270). Next, Whitaker noted that the DSM- III had 
been effective in uniting psychiatrists’ efforts to amalgamate the discipline within the 
medical model (i.e., p. 271).  
 The researcher found six criticisms of the DSM within Anatomy of an Epidemic 
(2010). Five of these critiques focused on the manual’s construct validity and one critique 
challenged the DSM’s reliability. In addressing the DSM’s construct validity Whitaker 
(2010) described ADHD as a disorder with an unknown etiology whose diagnosis is 
primarily based on “teacher complaints” (p. 220). Further, Whitaker asserted that:  
There was a long record of speculation within medicine that extremely 
hyperactive children suffered from brain dysfunction of some kind, which was 
certainly a reasonable  thought, but the nature of that dysfunction was never 
discerned, and then, in 1980,  psychiatry simply created with a stroke of its pen in 
DSM-III, a dramatically expanded definition of ‘hyperactivity’. The fidgety 
seven-year old boy who might have been dubbed a ‘goof-off’ in 1970 was now 
suffering from a psychiatric disorder. (p. 221) 
  
Also within the context of discussing the DSM-III, Whitaker noted that:  
it was difficult to understand why this manual should be regarded as a great 
scientific achievement. No scientific discoveries had led to this reconfiguring of 
psychiatric diagnoses. The biology of mental disorders remained unknown, and 
the authors of the DSM-III even confessed that this was so. Most of the diagnoses, 
they said, ‘have not yet been fully validated by data about such important 
correlates as clinical course, outcome, family history, and treatment response 




 Next, in discussing the marketing of psychotropic drugs Whitaker (2010) 
suggested that the DSM-III was part of a “rebranding effort” designed to inform people 
that psychological disorders were valid diseases (p. 316). Further, in referencing the 
DSM-IV, the text stated that “New and expanded diagnoses invite more people into the 
psychiatric drugstore” including individuals diagnosed with social anxiety disorder which 
“in the past might have been characterized as character trait” (p. 317).   Finally, in 
discussing the manual’s inter-rater reliability levels, the text noted that “Spitzer and 
others argued that such diagnostic categories [within the DSM-II] were notoriously 
‘unreliable’ (Wilson, 1993)” (Whitaker, 2010, p. 269).    
 It is noteworthy that a considerable amount of content about the DSM fell outside 
of the study’s coding framework which required that the manual be explicitly mentioned 
on the page it was discussed. As with the NSP books, this relevant information was 
documented within the “comments” section.  The sheer volume of these findings proved 
troublesome to consolidate and problematic for inter-rater reliability. While some of this 
content pertained to the use of DSM nomenclature (i.e., identifying various diagnoses and 
symptomatology), there were also a considerable number of critiques. For example, 
Carlat (2010) noted that:  
Our diagnostic system is shallow and is based on an elaborate checklist of 
symptoms, leading us sometimes to overdiagnose patients with disorders of 
questionable validity, or conversely, to miss the underlying problems in our rush 
to come up with a discrete diagnostic label that will be reimbursed by the 
insurance company. (p. 15) 
 
Carlat (2010) also asserted that the causes of psychiatric symptoms are “unknown” 
(p. 21) and “Our diagnoses are subjective and expandable, and we have few rational 




Epidemic, Whitaker (2010) questioned the controversial idea that antidepressants or 
stimulants could “unmask” pre-existing mania. Further, Whitaker stated that “by greatly 
expanding diagnostic boundaries, psychiatry is inviting an ever-greater number of 
children and adults into the mental illness camp” (Whitaker, 2010, p. 209).   
 Next, Conrad (2007) quoted Horwitz in asserting that, over time, medical 
diagnoses are “taken for granted as an objective natural entity” (p. 67), and noted that 
there “have long been pockets of resistance to medicalized disorders like ADHD” 
(p. 158). Additionally, Conrad (2007) posited that “the diagnosis of intermittent explosive 
disorder, represents a medicalization of having a ‘bad temper’—surely a problem, but is 
it a medical disorder?” (p. 168). In the same vein Cassels and Moynihan (2005) 
challenged the validity of FSD, PMDD, and ADHD. For example, the authors questioned 
the wisdom of “diagnosing and medicating children whose symptoms include often fidget 
with hands or feet and prescribing lifelong speed to adults who drum their fingers” 
(p. 81). For his part Healy (2003) queried “Have physicians protested the thousandfold 
increase in the diagnosis of depression in the psychotropic era?” (p. 377). 
 C/S/X. Two of the Semester Project textbooks disseminated content about the 
c/s/x movement. This included Robert Whitaker’s (2010), Anatomy of an Epidemic, 
Daniel Carlat’s (2010), Let Them Eat Prozac (see Figure 7). While Conrad listed the 
MindFreedomInternational website within his book’s reference section, the researcher 
could not find any citations for the organization within the text itself. In response, Conrad 
noted that “I don't recognize what c/s/x movement means.  I don't recall where 
www.MindFreedomInternational.org is in the book; perhaps it was mistakenly put in the 




Healy addressed a variety of critiques being levied against psychiatry by various “fringe” 
group but there were no explicit mentions of the c/s/x movement. Further, and in 
response to the researcher’s query about this observation, Healy stated that:  
I have co-authored a book on the history of ECT where this is picked up in greater 
detail.  Groups like MindFreedomInternational etc.—their origins and 
developments are covered. I think survivor groups certainly in 1990’s, which is 
the period Let Them Eat Prozac covers, had very little part to play in the story; 
unlike the ECT story for instance. I think survivor groups still have comparatively 
little effect within psychopharmacology. It astonishes me that they don’t see that 
more harm is being done by the meds than ECT etc. (D. Healy, personal 
communication, June 13, 2014)   
   
Based on Conrad and Healy’s responses, the researcher did not identify any c/s/x content 







□ = Anatomy of an Epidemic  
□ = Let Them Eat Prozac 
□ = Unhinged  
 
Figure 7. Number of pages with c/s/x content by topic within the three semester project 
books that addressed the c/s/x movement.   
  
Anatomy of an Epidemic (2010) discussed c/s/x related campaigns, events, and 
activism to varying degrees on 15 pages of text. In addition, the book addressed c/s/x 
organizations and c/s/x history on 15 pages, and integrated personal stories about c/s/x 
activists on 32 pages of text. Whitaker (2010) identified critiques of the c/s/x movement 
and challenged these critiques on four pages of Anatomy of an Epidemic.  
 There were seven instances in which members of the c/s/x movement were cited. 
For example, in discussing the MindFreedomInternational hunger strike in 2003, 




and other allies of MindFreedomInternational) wrote to the American Psychiatric 
Association.   Whitaker also referenced his interview with David Oaks. In addition to 
being a member of the MindFreedomInternational hunger strike, Oaks was one of the 
MFI’s founders and the organization’s Director until 2012. Next, Whitaker discussed his 
interview with John Gottstein, a c/s/x activist, human rights lawyer and president of 
PsychRights. In addition, John Modrow’s (2003) book, How to Become a Schizophrenic: 
The Case against Biological Psychiatry, was quoted and cited.  
 In considering critiques levied against the c/s/x movement, the text quoted an 
American Psychiatric Association press release which was submitted just after the 
MindFreedomInternational activists broke their hunger strike (Whitaker, 2010). The press 
release noted that organizations like the American Psychiatric Association, and NAMI 
“will not be distracted by those who would deny that serious mental disorders are real 
medical conditions that can be diagnosed accurately and treated effectively” (Whitaker, 
2011, p. 332).  
 Content that met the coding requirements for having challenged a critique of the 
c/s/x movement included Whitaker’s (2011) comments about the legitimacy of 
MindFreedomInternational’s hunger strike. For example, the author stated that “it was 
clear to all observers who had won this battle. The striker’s had called the APA’s bluff, 
and the APA had come up empty. It hadn’t come up with a single citation that supported 
the ‘brain disease’ story told to the public” (p. 332). Further, Whitaker noted that the 
American Psychiatric Association’s letter had directed the MindFreedomInternational 
activists to an introductory textbook on psychiatry. In sharing his reaction to the 




stated that “Only the uneducated, it seemed, asked such dumb questions” (p. 332).     
 Carlat’s (2010) Unhinged contained a brief critique of the c/s/x movement on one 
page. Here, Juli Lawrence’s (a c/s/x member) personal experiences with electro 
convulsive therapy were discussed. This included a cited position statement by Lawrence 
and a reference to her website.   
Non-Textbook Readings 
 Etiology of depression.  Of the 57 required non-textbook readings, five contained 
material that met the coding requirements for neurobiological hypotheses of depression’s 
etiology (see Appendix Q).  Three of these articles addressed a genetic hypothesis for the 
disorder and two focused on a neurotransmitter hypothesis. For example, Austin’s (2013), 
Genetic Testing for Psychiatric Disorders: Its Current Role in Clinical Psychiatric 
Practice, discussed a genetic etiology for depression on one page. Here, the author noted 
that “Research data from family, twin, and adoption studies show that psychiatric 
disorders (such as depression, schizophrenia, anxiety, and bipolar disorder) are complex 
(or multi-factorial) disorders that typically arise as a result of the combined effects of 
genetic and environmental factors” (p. 1).  
 Genetic Testing for Psychiatric Disorders was the sole non-textbook reading to 
include a critique for a neurobiologically based hypothesis of depression, albeit within 
the context of discussing psychiatric disorders in general (Austin, 2013). Here, Austin 
(2013) noted that:  
linkage studies were responsible for locating the genes responsible for both cystic 
fibrosis and Huntington disease. However, when applied to the study of 
psychiatric disorders,  linkage studies offered only equivocal results. Attempts to 
replicate initial findings produced only partial or conditional success. The 




that contribute to the development of psychiatric disorders were typically of an 
effect size that was not large enough to be detected by linkage studies. (p. 1) 
    
 The second paper to focus on genetics pertaining to a neurobiological hypothesis 
for depression was the Department of Defense Veteran Affairs PTSD Guidelines (2010) 
which posited that:  
Family history of any psychiatric disorder or possible genetic differences in 
regulating pre-synaptic uptake of serotonin (or other neurobiological mechanism)  
can increase risk. Genetic research has shown that of the two variants of the gene 
regulating pre-synaptic uptake of serotonin, the long form appears to be 
associated with resilience and the short form with the vulnerability to stress 
events. Individuals who inherited the short form and were exposed to four of more 
stressful life events were much more likely to develop PTSD and depression and 
to attempt suicide (Koenen et al., 2009, pp.73–74)   
 
 A third paper, the American Academy of Child and Adolescent Psychiatry 
Practice Parameter for the Assessment and Treatment of Children and Adolescents With 
Depressive Disorders, discussed a genetic etiology for depression on two pages within 
the context of addressing risk factors for major depressive disorder (Birmaher et al., 
2007, p. 1506) and in positing the importance of psycho-education as a treatment 
intervention (i.e., “Depression is presented as an illness, not a weakness, which is no 
one’s fault but has genetic and environmental contributions” (Birmaher et al., 2007, 
p. 1510)).  The researcher did not find critiques for either of these instances in which the 
neurotransmitter hypothesis for depression was discussed. 
 Next, a paper on serotonin syndrome by Sorenson (2002) noted that:  
Serotonin is one of three monoamine neurotransmitters most often associated with 
depression. Although serotonin is generally associated with clinical depression, 
there are over ten known serotonin receptor subtypes found throughout the body 





No critique of a neurotransmitter hypothesis for depression was provided within this 
paper and no other neurobiological hypotheses for depression were addressed.   
 DSM.  Eleven of the 57 required non-textbook readings included DSM content 
that met the coding category requirements for this topic (see Appendix X).  This included 
information about general aspects of the manual, its guidelines, and/or applications. Five 
of the 11 papers addressed aspects of the DSM’s history and development and four 
papers discussed the manual’s benefits/strengths.  The researcher found seven papers that 
critiqued the manual; four of these articles focused attention on the DSM’s empirical 
rigor. Two of the four papers critiquing the manuals’ rigor challenged its reliability and 
all four identified problems with the DSM’s construct validity.    
 The researcher found two pages with content on the DSM inside the Annual 
Research Review: Impact of Advances in Genetics in Understanding Developmental 
Psychopathology article (Addington & Rapoport, 2012). This included a statement about 
the development of the DSM and the limits of its construct validity within the context of 





















 The researcher’s analysis of Mental Illness Surveillance Among Adults in the 
United States. Atlanta: Centers for Disease Control and Prevention found three pages 
with content on the DSM that met the study’s coding requirements (Reeves et al., 2011). 
Two of these pages discussed the DSM’s development and efforts to co-ordinate 
diagnoses with the ICD (i.e., pp. 3, 4). Next, the manual’s criteria for major depressive 
disorder and its applications within the study’s survey were addressed. This discussion 
also noted the DSM’s role in a variety of other assessment tools and in establishing the 
prevalence of psychiatric symptomatology across populations to identify trends (i.e., pp. 
2, 3, 4).   
 In discussing the limits of the DSM, Reeves and colleagues (2011) noted that the 
manual’s diagnostic categories had changed over time and stated that “the relationship 
among the disorders described by these different terms is often unclear” (p. 3).  Potential 
confounds to reliability were identified with the assertion that “In practice, regardless of 
the diagnostic system used, diagnoses vary according to the training of the coder, local 









role	in	selecting participants.  
 The	Texas	Medication	Algorithm	Project	explicitly	identified	the	DSM	on	two	
pages	(Suehs et al., 2008).	Here,	the	DSM was referenced in a discussion about the 
Quick Inventory of Depressive Symptomatology (QIDS) measure, which is based on the 
manual’s diagnostic criteria for major depressive disorder (i.e., p. 21). The paper also 
referenced the manual within a	Clinical	Record	From	located	in	the	appendix	(i.e.,	p.	
66).		   
 The researcher found two pages within Effectiveness of Antipsychotic Drugs in 
Patients with Chronic Schizophrenia on which the DSM was identified (Lieberman et al., 
2005). Here, the manual’s applications for diagnosing and selecting study participants 
were highlighted (i.e., pp. 1210, 1213). 
 In the VA/DoD Clinical Practice Guideline for Management of Post-Traumatic 
Stress, the researcher found twenty-two pages with content that met the coding 
requirements for this topic (The Management of Post-Traumatic Stress Working Group, 
2010). This included general references to the manual within the paper’s list of Tables 
(i.e., p. 2) and acronym list (i.e., p. 206), and in defining the DSM-IV criteria for post-
traumatic stress disorder (i.e., pp. 4, 21, 80, 81, 96), and acute stress disorder (i.e., pp. 40, 
41, 206).  Next, comorbidities between PTSD and other DSM disorders were noted (i.e., 
p. 24), and the manual was mentioned in discussing triage assessments (i.e., p. 79). The 
DSM was also cited in discussions surrounding its research applications (e.g., 
epidemiological surveys) (i.e., pp. 5, 81), screening scales/checklists (i.e., pp. 18, 20, 96, 




interventions (i.e., p. 137). In addition, the manual’s use within primary care settings was 
noted (i.e., p.79).       
 Content within three pages of the VA/DOD guidelines challenged the DSM’s 
rigor (Department of Veterans Affairs [VA/DoD], The Management of Post-Traumatic 
Stress Working Group, 2010). For example, the text questioned the construct validity of 
the DSM’s approach to trauma and noted that “military personnel do not always respond 
in the same way as civilian victims of traumatic events, and the criteria for ‘fear, helpless, 
or horror’ are being reconsidered in the proposed future DSM criteria” (VA/DoD, The 
Management of Post-Traumatic Stress Working Group, 2010, p. 21). Next, the paper 
posited that “Although acute stress reaction (ASR) is not defined in the DSM-IV, there 
has long been recognition among mental health professionals that individuals who 
experience a traumatic event react in certain predictable ways” (VA/DoD, The 
Management of Post-Traumatic Stress Working Group, 2010, p. 28, also see p. 4).  
Limits of the manual were also identified via statement that: 
 
These diagnostic criteria and the DSM-IV classification of mental disorders 
reflect a consensus of current formulations of evolving knowledge in our field. 
They do not encompass, however, all the conditions for which people may be 
treated or that may be  appropriate topics for research efforts. (VA/DoD, The 
Management of Post-Traumatic Stress Working Group, 2010, p. 81)   
 
 The development of the DSM and its merits were discussed within the context of 
addressing the revision process (VA/DoD, The Management of Post-Traumatic Stress 
Working Group, 2010). For example, the paper noted that, in an effort to prevent the 
pathologization of transient reactions, the DSM-IV had introduced acute stress disorder 
(ASD). Further, the guideline indicated that this particular diagnosis was used “to 




chronic PTSD” (VA/DoD, The Management of Post-Traumatic Stress Working Group, 
2010, p. 40).  
 Next, the guidelines asserted that “The specified diagnostic criteria for each 
mental disorder are offered as guidelines for making diagnoses, because it has been 
demonstrated that the use of such criteria enhances agreement among clinicians and 
investigators” (VA/DoD, The Management of Post-Traumatic Stress Working Group, 
2010, p. 80). Further, that “The purpose of the DSM-IV is to provide clear descriptions of 
diagnostic categories in order to enable clinicians and investigators to diagnose, 
communicate about, study, and treat people with various mental disorders” (p. 80).  
 The analysis of the Practice Parameters for the Assessment and Treatment of 
Children & Adolescents (AACAP) with Bipolar Disorder, found 11 pages with content 
on the DSM that met the study’s coding requirements for this topic (McClellanet al., 
2007).  This included details about the manual’s criteria for psychiatric disorders (i.e., 
pp. 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118), information surrounding the 
manual’s development (i.e., pp. 108, 109), research applications (i.e., pp. 108, 109, 111, 
113), and utilization as a reference tool for epidemiological findings (i.e., pp. 109, 112, 
118).  
 There were also nine pages on which a variety of questions and concerns about 
the DSM’s rigor were raised (McClellan et al., 2007).  For example, the practice 
parameters noted limitations with the DSM’s criteria for bipolar disorder. Here, the 
authors asserted that “there has been a shift in how the disorder is defined in juveniles. 
There are also similar debates about how broadly to define the disorder in adults” 




individuals, children and adults, are characterized as having sub-threshold or atypical 
cases based on periods of elated, expansive, or irritable mood” (pp. 107–108).  
 Next, the guidelines noted that “Although current DSM-IV-TR nosology does not 
distinguish age-specific criteria for bipolar disorder, the patterns of illness and symptom 
definition described in children often vary from the classic description of the disorder in 
adults” (McClellan et al., 2007, pp. 107–108). Similarly, the practice parameters asserted 
that “whether these presentations are bipolar disorder and/or represent the same condition 
classically described in adults has become an area of controversy and scientific debate” 
(p. 108). 
 Controversy surrounding the diagnosis of bipolar in children was reiterated on the 
following page as well (McClellan et al., 2007).  Here, the diagnostic criteria being 
disseminated within current juvenile bipolar literature (i.e., ultrarapid cycling and 
ultradian cycling) was contrasted with the DSM-IV-TRs criterion for bipolar disorder 
(p. 109).  In the same vein, the paper noted that, for children and adolescents “Changes in 
mood, energy levels, and behavior are often markedly labile and erratic rather than 
persistent. Irritability, belligerence, and mixed manic-depressive features are more 
common than euphoria” (p. 111). A section of the paper titled Diagnostic Controversy 
further encapsulated the question of how best to categorize age specific presentations of 
bipolar disorder:   
The debate and controversy over juvenile bipolar disorder are not whether there 
are a significant number of youths who are explosive, dysregulated, and 
emotionally labile or whether these youths suffer significant impairment or are at 
risk for a variety of adverse outcomes, including substance abuse. These 
difficulties and concerns are commonplace, especially in community mental 
health settings and systems of care that deal with at-risk youths (e.g., juvenile 




characterized as bipolar disorder and, more important, whether juvenile mania is 
the same illness as that classically described in adults. (McClellan et al., 2007, 
pp. 111–112)  
 
 Next, the paper described how overlapping symptomatology could complicate the 
diagnostic picture:  
Mood dysregulation in children and adolescents is often associated with features 
of borderline personality disorder. This raises questions of diagnostic specificity 
and the overlap between mood and personality disorders, while also generating 
concerns regarding the validity of personality disorder diagnoses in youths. A 
related debate occurs  in the adult literature, in which bipolarity overlaps with a 
broad array of mood and anxiety problems, including difficulties attributed to 
personality disorders or substance abuse. (McLellan et al., 2007, p. 112) 
  
Questions surrounding diagnostic accuracy based on contradictory epidemiological 
findings in adults and heritability studies were also raised (McClellan et al., 2007, 
p. 112).   
 Similarly, in discussing the DSM’s construct validity and reliability the practice 
parameter asserted that  
The lack of a gold standard, independent of diagnostic criteria, for confirming a 
diagnosis remains the major challenge. This is a problem for all psychiatric 
research because ultimately the application of diagnostic criteria is dependent on 
the clinician’s or investigator’s views as to what constitutes a symptom. 
(McClellan et al., 2007, p. 113) 
 
 Further, the paper posited that “The validity of diagnosing bipolar disorder in 
preschool children has not been established” (McClellan et al., 2007, p. 113) and “There 
are no biological tests, including imaging or genetic studies that are helpful in making the 
diagnosis of a bipolar disorder” (p. 114)—a sentiment reiterated on page 116. This 
practice parameter also challenged the DSM’s characterization of an antidepressant 
precipitated manic episode as being substance induced versus the unmasking of 




 The analysis of Practice Parameters for the Assessment and Treatment of 
Children & Adolescents with ADHD, found DSM content meeting criteria for the topic’s 
coding categories on seven of the paper’s 28  pages (Pliszka. 2007). This practice 
parameter addressed aspects of the DSM-IV-TR’s diagnostic criteria for ADHD on five 
pages (Pliszka, 2007) (i.e., pp. 895, 898, 899, 901, 902). Next, ADHD and its 
comorbidity with other DSM disorders was discussed (i.e., pp. 896,899, 901, 902), as 
were the manual’s applications in ADHD rating scales (i.e., p. 899).   
 In terms of critiques, the paper questioned the construct validity of using DSM-
IV-TR criteria for diagnosing ADHD in adults (Pliszka, 2007). For example, the practice 
parameter asserted that “an adult may suffer significant impairment even though he or 
she suffers from fewer than six of nine symptoms in these areas” (Pliszka, 2007, p. 895). 
Next, the guideline stated that “the prevalence of mood disorders in patients with ADHD 
is more controversial” (p. 896) and the authors posited that neuroimaging was not useful 
in diagnosing the disorder “unless there is strong evidence for such factors in the medical 
history” (pp. 897–898). A third critique of the manual’s construct validity pertained to the 
number of environments in which problematic symptoms are required for diagnostic 
criteria to be met. For instance the paper asserted that  “DSM-IV requires impairment in 
at least two settings (home, school, or job) to meet criteria for the disorder, but clinical 
consensus agrees that severe impairment in one setting warrants treatment” (Pliszka, 
2007, p. 898).   
 The researcher’s analysis of the Practice Parameters for the Assessment and 
Treatment of Children & Adolescents with Anxiety Disorders, found DSM content 




(Connolly et al., 2007). There was one page on which the DSM’s rigor was challenged. 
Here, the practice parameters questioned the manual’s capacity to discern clinical levels 
of anxiety symptomatology. For example, the authors posited that there is “evidence that 
disability can be associated with subthreshold anxiety symptoms that may not meet full 
criteria for a DSM-IV diagnosis” (p. 269).  
 The American Academy of Child and Adolescent Psychiatry Practice Parameter 
for the Assessment and Treatment of Children and Adolescents with Depressive 
Disorders, was coded for DSM content on five of the document’s 24 pages (Birmaher et 
al., 2007). There was one case in which a potential problem with using the DSM was 
raised. Here, the paper posited that: 
DD [Dysthymic Disorder] consists of a persistent, long-term change in mood that 
 generally is less intense but more chronic than in MDD. As a consequence, DD is 
often overlooked or misdiagnosed. Although the symptoms of dysthymia are not as 
severe as in MDD, they cause as much or more psychosocial impairment. 
(Birmaher et al., 2007, p. 1504)  
 
 The paper did not extrapolate on the extent of this problem or clarify whether 
these concerns pertained to specific limitations with the manual’s reliability and/or 
construct validity (Birmaher et al., 2007, p. 1505). Next, the practice parameter asserted 
that diagnosing children and adolescents “can be challenging because it is difficult to 
differentiate whether their depression is part of unipolar major depression or the 
depressive phase of bipolar disorder” (p. 1505). It was also posited that “not all children 
who become activated or hypomanic while receiving antidepressants have bipolar 
disorder” (p. 1505).  In discussing the use of neuroimaging for diagnostic purposes the 
paper asserted that “At present, no biological or imaging tests are clinically available for 




 Additionally, the manual was referenced in a section defining depression and in 
identifying the DSM-IV-TR criteria for mood disorders (i.e., pp. 1504–1505, 1507) 
(Birmaher et al., 2007). Next, the manual’s applications in screening and in measuring 
treatment responses were noted (i.e., pp. 1507, 1520).     
 C/S/X  
 The researcher did not find content about the c/s/x movement within the Non-
Textbook readings. 
Videos  
Etiology of depression. The researcher examined the Biological Basis of 
Depression, and Pharmacotherapy for Depressive Disorders videos from the Treatment 
Issues in Psychopharmacology: Affective Disorders class (Psychologist Postdoctoral 
Psychopharmacology Program Syllabus, 2014b). Videos for this particular course that 
were not analyzed for the study included Pharmacotherapy of Bipolar Disorders and 
Treatment Guidelines and Considerations for Bipolar Disorder.  
 The Biological Basis of Depression video identified the following learning 
objectives: “describe the various biological models used to explain the etiology of 
affective disorders, describe the biochemical basis of depression and bi-polar disorder 
and describe the proposed neural circuitry associated with depression and mania” 
(Anonymous, n.d.) (i.e., from 01:00 to 01:31 in the video). Neurobiological hypotheses of 
depression addressed within this video included the chemical imbalance hypothesis 
(neurotransmitter hypothesis), as well as the neurotransmitter receptor, 




 The majority of this presentation focused on the purported relationships between 
genes, proteins, neurocircuitry and depression (Anonymous, n.d.) (i.e., from 01:42 to 
40:03 in the video). For example, during the introduction, the presenter (a psychiatrist) 
noted that: 
I call this genes, proteins, neurocircuits, symptoms, and syndromes, and that’s the 
progression. Essentially we inherit genes from our parents, these genes will code 
for different proteins, these proteins can be receptors, enzymes, etc.; they code for 
a variety of things.  If you have abnormal genes you’ll have abnormal proteins, 
and this is what we call mutations. If you get enough of these abnormal proteins 
together, and if they’re in a certain part of the brain, in a certain set of 
neurocircuitry, those circuits may malfunction and malfunctioning means to me 
that the circuits are too hot or too cold, which means that it’s too hyperactive or 
too underactive or hypoactive. (i.e., from 01:42 to 02:26 in the video)  
 
 Next, the presenter suggested that when a sufficient number of these proteins 
accumulate, “malfunctioning” of the brain’s neurocircuitry could occur, leading to 
psychological disorders like depression (Anonymous, n.d.) (i.e., from 03:03 to 03:46 in 
the video). The presenter subsequently provided a disclaimer (i.e., “Even though I’m 
giving a fairly neuroscientific, biological type talk, there are clearly gene and 
environment interactions. There’s a psyche there’s a heart and there’s a soul. But again 
my job is to teach the more biological underpinnings”) (i.e., from 03:34 to 03:46 in the 
video). The Biological Basis of Depression video also tied specific symptoms of 
depression (e.g., fatigue) to “incorrect proteins” and “neurocircuitry problems” (i.e., from 
05:54 to 05:56 in the video).  
 During this discussion the presenter asserted that no single gene codes for a 
particular DSM disorder (Anonymous, n.d.). Rather, the presenter posited that a gene 
codes for a symptom implicated in a variety of different disorders.   Next, in the process 




PowerPoint slide with a drawing of a “hyperactive amygdala” (i.e., at 06:18 in the video). 
The presenter asserted that it was currently infeasible to diagnose depression using 
neuroimaging findings. Similarly, it was posited that genetic testing was still in its 
infancy in terms of its capacity to determine risk for a psychiatric illness. 
 The chemical imbalance hypothesis was introduced within this video as one of the 
“leading theories” for depressive disorder (Anonymous, n.d.) (i.e., from 09:24 to15:30 in 
the video). The presenter stated that, “One idea is you’re low on a certain chemical and 
depression will ensue” (i.e., from 09:30 to 09:36 in the video). Next, links between 
dopamine, norepinephrine, and attentiveness were discussed and connections between 
serotonin and emotional experiences such as sadness, guilt or suicidality were posited. In 
addition, the presenter stated that:   
In theory, if someone is sitting across from you talking about their typical major 
depressive disorder symptoms, if they tell you they’re a bit more anxious, sad, 
weepy, and a lot more suicidal, I would start thinking in my practice that their 
brain is probably a bit lower, underactive in serotonin. If that different patient is 
sitting across from me telling me that they’re tired fatigued, amotivated, 
melancholic, I start thinking they’re probably a bit more low, so to speak, in 
norepinephrine and/or dopamine. (i.e., from 12:20 to 12:50 in the video)   
   
 The presenter qualified a subsequent discussion on antidepressants’ mechanism of 
action, by linking neurotransmitters to specific symptoms of depression (Anonymous, 
n.d.). Here, it was posited that:  
Again this is theoretical, there are some human lab studies, there are some 
pharmaceutical studies, you know you look at drugs that are more norepinephrine 
or more serotonin based and you try to decide if they’re better. I’m not sure that 
we’ve  proven this although many psychopharmacologists feel this way in 
practice. (i.e., from 12:59 to 13:21 in the video)  
 
 A PowerPoint was used to reiterate links between increased negative affect with 




dopamine (Anonymous, n.d.) (i.e., from 13:17 to14:27 in the video). The presenter also 
posited that “The idea is that you can try to start guessing which transmitter, what 
neurocircuitry system is faulty” (i.e., from 14:20 to14:27 in the video). By linking 
neuroimages of “hyper” and underactive neurocircuitry to depressive symptoms, the 
presenter asserted that “We’re trying to delineate which specific part of the brain serves 
which function” (i.e., from 14:54 to 14:58 in the video).  
 The presenter returned to the monoamine hypothesis in discussing the monoamine 
receptor hypothesis of depression (Anonymous, n.d.). Here, he asserted that “It’s also 
possible that you have depression because of the first theory. You have less serotonin 
because maybe you make less serotonin” (i.e., from 16:20 to 16:28 in the video). The 
chemical imbalance hypothesis was also mentioned briefly within a discussion about 
brain atrophy. In this case the presenter stated: 
So having enough BDNF is a good thing. But what if that gene is turned off and 
now you won’t have enough? You might actually turn on more mechanisms to 
make more serotonin so you have your chemistry; your chemical imbalance 
doesn’t happen because you make enough. What if that gene doesn’t work? Now 
you’re going to be low on the chemical. (i.e., from 22:27 to 22:47 in the video) 
 
 Next, in discussing comorbidity of depression with Parkinson’s disease, the 
presenter stated: 
That’s more in the limbic system. That’s in the deep part of the brain and what we 
would  notice is that they have less dopamine. So down here you would notice 
normal functioning of dopamine and here’s the Parkinson’s patient and notice that 
they have less  red, less active dopamine, they are more likely to become 
depressed. That may be your  chemical imbalance theory at work. (Anonymous, 
n.d.) (i.e., from 31:05 to 31:30 in the  video) 
 
 During the latter part of the video within the context of differentiating bipolar 




hypothesis of mania? Again, opposite of depression—low dopamine is depression, high 
dopamine might be mania” (Anonymous, n.d.) (i.e., from 35:55 to 36:00 in the video). In 
addition, the video’s presenter asserted that “We talk about neurotransmitter being too 
high in mania, maybe too low in depression” (i.e., from 38:38 to 38:43 in the video).  
 In the process of introducing the monoamine receptor hypothesis the presenter 
asserted that “So it does become a chicken or the egg phenomenon. But it’s theoretically 
possible that somebody has a depression based on low monoamine levels, and it’s also 
possible that the next person has depression based on having too many monoamine 
receptors” (Anonymous, n.d.) (i.e., from 16:34 to 16:48 in the video). The video 
ultimately conceptualized the monoamine receptor and neurotransmitter imbalance 
hypotheses of depression as corollaries for dysfunctional circuitry (i.e., from 15:28 to 
19:50 in the video). For example, it was noted that “What happens is [when] you have a 
bad number of receptors and a bad amount of neurotransmitters, the ratio is off, and what 
happens is that causes that specific part of the brain or that neurocircuit to fire too much 
or too little” (i.e., from 17:17 to 17:23 in the video).  Further:  
So we have studies, we have models, you know if you were to look at some of 
those things, here are some of those brain scan pictures of those things that are too 
cold or too hot. And, so again, if you look at those parts of the brain, this is 
normal sadness. We all get sad, and you see this bright hot area of the brain and 
that may be indicative of normal sadness. Now people who are depressed in 
general will have this as well. It’s just stuck  that way, more permanently. It’s like 
the brain can’t turn that section off. (i.e., from 17:30 to 18:04 in the video) 
 
 The video also used neuroimaging to discuss fluoxetine’s mechanism of action. 
Here, it was posited that the drug and, in some cases, a placebo could purportedly “turn 
that hot area of the brain cold” (Anonymous, n.d.) (i.e., from 18:10 to18:17 in the video). 




many receptors, too little transmitters. But when you look at the parts of the brain being 
hyper or hypoactive these are real findings in real patients” (i.e., from 19:15 to 19:29 in 
the video).  
 In another reference to the receptor hypothesis of depression, the presenter noted 
that: 
My residents, what they’re taught to answer on exams is that the number one  
theory of depression right now is that we have too many receptors and we treat 
them by downregulating them. We give a lot of antidepressant which raises a lot 
of neurotransmitter and those receptors shrink and downregulate. They disappear 
and then you restore your balance between the number of receptors and the 
number of transmitter  molecules around. (i.e., from 33:15 to 33:40 in the video)  
 
 Later in the Biological Basis of Depression video, genetics were linked to 
research which observed decreased brain volumes among some depressed subjects 
(Anonymous, n.d.) (i.e., from 19:51 to 21:13 in the video). The presenter also discussed 
correlations between depression, genetics and proteins like brain derived neurotrophic 
factor (BDNF) (i.e., from 21:13 to 23:33 in the video).  In addition, the video presentation 
noted that environmental factors play an important role in major depression and that 
irreparable damage could ostensibly occur in the brain from multiple depressive episodes. 
However, the neurogenesis hypothesis was not explicitly mentioned within this context.     
 The video subsequently revisited a genetic etiology for depression and in doing so 
included the caveat that “These are findings that have been replicated by a few labs. 
There have also been some negative studies so this is still theoretical” (Anonymous, n.d.) 
(i.e., from 26:07 to 26:14 in the video). Within this context the presenter discussed the 
Serotonin Transporter Gene, and noted that inheriting the S- allele could lead to serotonin 




(i.e., suicidal ideation and suicide)( i.e., from 26:04 to 27:17 in the video). Abnormal 
genes for dopamine and glutamate were also linked to an increased risk of depression 
(i.e., from 27:18 to 27:35 in the video).  
 Next, the endocrine system’s role in depression’s etiology was discussed 
(Anonymous, n.d.) (i.e., from 27:37 to 29:10 in the video). Here, the negative impact of 
glucocorticoids on BDNF levels was correlated with apoptosis and depressive symptoms. 
The thyroid’s role in depression was also noted, albeit not explicitly as a neurobiological 
source for the disorder. Additionally, the presenter posited how cerebral asymmetry from 
strokes supported a neuroanatomical etiology of depression and that the pathophysiology 
of Parkinson’s (i.e., decreased dopamine) could be viewed as evidence for the chemical 
imbalance hypothesis of major depressive disorder (i.e., from 30:30 to 31:30 in the 
video).  
 In concluding the neurobiology of depression portion of this video, the presenter 
stated that “There are many potential neurochemical causes of major depressive disorder. 
There are hormonal ones, there are neurodegenerative ideas. And again it may come 
down to what genes you have, what proteins you have, what circuits are hot and cold” 
(Anonymous, n.d.) (i.e., from 31:35 to 31:44 in the video). 
 On introducing bipolar disorder the presenter stated, “Not sure there’s as much 
information or replicated information and the theories may not be as solid for mania as 
for depression” (Anonymous, n.d.) (i.e., from 34:06 to 34:15 in the video). The presenter 
also reiterated that there was no single gene for depression (i.e., from 34:34 to 34:54 in 
the video). Next, the idea of low norepinephrine and depressive symptomatology was 




Additionally, the presenter stated that “So again there’s theory and we’re starting to 
develop these neuroimages that really show that brains operate differently when you have 
a psychiatric illness versus when you don’t” (i.e., from 39:09 to 39:19 in the video).    
 Towards the end of the video, the presenter repeated that it was unlikely for a 
single gene to be responsible for depression or mania, and that environmental factors 
played a role in depression’s etiology. In addition, the presenter noted that degenerative 
changes and inter-relationships between malfunctioning genes, proteins, and circuits, 
might precipitate depressive symptomatology (Anonymous, n.d.) (i.e., from 39:44 to 
40:02 in the video). Finally, none of the researcher’s listed critics were cited or 
referenced within the video.     
 In the Pharmacotherapy for Depressive Disorder video, the presenter stated: 
Let’s take a look at the neurochemistry of depression. So biochemically what 
occurs in depression? While there’s still a lot that’s unknown it appears that the 
neurotransmitters serotonin and norepinephrine play an essential role in 
depression. To simplify a great deal, the depletion of these transmitters is 
indirectly correlated with depression just as  potentiating these neurotransmitters 
is beneficial with many cases of depression.  Dopamine, on the other hand, 
appears to be only secondarily associated with depression.   And an increase in 
dopamine also appears to aid in some cases of recovery in depression. (i.e., from 
01:23 to 02:20 in the video)  
   
 The video subsequently discussed the biochemistry of these neurotransmitters 
(Anonymous, n.d.) (i.e., from 02:21 to 06:30 in the video). Next, in discussing the 
neuropharmacology of depressive disorders, the presenter noted that “Based on the 
serotonin deficiency hypothesis serotonin seems particularly implicated in depression just 
as 5-HT increase is particularly implicated in the treatment of depression. Nonetheless, 




from 15:58 to 16:20 in the video). This latter caveat was reiterated in a discussion about 
atypical antidepressants, Mirtazapine, Trazodone, and Bupropion.  
 Next, in discussing bipolar disorder, the presenter asserted:  
Bipolar disorder has forced us to look beyond the immediate neurotransmitters 
and to  look inside of the cell. In fact neuroscience is finding that all conditions 
from depression to anxiety to psychosis are characterized by gene expressions that 
modulate initial superficial actions at the synapses level. (i.e., from 24:02 to 24:43 
in the video)   
 
 Further, in the process of differentiating between the neurochemistry of bipolar 
disorder and depression, the presenter asserted that: 
The inositol hypothesis states that transmission of certain monoamines, 
norepinephrine and dopamine during an initially adaptive stress response leads to 
transduction through  G-protein receptors into a perseverating increase on 
inositol. Inositol as an intracellular messenger may play a role in increased 
glutamate activity. Glutamate is an excitatory neurotransmitter emitted by 
glutamatergic inter-neurons found throughout the brain. It is also a neurotoxin in 
high sustained quantities. The inositol theory, but one among many, states that 
bipolar disorder is the result of the nervous system’s inability to shut off the 
arousal phase of the stress response maintaining high activity in the glutamatergic 
pathways which creates manic acting out and, finally, neuronal death. 
(Anonymous, n.d.) (i.e., from 24:25 to 25:50 in the video)   
 
 DSM.  In the Biological Basis of Affective Disorders video, within the context of 
discussing the etiology of depression, the presenter asserted:  
If you develop enough of these gene mutations, abnormal proteins, 
malfunctioning circuits, you now have multiple symptoms, and if those coalesce 
you start to get these categories, DSM like categories or diagnoses. For example, 
schizophrenia, [and] major depressive disorder. (from 02:58 to 03:17 in the video) 
 
 The presenter also posited that “The categorical diagnosis used by the DSM 
probably isn’t the way that the brain truly functions” (i.e., from 05:00 to 05:07 in the 
video). Next, the presentation discussed depressive symptoms and the diagnosis of 




stated that “If you develop at least five out of nine DSM depressive symptoms because 
you have five out of nine brain areas that are abnormally active than maybe you have a 
diagnosis” (from 15:05 to 15:15 in the video).    
 The researcher did not find content which met the study’s coding framework 
requirements for this topic, within the Pharmacotherapy of Depression video 
(Anonymous, n.d.). However, the presenter for this video did identify depressive 
symptomatology (e.g., low mood, concentration difficulties, psychomotor retardation or 
agitation, guilt, suicidal ideation, appetite changes, motivation, and suicidal ideation), in 
discussing psychopharmacological treatments for the disorder. Next, the presenter 
referred to a number of DSM disorders (e.g., bipolar disorder, depression, ADHD, and 
schizophrenia). Further, manic behavior was mentioned on a number of occasions in 
which psychopharmacological treatments for bipolar disorder were discussed.   
 C/S/X. The researcher did not find information about the c/s/x movement within 
either of the examined psychologist postdoctoral psychopharmacology program’s 
analyzed videos.   
Division 55 PEP Review DVD 
The Division 55 PEP Review DVD was comprised of ten learning Modules in 
addition to a short introductory PowerPoint which outlined the training materials in broad 
strokes. All of the learning Modules used PowerPoint presentations to disseminate 
content and the majority of these slides contained an audio clip. The audio clips were 
predominantly verbatim readings of the slides’ written content. For a list of the learning 
modules including the numbers of slides for each module and the percentage of questions 





 = Number of Power Point slides per topic 
 = Percentage of questions for each topic within PEP Exam  
 
Figure 8. Number of division 55 pep review dvd power point slides afforded per topic 
and percentage of questions within psychopharmacology examination per topic. 
   
Neurobiological etiology of depression.  Five slides from the Division 55 PEP 
Review DVD’s ten learning Modules addressed neurobiologically based hypotheses of 
depression’s etiology.  For example, the audio clip for one slide (#64) within the Nervous 
System Pathology Module noted a genetic hypothesis for the etiology of depression, and 
the audio clips from two slides (i.e., #16, #69) within this Module implicated 




 Next, the Pharmacology Module pointed to a neurotransmitter based etiology of 
depression in slide #68 and noted “Knowledge of theoretical relationships thought to 
exist between neurotransmitter systems and psychopathological conditions based on 
known mechanisms of action and clinical observation. Examples: roles of serotonin in 
depression.” In addition, slide # 43 from the Integration Module described what could be 
interpreted as an anatomical hypothesis for the etiology of depression. For example, the 
slide stated that “[The] amygdala  doesn’t turn off in some depressed patients.” 
 In the Nervous System Pathology Module, various disorders of the nervous system 
with depressive symptomatology were addressed. Slide #6 from the Research Module 
provided a link to the Carlat Report (2015). Carlat was one of the study’s listed critics 
and while his report was not analyzed for this study, it does contain challenges of 
conventional viewpoints about psychopharmacology.  
 The Neuroscience Module (i.e., audio clip for slide #4), recommended that 
students use a neuroanatomy text in conjunction with the presentation. Similarly, slide 
#35 associated a number of brain areas with psychopathology and suggested that students 
familiarize themselves with these regions.  Next, the audio clip for slide #61 referred 
students to chapters six and seven from Stahl’s Essentials of Psychopharmacology 
(2008), in order to increase familiarity with brain regions and tracts implicated within 
conditions commonly treated via prescription psychotropics.  
 An analysis of both chapters for content on neurobiological etiologies of 
depression found a genetic hypothesis for the disorder was mentioned in chapter six with 
the caveat that “depression is moderately biologically determined in many individuals—




presence of major stressors” (Stahl, 2008, p. 192). The text also noted that “Major 
Depressive Disorder may be less robustly biologically determined than schizophrenia” 
(p. 193). In chapter seven, the researcher did not find content about a neurobiological 
etiology of depression that met the coding categories for this topic (Stahl, 2008).   
 The Division 55 PEP Review DVD’s computer file of “supplemental materials” 
was comprised of two papers on medication dosages and applications, an Excel template 
for documenting drug references, a list of pregnancy related medication safety 
classifications, the PEP Candidate Guide, the Mental Health: Culture, Race, and 
Ethnicity: A Supplement to Mental Health: A Report of the Surgeon General (Rockville, 
2001), and the National Healthcare Disparities Report (U.S. Department of Health and 
Human Services, 2006). An analysis of these materials yielded one case of content 
pertaining to a neurobiological hypothesis of depression.  
 For example, the Surgeon General’s report noted the potential role that genetics 
play in depression’s etiology. The report also challenged the veracity of this claim 
positing “less heritability for depression than for bi-polar disorder and schizophrenia” 
(Rockville, 2001, chapter 1, p. 26). The PEP Candidate Guide and Application Materials 
noted connections between depression and the endocrine, hematological, and 
immunological systems and commented on the existence of depressive symptoms within 
some medical disorders (American Psychological Association College of Professional 
Psychology, 2006).   
 The Division 55 PEP Review DVD also provided links to a variety of different 
organizations disseminating information about psychopharmacology (Division 55 & 




Epocrates, the National Institute of Health, the sites at Harvard University and Stanford 
University, and the Psychiatric Times. The Division 55 PEP Review DVD’s 
supplemental resource list also included a link to the aforementioned Carlat Report—a 
blog written by Daniel Carlat (one of the researcher’s listed critics) which addresses a 
variety of nonconventional perspectives about psychopharmacology.  
 In addition, students were encouraged to read Patient Centered Method and Self-
Directed Behavior Change, by Eivind Meland (1995) and, The Cost effectiveness of 
Anxiety Nervosa Treatment, by Crow and Nyman (2003). The researcher did not find 
content on neurobiological hypotheses of depression within either of these papers.  
 DSM.  The researcher did not find DSM content that met criteria for this topic’s 
coding framework within the Division 55 PEP Review DVD’s learning modules 
(Division 55 & Hoover, n.d.).  However, the audio clip for slide #61 within the 
Neurosciences Module referred students to chapters six and seven from Stahl’s Essentials 
of Psychopharmacology (2008) to increase familiarity with brain regions and tracts 
implicated within conditions typically treated with prescription psychotropics (Division 
55 & Hoover, n.d.). The DSM was explicitly referenced on two pages in chapter six of 
this text (Stahl, 2008). One of these pages included content on the limits of the DSM 
including a critique of its construct validity. For example, Stahl noted that the manual 
was based on “consensus statements” and that “mental illnesses are not diseases” 
(p. 178). Stahl also noted that the manual was useful as a tool that aided communications 
about the symptomatology of mental illness (i.e., p. 178).  In addition, Stahl referenced 




did not code for any DSM content within chapter seven. Similarly, the researcher did not 
locate any DSM content within the PEP Practice Questions provided by Dr. Hoover.  
 The researcher found content that fit the coding framework for the DSM within 
one of the Division 55 PEP Review DVD’s (n.d.) Supplemental Articles (i.e., the 
Surgeon General’s supplemental report, Mental Health: Culture, Race, and Ethnicity 
(Rockville, 2001)). In total, there were 27 pages on which the DSM was addressed in 
general terms therein, including discussions about its applications and guidelines. Eleven 
of the 27 pages contained information about the manual’s development and ten pages 
integrated critiques, limitations, or criticisms of the DSM. In addition, aspects of the 
DSM’s strengths and merits were identified on six pages of text.  
 Critique wise, the DSM’s content validity was challenged on five pages of the 
report and there was one page on which the manual’s inter-rater reliability was critiqued 
(Rockville, 2001). The researcher did not find statistics about the DSM’s rigor within this 
report.  References to the manual’s merits focused on Rockville’s assertions that the 
manual’s authors had a concerted effort to consider the impact of culture, race, and 
ethnicity on symptom presentation and diagnostic considerations.  
 There was no DSM content meeting the study’s coding frameworks for this topic 
within the articles by Meland (1995) or Crow and Nyman (2003). Finally, the researcher 
did not find content on the DSM within the PEP Practice Questions provided by Hoover.  
 C/S/X. The researcher did not locate any c/s/x content that met the study’s coding 
requirements for this topic, within the Division 55 PEP Review DVD’s (n.d.) ten 
PowerPoint learning Modules or chapters six and seven from Stahl’s Essentials of 




was one example of c/s/x content within the Division 55 PEP Review DVD (n.d.) 
Supplemental Materials that met the criteria for the study’s c/s/x coding category 
framework for this topic. This was located within a footnote of the first chapter of the 
Surgeon General’s report which noted that consumers, survivors, and ex-patients were 
terms that “identify people who use or have used mental health services” (Rockville, 
2001, p. 16). There was also some content within the report falling outside of the coding 
categories that warrants mentioning—in chapter two of Rockville’s report it was noted 
that anti-psychiatry groups had exploited pre-existing African-American mistrust of 
mental health professionals (p. 29). However, it was unclear whether the authors were 
considering c/s/x groups within this context.  
 The report also noted the importance of a “voluntary support network,” but no 
further clarification was provided in this regard (Rockville, 2001, p. 33). In addition, 
page 166, in chapter seven noted the benefit of including “representatives from the 
community being served in the design, planning, and implementation of services.” Again, 
there was no explicit mention of the c/s/x movement within this context.    
 A comment within Eivind Meland’s (1995) article bears mentioning as well: “As 
society changes the paternalistic role must change in accordance with the lay consumer 
and patient movement” (p. 1.). Again, it was unclear whether the author was referring to 
the c/s/x movement in this regard. Similarly, an assertion within the National Disparities 
Report (U.S. Department of Health and Human Services, 2006) asserted that patient 
centered care involved “Providing care that is respectful of and responsive to individual 
patient preferences, needs, and values and ensuring that patient values guide all clinical 




reference to the movement in the article and for this reason none of the aforementioned 
content was coded as such. The researcher did not find c/s/x content in the article by 
Crow and Nyman or within the PEP Practice Questions provided by Hoover.  
Listed Critics 
 In terms of the examined psychologist postdoctoral psychopharmacology program 
none of the Non-Semester Project (NSP) books or non-textbook readings cited the 
study’s listed critics within discussions about the DSM or neurobiological hypotheses of 
depression. The c/s/x movement was not addressed therein.  
 Three of the Semester Project (SP) books were authored by a critic (i.e., Carlat, 
Healy, and Whitaker). Four of the SP books cited one or more of the listed critics in 
addressing the etiology of depression. In Selling Sickness, for instance, Moynihan and 
Cassels (2005) cited David Healy on three occasions in which a neurotransmitter 
hypothesis for depression was discussed. Two of these citations were for Healy’s (2003), 
Let Them Eat Prozac, and the third was for an interview with Healy within the 
documentary Selling Sickness (Moynihan & Cassels, 2005). 
 In Let Them Eat Prozac, Healy (2003) cited two of his own works (2000, 2001)in 
the process of critiquing the chemical imbalance hypothesis of depression. Similarly, in 
Psychotropic Drug Prescriber’s Survival Guide, Dubovsky and Dubovsky (2007) cited a 
1999 article by Healy in their critique of the monoamine hypothesis  In addition, in 
Anatomy of an Epidemic, Whitaker (2010) cited three of the researcher’s listed critics in 
challenging the neurotransmitter premise for depression. This included three citations for 
a 2005 article by Jeffery Lacasse about pharmaceutical marketing and the portrayal of 




paper by Healy on antidepressant advertising.  Whitaker (2010) also noted that Healy 
“has written a number of books on the history of psychiatry” (p. 74). Finally, in referring 
to the monoamine hypothesis for depression, Whitaker (2010) quoted Joseph Glenmullen 
from his book 2000 Prozac Backlash, and the latter’s assertion that “in every instance 
where such an imbalance was thought to be found it was later proved to be false” 
(Whitaker, 2010, p. 78).  
 Anatomy of an Epidemic also included two citations for one listed critic within 
critiques of the DSM’s rigor that met coding requirements for this topic (Whitaker, 
2010). For example, Peter Breggin’s (2001) book, Talking Back to Ritalin, was 
referenced in a discussion about the development of the DSM-III and the purported lack 
of evidence to support a neurobiological basis for ADHD (as cited in Whitaker, 2010, 
p. 221).  Whitaker (2010) also referenced Breggin’s 1991 book, Toxic Psychiatry, in 
discussing the economic benefits that the DSM-III’s publication and subsequent sales 
brought the American Psychiatric Association (p. 272).  
 In addition, a number of the researcher’s listed critics were also cited within 
discussions that fell outside of the study’s three topics of analysis.  Three of the examined 
NSP textbook chapters, all of the SP books, and five of the non-textbook readings cited 
one or more of the researcher’s listed critics within this context. For example, in A 
Primer of Drug Action, Daniel Carlat (2010) was cited within a discussion about 
prescriptive authority for psychologists (as cited in Julien et al., 2013, p. 682). Next, in 
Pharmacotherapy for Psychologists: Prescribing and Collaborative Roles, two works by 




(Antonuccio, Danton, DeNelsky, Greenberg, & Gordon, 1999; Brown, Antonuccio, 
DuPaul, Fristad, King, Leslie, et al., 2008, as cited in McGrath & Moore, 2010, p. 98).   
 In chapter six of Pharmacotherapy for Psychologists: Prescribing and 
Collaborative Roles, LeVine and Foster, referenced a paper by Carlat on the kindling 
hypothesis and its implications to psychiatry with regard to establishing rapport with 
clients (2008, as cited in LeVine and Foster, as cited in McGrath & Moore, 2010, p. 125). 
Next, chapter seven of McGrath and Moore’s text included a section on research 
methodology in which the last-observation-carried-forward (LOCF) procedure was 
examined and a citation for Irvine Kirsch integrated therein (as cited in McGrath & 
Moore, 2010). In the same chapter, Joanna Moncrieff’s research on medication side 
effects and the purported issue of unblinding within placebo controlled antidepressant 
drug trials was noted (Moncrieff, Wessely, and Hardy, 1998, as cited in McGrath & 
Moore, 2010, p. 136).  
 Finally, in Essential Evidence Based Psychopharmacology, a paper co-authored 
by Kirsh and Deacon was cited in examining the implications that study participants’ 
baseline symptoms could have on the results of antidepressant drug trials (Kirsch, 
Deacon, Huedo-Medina, Scorbia, Moore, and Johnson, 2008, as cited in Stein et al., 
2012) Another page referenced a meta-analysis co-authored by Healy on suicide risk and 
antidepressant drug trials (Fergusson, Doucette, Glass, Shapiro, Healy, Hebert, et al., 
2005, as cited in Stein et al., 2012).  
 In terms of non-textbook readings, Antonuccio was cited on three occasions 
within Practice Guidelines Regarding Psychologists' Involvement in Pharmacological 




example, one of these papers was cited within a discussion about “professional 
challenges” conceivably faced by prescribing psychologists (Antonuccio, Danton, & 
McClanahan, 2003, as cited in American Psychological Association, 2011, p. 835). 
Concerns about “iatrogenic medication effects” and the comparable level of efficacy 
between treating depression with psychotherapy or psychopharmacology were also noted 
(Antonuccio, Burns, & Danton, 2002, as cited in American Psychological Association, 
2011, p. 841; Antonuccio et al.., 1999, as cited in American Psychological Association, 
2011).   
 The article, Antidepressant Drug Effects and Depression Severity: A Patient-Level 
Meta-Analysis, referenced a paper by Kirsch et al., on the potential for baseline symptom 
severity to impact drug trial results (2008, as cited in Fournier et al., 2010). Next, another 
of  Kirsch’s  papers, this one questioning the efficacy of antidepressants, was cited in 
Smith’s article, “Research Shows that all too Often, Americans are Taking Prescriptions 
that may not Work or May be Inappropriate for their Mental Health Problems” (2008, as 
cited in Smith, 2012).   
 Smith`s (2012) article also referenced Carlat’s (2010) book, Unhinged, in 
discussing the financial incentives for psychiatrists who prescribe medications instead of 
making provisions for psychotherapy. Next, Carlat was cited in a discussion about the 
purportedly unrealistic expectations that some patients have surrounding the effectiveness 
of psychotropic medications (2010, as cited in Smith, 2012).   
 The examined study by Cuijpers and colleagues on the effectiveness of 
medications for treating anxiety and depression referenced a meta-analysis coauthored by 




antidepressants (Spielmans,	Berman,	&Usitalo,	2011,	as	cited	in	Cuijpers	et	al.,	2013).  
Next, the Department of Defense/Veterans Affairs PTSD Guidelines referenced four 
articles on hypnosis by Kirsch in discussions about the treatment of trauma symptoms via 
adjunct interventions (1994, 1995, 1996, 1999, as cited in VA/DoD, The Management of 
Post-Traumatic Stress Working Group, 2010).   
 There were also a number of instances within the Semester Project books in 
which listed critics were cited for content that fell outside of the study’s three topics of 
analysis. For example, in chapter four of Unhinged, Carlat quoted Healy in a discussion 
about concerns surrounding the over-prescription of psychotropic medications (1997, as 
cited in Carlat, 2010). Healy was also cited along with Joseph Glenmullen, regarding 
risks of medication side effects (Healy, 2004, and Glenmullen, 2001, as cited in Carlat, 
2010).  Next, Joanna Moncrieff was referenced within the context of critiquing the 
dopamine hypothesis for schizophrenia (2009, as cited in Carlat, 2010). Also in chapter 
four, an article by Lacasse and Leo was referenced within a discussion about Eli Lilly’s 
use of the neurotransmitter deficiency hypothesis to market Cymbalta (2005, as cited in 
Carlat, 2010).   
 In chapter five of Unhinged, Carlat cited Marcia Angel’s book, The Truth About 
the Drug Companies, as being an “invaluable source” of information about the 
“deceptive marketing strategies of the pharmaceutical industry” (2005, as cited in Carlat, 
2010, p. 231). Next, Healy and Cattell’s article outlining concerns about ghost writing, 
was referenced in a section of Unhinged that addressed the pharmaceutical industry’s 




addition, a work by Healy outlining the history of ECT was referenced in chapter eight 
(2007, as cited in Carlat, 2010).  
 Carlat (2010) cited a number of his own works within chapters five, six, seven, 
eight, and ten for topics ranging from the author’s experiences as a Wyeth speaker, as 
well as his concerns about ghost writing, bipolar and ADHD diagnoses in children, the 
validity of ADHD testing, and unethical pharmaceutical marketing (2006a, 2006b, 2007a, 
2007b, 2008, as cited in Carlat, 2010).    
 In, The Medicalization of Society, Conrad (2007) cited three of the researcher’s 
listed critics within content that fell outside of the study’s three topics of analysis. Here, 
Angel was cited in a discussion about the growing influence of the pharmaceutical 
industry, while Breggin was referenced in relation to his critiques surrounding the 
construct validity of ADHD and the use of Ritalin to treat the disorder (Angel, 2003, and 
Breggin, 1998, as cited in Conrad, 2007). In chapter seven, Healy and Angel were both 
cited within a section on the history and development of pharmaceutical marketing 
(Healy, 1997, Relman & Angel, 2002, as cited in Conrad, 2007).    
 Similarly, in Selling Sickness, Moynihan and Cassels referenced Angel’s article, 
Is Academic Medicine for Sale, in discussing the relationship between psychiatry and the 
pharmaceutical industry.  In addition, Healy was cited on eight occasions within the 
context of discussing antidepressants, iatrogenic suicide risk, pharmaceutical marketing, 
and the medicalization of human experience (Angel, 2000, 2003, and Healy, 2003, 2004a, 
2004b, as cited in Moynihan & Cassels, 2006). Next, Antonuccio was referenced twice 




questioning the efficacy of antidepressants (1995, 1999, as cited in Moynihan & Cassels, 
2006).  
 In chapter four, Moncrieff was cited on three occasions. For example, in 
discussing the prevalence of ADHD in children, questioning the validity of the ADHD 
diagnosis, and in raising concerns about the implications of pharmaceutical company’s 
efforts to partner with parents of children diagnosed with ADHD (Moncrieff, 2003, 2007, 
and Timimi, Moncrieff, & Jureidini, 2004, as cited in Moynihan & Cassels, 2006). 
Moynihan and Cassels also referenced Healy in a discussion about the ways in which 
pharmaceutical marketing reportedly shapes societal conceptualizations of mental distress 
(2003, as cited in Moynihan & Cassels, 2006). 
 There were also cases in Let Them Eat Prozac (2003), where critics were listed 
for topics that fell outside of the study’s analysis. Within this context, Healy (2003) cited 
44 articles, two replies to articles, and six books he had authored, coauthored, edited, or 
co-edited. In addition, Healy referenced documents from three trials he had taken part in 
(i.e., a testimony, expert witness statement, and three depositions). Healy’s critical 
analysis of Prozac also addressed concerns surrounding the drug’s development process 
(i.e., research, publications, FDA process), marketing (i.e., fraudulent claims), safety (i.e., 
increased risk of harm to self and others), and efficacy (i.e., compared to other 
antidepressants and psychotherapy).  
 In addition, Let Them Eat Prozac (2003) referenced Glenmullen’s (2001) book 
Prozac Backlash, five times across chapters two, four, nine, ten, and twelve. Here, 
Glenmullen was cited in discussing the antidepressant poop-out effect, the Joseph 




Healy also discussed the criticism Glenmullen faced after publishing Prozac Backlash. 
Next, Breggin was cited on nine occasions across chapters three, four, five, six, and 
seven, within the context of discussing the 1991 Food and Drug Association’s advisory 
committee on Prozac, the effectiveness of psychotherapy, and Breggin’s role as an expert 
in lawsuits against pharmaceutical companies (1991, 1994,  as cited in Healy, 2003).  
 Breggin’s (2001) book, Toxic Psychiatry, was also referenced by Healy. For 
example, in discussing negative reviews of that text including Eli Lilly’s purported 
efforts to portray Breggin in a negative light (as cited in Healy, 2003).  In addition, Healy 
cited Breggin and Whitaker in addressing concerns surrounding the use of 
pharmaceutical company donations to support patient organizations like CHADD 
(Breggin, 1991, and Whitaker, 2002, as cited in Healy, 2003). Next, Marcia Angell’s 
book, Science on Fire, was referenced in discussing breast implants and associated law 
suits (1997, as cited in Healy, 2003). Healy (2003) noted that these litigations brought 
“corporations to their knees using medico-legal experts who were all but charlatans” 
(p. 335).     
 In Drug Prescriber Survival Guide, Dubovsky and Dubovsky (2007) cited 
Angel’s book, The Truth about Drug Companies, on twelve pages of text for content that 
fell outside of the study’s three topics of analysis (2005, as cited in Dubovsky & 
Dubovsky, 2007). Here Angel was cited within content that focused on the 
pharmaceutical industry’s purportedly negative impacts on the field of medicine. For 
example, partnerships between drug companies and universities, industry sponsored 
CME programs, manipulations of physician’s prescribing habits, problems with the FDA 




advertising claims were inconsistent with research findings (Angel, 2005, as cited in 
Dubovsky & Dubovsky, 2007. 
 Similarly, four of Healy’s works were referenced on eleven pages of Drug 
Prescriber Survival Guide in addressing the pharmaceutical industry’s impacts on the 
profession of psychiatry, the history of antidepressants, concerns about the increased 
prevalence of depression, the extent of industry sponsored research, and links between 
the pharmaceutical industry, academia, and physicians’ prescribing habits (Healy, 1999, 
Healy & Cattell, 2003, Healy & Thase, 2003, as cited in Dubovsky & Dubovsky, 2007). 
Further, Healy was referenced in the text’s discussions about the pathologization of 
human behaviours, biases in the reporting of research findings, the limits of data from 
industry sponsored trials, and issues surrounding the side effects of SSRIs (1999, Healy 
& Cattell, 2003, Heal & Thase, 2003, 2006, as cited in Dubovsky & Dubovsky, 2007).     
 In addition to the listed critics cited within discussions about the DSM and the 
chemical imbalance hypothesis of depression, Anatomy of an Epidemic included 
references to works by Breggin, Kirsch, Moncrieff, Healy, Carlat, Leo, and Glenmullen 
in addressing other topics related to psychopharmacology (Whitaker, 2010). For example, 
seven works by Breggin were cited on 17 pages across chapters six, eleven, thirteen, and 
fourteen (Breggin, 1991, 1993, 1997, 2001a, 2001b, 2008a, 2008b, as cited in Whitaker, 
2010). This content focused on iatrogenic effects of antipsychotics, challenges to the 
validity of a neurobiological hypothesis for ADHD, concerns about the methodology of 
ADHD research, and questions surrounding the safety and efficacy of prescribing Ritalin 




 Whitaker also referenced Breggin in discussing the efficacy and side effects of 
SSRI’s (i.e., suicide risk, apathy syndrome, and cognitive decline), the development of 
the DSM, and concerns about partnerships between the American Psychiatric Association 
and the pharmaceutical industry (Whitaker, 2010). Finally, Whitaker (2010) cited a 
number of Breggin’s works in the process of challenging claims about neurobiological 
theories of mental distress, and in discussing the marketing of xanax and the purportedly 
negative impacts that challenging pharmaceutical companies and the American 
Psychiatric Association had on Breggin’s career. 
 Additionally, a meta-analysis by Kirsch and colleagues was cited in chapter eight 
of Anatomy of an Epidemic within the context of questioning the efficacy of 
antidepressants (Kirsch et al., 2008, as cited in Whitaker, 2010). Next, Joanna 
Moncrieff’s works were cited in chapters eight and nine, in the process of discussing 
British sickness benefits and trends therefore. Further, her book, The Myth of a Chemical 
Cure, which outlined potential risks associated with long term lithium therapy, was 
referenced (2000, 2008, 2009, as cited in Whitaker, 2010). Next, the article by Jonathon 
Leo, SSRI Trials in Children, was cited in a discussion about methodological concerns 
pertaining to SSRI drug studies (i.e., manipulation of placebo responders) (2006, as cited 
in Whitaker, 2010).         
 Whitaker also referenced works by Angel and Carlat in discussing pharmaceutical 
company’s relationships with physicians and psychiatrists who are hired to speak at 
industry sponsored drug information sessions (Angel, 2000, and Carlat, 2007, as cited in 
Whitaker, 2010, p. 278). In addition, Glenmullen’s Prozac Backlash, was referenced by 




(2000, as cited in Whitaker, 2010, p. 307). Healy was cited on a total of 13 pages within 
chapters nine, eleven, fourteen, and sixteen, which included references to eight of his 
works (2000, 2001a, 2001b, 2004, 2005, 2008, 2009a, 2009b, as cited in Whitaker, 
2010). More specifically, Healy was cited within content about the history of manic 
depression, suicide risk associated with SSRIs, Eli Lilly’s “fraudulent” marketing of 
Prozac, and the marketing of pharmaceuticals via collaborations between the National 
Institute of Mental Health and Eli Lilly (Whitaker, 2010, p. 284). Healy was also 
referenced within Whitaker’s content about the history of asylums, psychiatric bed 
utilization, the dangers of over-prescribing, and the negative impact that speaking about 
the suicide risks associated with SSRIs had on the former’s career (as cited in Whitaker, 
2010).  
 The researcher did not find any of the study’s listed critics within the PEP Review 
DVD materials. 
Relevant Content Falling Outside of the Coding Framework Requirements  
 The researcher found a number of instances in which there was relevant content 
that fell outside of the study’s coding categories for information about a 
neurobiologically based etiological hypothesis of depression (within the examined 
materials from the analyzed psychologist postdoctoral psychopharmacology program). 
For the Non-Semester Project books, this included comments about the apparent role that 
genetics, neuroanatomy, neurocircuitry, receptors, and neurotransmitters play in the 
neurobiological etiology of psychiatric disorders in general. There were also some 
instances within these texts where broad critiques of neurobiological hypotheses for the 




Psychopharmacology for Nurses, Leahy and Kohler (2013) asserted that “Although the 
field of psychopharmacology has experienced a revolution over the past two decades, 
much remains unknown about the human brain, neuropathology, and neurotransmitters as 
they relate to an individual’s thoughts, moods, and behaviours” (p. xxviii). Similarly, 
McGrath and Moore (2010) stated that “The psychobiosocial model does not 
circumscribe the nature of human suffering or problems with adaptation as a ‘chemical 
imbalance’” (p. 113). In the same vein, Blumenfeld (2010) stated in his neuroanatomy 
textbook that “Emotions and drives are almost as difficult to explain as consciousness 
itself” (2010, p. 976).  
 The Semester Project books also included a number of critiques within the scope 
of relevant content falling outside of the coding frameworks for this topic. For example, 
Carlat, Healy, Moynihan and Cassells, and Whitaker all made broad assertions that the 
neurobiology of psychiatric disorders was unknown. Further, Conrad’s book on 
medicalization noted skepticism about the validity of ADHD. There was one Non-
Textbook reading in which the researcher found relevant content that fell outside of the 
coding framework requirements for a neurobiological hypothesis of depression’s 
etiology. In this instance, the authors of Psychotherapy and Psychopharmacology: 
Different Universes or an Integrated Future? noted that some patients requested 
medications for the explicit purpose of treating chemical imbalances (Winston, Been, & 
Serby, 2005). However, the theory was not challenged and there was no further 
discussion about how best to address the limitations of this hypothesis with patients.  
   In terms of the videos, relevant content falling outside of the coding framework 




Affective Disorders, about neurochemistry’s  role in every cognitive-emotional  
experience (i.e., from 38:59 to 38:57 in the video) and the comment that: 
 The chemistry involved in complex biopsychosocial operations is well beyond 
our present day ability to calculate let al.one measure and control. Key to 
appreciating this complexity nevertheless is the acknowledgement of interplay 
and multiple feedback systems at the molecular as well as global levels. For the 
time being it takes deductive  reasoning and an act of faith to understand the 
complex role of neurochemistry and even the simplest of mental operations. (n.d., 
from 39:11 to 39:44 in the video) 
  
 The PEP Training DVD’s supplemental materials also included relevant content 
about a neurobiological etiology of depression that fell outside of the coding categories.  
In this regard, the examined chapters of Stahl (2008) and Rockville’s (2001) paper made 
a number of general references to a neurobiological etiology of mental distress involving 
neurotransmitters, neurocircuitry, neuroanatomy, and genetics. Next, in terms of 
critiques, Stahl (2008) discussed the complexity involved in trying to determine links 
between genetics and mental distress. Finally, Rockville (2001) asserted that “The precise 
causes of most mental disorders are not known: the broad forces that shape them are 
genetic, psychological, social, and cultural, which interact in ways not yet fully 
understood” (p. 7). 
 In summary, there were a few critiques surrounding the validity of a genetic based 
neurobiological etiology for mental distress, and an assertion about the lack of 
neurobiological evidence for explaining casual factors pertaining to psychiatric disorders 
as a whole.  However, there were no specific references to depression or specific 
hypotheses for the disorder’s etiology within the context of relevant content not captured 




 There was a substantial amount of information about the DSM falling outside of 
the coding framework’s requirement that the manual be explicitly mentioned on the page 
it was discussed. This content was documented within the “comments” section of the data 
collection spreadsheet. The volume of these findings was challenging to consolidate and 
also proved to be problematic for inter-rater reliability. This latter issue will be discussed 
in more detail within the limitations section. The majority of this content included 
references to DSM nosology, although there were also some cases in which the manual’s 
construct validity was briefly challenged. For example, in Primer of Drug Action, Julien 
and colleagues (2011) asserted that the diagnosis of bipolar disorder in childhood or 
adolescence was “difficult and it is still being debated” (p. 196). In addition, the text 
posited that it was unclear whether “ADHD is a medical disorder, a behavioral problem 
mainly manifest in schools, or a disorder of human adaptation (Mayes et al.., 2009)” 
(Julien et al., 2011, p. 610).  
 Similarly, Stahl (2013) asserted that the diagnostic criteria for schizophrenia and 
bipolar disorder were not sufficiently sensitive to capture some relevant cases that would 
be overlooked by the DSM-IV-TR’s criterion.  In addition, Stahl noted that the manual’s 
interpretation of antidepressant induced mania as a substance induced disorder ignored 
the possibility of a pre-existing disposition for bipolar. The researcher did not find any 
critiques of the DSM’s inter-rater reliability within this subset of relevant, albeit uncoded, 
content. Thus, overall, a comprehensive analysis of the DSM that addressed issues 
surrounding race, gender, socioeconomic status, and well established problems with the 




examined materials regardless of whether the relevant content falling outside of the 
coding categories was included.      
Interview With Examined Psychologist Postdoctoral Psychopharmacology Training 
Program’s Director  
 The examined psychologist postdoctoral psychopharmacology program’s Director 
was interviewed for roughly an hour on April 10, 2015. However, on April 12, 2015, the 
Director requested that the interview responses be excluded from the study. For a list of 




Chapter IV: Discussion 
 The discussion addresses considerations surrounding the extent to which the 
analyzed curriculum materials from the examined psychologist postdoctoral 
psychopharmacology program’s curriculum and the PEP Review DVD materials 
(including the PEP Practice Questions), integrated critiques of neurobiologically based 
hypotheses of depression, identified challenges to the DSM’s rigor, and discussed the 
c/s/x population and movement. This will be followed by an Integrative Discussion.    
Examined Psychologist Postdoctoral Psychopharmacology Training Program  
 Syllabi. The brevity of the syllabi’s format conceivably limited the extent to 
which the three analyzed topics could be addressed therein. Nonetheless, the study’s 
analysis of the examined program’s syllabi indicated that some efforts had been made to 
address nonconventional perspectives about psychopharmacology. For example, the 
Semester Project (SP) required students to read one book that critiqued various aspects of 
psychopharmacology and write a paper critiquing the author’s main arguments. However, 
it could be argued that challenging a critique of conventional perspectives about 
psychopharmacology leads the student back to conventional thinking—unless students 
are required to critique conventional viewpoints as well.  It also warrants mentioning that 
students were required to read two articles and watch a TedTalk video that challenged 
conventional perspectives about pharmacological interventions.  
 Next, the analysis of the syllabi clarified that neurobiologically based hypotheses 
for the etiology of depression were being addressed within the examined iteration of the 
analyzed psychologist postdoctoral psychopharmacology program. It also warrants 




source which critically analyzes a variety of psychopharmacology topics 
(www.thecarlatreport.com). While this indicated that students were encouraged to be 
critical of conventional perspectives there was no way to confirm whether these materials 
were being accessed or, if they were, which articles students were choosing to read. 
Further, there is evidence that compliance rates for required readings are low, particularly 
for graduate students with work and family responsibilities. Additionally these readings 
were recommended and non-specific which also raises questions about the likelihood of 
compliance.        
  Further, in considering c/s/x content it is noteworthy that a search of the Carlat 
Report’s website did not yield any information for the following search terms: 
“survivor,” “MindFeedom,” “Icarus Project,” “MadPride,” “c/s/x,” “ex-patient” 
(www.thecarlatreport.com). Additionally, a search of the website using the term 
“consumer” yielded links to six documents—one which focused on depression and how 
to be a more “informed consumer of medical research,” another that examined which 
Electronic Health Records consumers should purchase, and a third paper which explored 
issues surrounding psychiatrists’ management of their web presence (i.e., nothing about 
the c/s/x movement). Similarly, the fourth paper addressed the FDA’s order for consumer 
medication guides for stimulant medications, the fifth paper covered the use of Adderal 
by college students, and the sixth article explored the complexities of prescribing generic 
drugs to patients. Consequently, while the Carlat Report likely provides some critiques of 
hypotheses for neurobiological etiologies of depression and the DMS’s rigor, it seems 





Non-Semester Project Books   
 Etiology of depression. It was notable that the majority of the examined Non-
Semester Project books did not critique all of the neurobiological hypotheses of 
depression disseminated. Further, only one of the examined NSP readings made an effort 
to outline a variety of different problems with a particular hypothesis. For example, 
Stahl’s (2013) critique of the monoamine hypothesis for depression provided a relatively 
detailed critique that outlined the origins, support, and shortcomings of this hypothesis.  
In other cases, challenges to neurobiological hypotheses of depression being 
disseminated within the examined NSP texts’ readings provided only cursory critiques.  
Here, the readings noted that research findings were “inconsistent,” “disparate,” 
“controversial” or “discordant” or, in some cases, the existence of “conflicting evidence” 
was identified (Brunton et al., 2010, p. 708; Schatzberg & Nemeroff, 2009, pp. 488, 911, 
913, 928). In rare occurrences, the limits of a particular study’s methodology were briefly 
mentioned (i.e., the “use and overuse” of brain scans) (McCance et al., 2010, p. 646).  
 In this regard, it would have been useful for the text to offer at least a brief 
summary surrounding the limits of psychopathology based neuroscientific research as a 
means to identify important caveats for the findings being presented  (i.e., by reviewing 
the limits of neuroimaging technology, identifying shortcomings of animal research, 
acknowledging problems with using the DSM as a diagnostic tool for research, and 
discussing potential biases in the reporting and publishing of some research findings).   
  Next, it warrants mentioning that the only examined NSP textbook reading (i.e., 
Pathophysiology: The Biological Basis of Disease, 2009), to critique all of the 




these challenges exclusively on PMDD - a condition that lay outside of the DSM-IV-
TR’s established disorders.   Similarly, it was notable that the brief critique of the 
monoamine hypothesis in the recommended Manual of Clinical Psychopharmacology for 
Nurses (2013) also occurred within the context of disseminating the symptoms of PMDD. 
It is unclear how the omission of consistent and/or thorough critiques of neurobiological 
factors for the etiology of depression impacts a new prescriber’s understanding about the 
causes of mental distress, the rigor of the DSM, and the implications this could have on 
acquiring informed consent. These latter considerations will be addressed in greater detail 
during the study’s Integrated Discussion. 
 It was also notable that four neurobiological based hypotheses for depression 
disseminated across the body of examined NSP readings were not critiqued at all and that 
four of the examined readings’ discussed the monoamine hypothesis of depression 
without any provisions for critiques therefore. The chemical imbalance hypothesis has 
not received sufficient support to warrants its consideration without a thorough 
deconstruction of the evidence used to support it (Stahl, 2008, 2013; Whitaker, 2010).  
 Next, the researcher queried the author of one NSP book that did not integrate 
critiques for a number of neurobiological hypotheses for depression’s etiology. This 
author, who wished to remain anonymous, reported having relied on support from 
colleagues with expertise in affective disorders (anonymous, personal communication, 
March 7, 2014).  His response raises questions about the responsibility of a primary 
author or editor when it comes to integrating critical analyses of content provided by 




  That none of the 16 examined chapters from The American Psychiatric 
Publishing Textbook of Psychopharmacology (2009) challenged the monoamine or 
neuroendocrine hypotheses of depression, despite having addressed these hypotheses in 
some detail, also warrants revisiting. Particularly since students were required to read 
roughly a quarter of this textbook. This raises questions surrounding the level of 
importance that the examined program’s curriculum developers placed upon critical 
examinations of conventional viewpoints.     
 Next, Neuroanatomy through Clinical Cases (2010)—which was read in its 
entirety—identified five neurobiological hypotheses for the etiology of depression, 
without critiquing any of them. While the text was not designed to focus on the 
neurobiology of affective disorders, it is concerning that no critiques were integrated 
therein. Again, this raises questions about the implicit message that omitting critiques 
might convey to students (i.e., that these critiques may not be essential to consider when 
it comes to safe and effective prescription practices and obtaining informed consent).   
 Additionally, the researcher observed some notable differences in the ways NSP 
textbooks conceptualized neurobiological causes of depression. For example, some 
neurobiological hypotheses of depression were ascribed to the disorder’s etiology while 
other authors conceptualized the same hypotheses within the context of disease 
pathophysiology. These heterogeneities in conceptualizing depression likely stem from 
ongoing uncertainties about depression’s neurobiological causes and symptomatology. 
Further, some degree of overlap might be expected between both characterizations of the 
disease process. For example, it is plausible that apoptosis may represent a cause and 




 Another observation was that Stahl (2013) referred to the “monoamine hypothesis 
of depression” and also called it a “classic theory about the biological etiology of 
depression” (p. 262). Whitaker (2010) referred to the “chemical imbalance theory” 
(p. 10) as did the presenters of both examined videos from the analyzed psychologist 
postdoctoral psychopharmacology training program. Carlat (2011) stated that “Officially 
this [chemical imbalance] theory of depression is known as the ‘monoamine 
hypothesis’.” Next, Julien and colleagues (2011) described the “neurogenic theory of 
depression” (p. 143)—a premise that has also been identified as the neurogenic 
hypothesis and neurogenesis hypothesis of depression (Eisch & Petric, 2012; Sapolsky, 
2004). The reason for these discrepancies is unclear although differences in opinion about 
the strength of the respective hypothesis or theory or loose adherence to scientific 
principles in this context, seem like plausible explanations.  
 Another observation with regard to the examination of NSP book findings was the 
complete absence of citations within Stahl’s Essential Psychopharmacology: 
Neuropsychological Basis and Practical Applications (2013). This omission made it 
difficult to determine which studies were being used to support the author’s assertions. In 
justifying the decision to omit citations, Stahl asserted “We have a large number of 
references at the end of the book, for each chapter.  Not every statement is referenced in 
the body of the text as this is a not a review, but a textbook” (S. Stahl, personal 
communication, November 12, 2014).  
 By comparison, Julien and colleague’s (2011) book incorporated 52 citations (the 
majority were primary source studies) for the first three chapters, while Stahl’s book 




from secondary sources and arguably not indicative of a “large number of references” 
(S. Stahl, personal communication , November 12, 2014). Similarly, while Stahl provided 
32 citations exclusively from primary sources for the chapters on mood disorders (chapter 
six), antidepressants (chapter seven), and mood stabilizers (chapter eight), Julien et al. 
(2011) cited 139 sources in their text’s chapter on antidepressants. 
 Stahl’s justification for omitting citations in favor of recommended readings is 
inconsistent with the book’s title which specified that the text would address the 
“Neuroscientific Basis” of psychopharmacology. According to the Merriam Webster 
dictionary, the term basis is defined as, “something on which something else is 
established or based” and the Oxford Dictionary’s definition states that basis is “the 
underlying support or foundation for an idea, argument, or process” and “the justification 
for or reasoning behind something.”     
 The relevant content that fell outside of the study’s coding categories also requires 
discussing. In retrospect, the provision of an additional category to capture “broad 
critiques” that challenged conventional viewpoints about the etiology of mental distress 
may have been more effective than documenting this information within a catch-all 
“comments” section.  For example, in the Manual of Clinical Psychopharmacology for 
Nurses, Leahy noted that “Although the field of psychopharmacology has experienced a 
revolution over the past two decades, much remains unknown about the human brain, 
neuropathology, and neurotransmitters as they relate to an individual’s thoughts, moods, 
and behaviors” (Leahy & Kohler, 2013, p. xxviii).  Similarly, in Neuroanatomy Through 
Clinical Cases, Blumenfeld (2010) posited that “many processes of the mind, particularly 




neurophysiological terms” and, “Emotions and drives are almost as difficult to explain as 
consciousness itself” (pp. 974, 976).  Further, in Psychopharmacology for Psychologists: 
Prescribing and Collaborative Roles, McGrath and Moore (2010) asserted that “The 
psychobiosocial model does not circumscribe the nature of human suffering or problems 
with adaptation as a ‘chemical imbalance’” (p. 113).  Next Blumenfeld (2010) asserted 
that “Emotions and drives are almost as difficult to explain as consciousness itself” 
(p. 976).  In the same vein, within the context of discussing the pharmacological 
treatment of depression, Bresee, Gotto, and Rapaport acknowledged “disparate biological 
findings” with regard to the disorder’s “biological underpinnings” (as cited in Schatzberg 
& Nemeroff, 2009, p. 1090). While these comments acknowledge that the body of 
evidence for neurobiological etiologies of mental distress is limited, they do not address 
the particular shortcomings of each theory. 
 Given that the majority of NSP books were not read in their entirety it warrants 
considering whether relevant content surrounding a neurobiological etiology of 
depression may have been missed within the unexamined chapters of the partially 
analyzed books. For example, in reviewing the American Psychiatric Publishing 
Textbook of Psychopharmacology’s (2009) chapter on the Neurobiology of Mood 
Disorders—which was not a required reading—the researcher found that  seven of the ten 
neurobiologically based etiological hypotheses of depression being presented were 
critiqued. This indicates that the topic was being addressed elsewhere in the book, albeit 
with inconsistent critiques. 
 It was notable that the study’s analysis of Stahl’s Essential Psychopharmacology 




addition, the study examined the book’s chapter on chemical neurotransmission, and 
another on transporters, receptors, and enzymes as targets of psychotropic drug action.  
All of these chapters cover topics related to the etiology of depression which suggests 
that this topic would have been covered within the required pages of this text. Similarly, 
while the analysis of A Primer of Drug Action (2011) did not examine nine of the book’s 
20 chapters, the study’s analysis did include the text’s required chapter on 
pharmacodynamics, another on neurotransmission, and a third on antidepressant drugs. 
Further, there was no chapter which explicitly noted depression or mood disorders within 
this book. Consequently, the three aforementioned chapters would ostensibly have been 
the most likely sources of information about a neurobiological etiology of depression 
within this textbook. 
  Next, in reviewing a chapter (not a required reading) in Pathophysiology: The 
Biological Basis for Disease in Adults and Children (2010) focusing on mood disorders, 
the researcher found a similar dearth of critiques. For example, five neurobiological 
hypotheses of depression’s etiology were addressed on 17 pages of text and there was one 
brief critique for a neurotransmitter hypothesis of depression’s etiology—this was located 
within the fine print below a figure and stated that “In depressed individuals, 
neurotransmitter levels are hypothesized to be reduced. The mechanisms responsible for 
this reduction are not understood” (Tackahashi, as cited in McCance et al., 2010, p. 655).  
 Additionally, in examining the index of Pharmacotherapy for Psychologists 
(2010), the researcher found that there were seven pages with content on “depression” 
and “major depressive disorder” and no listings for “mood disorders” or “affective 




readings focused attention on the etiology of depression. In Essential Evidence-Based 
Psychopharmacology (2012), the book’s index listed a total of 21 pages with content on 
“depression,” and “major depressive disorder”—there were no listings under “mood 
disorders” or “affective disorders.”  Five of these pages had not been examined as part of 
the study’s analysis and none of these pages contained content about the etiology of 
depression.  It is also notable that the study’s analysis of this text did include the required 
chapter on Evidence-Based Pharmacotherapy of Major Depressive Disorder—ostensibly 
the most likely source within that text for any content addressing a neurobiological 
etiology of depression.  
 Next, in reviewing the index for Neurosciences (2012), another text that was not 
analyzed in its entirety, the researcher found that a total of four pages were listed under 
“depression,” “major depressive disorder,” mood disorders,” and “affective disorders,” 
and all within one of the unexamined chapters.  These pages were part of the chapter on 
Emotions wherein Purves and colleagues (2012) noted that “Despite evidence for a 
genetic predisposition and an increasing understanding of the brain areas involved [in 
affective disorders], the cause of these conditions remains unknown” (p. 660).  It also 
warrants reiterating here that students were required to read this textbook’s chapter on 
Neurotransmitters and Their Receptors which contained a full page “Box” discussion 
about “Biogenic Amine Neurotransmitters and Psychiatric Disorders” (p. 126), and none 
of the content therein critiqued the chemical imbalance hypothesis of mental distress.  
 An analysis of the index from Goodman and Gilman’s: The Pharmacological 
Basis of Therapeutics (2011) found 19 pages of text listed under primary headings for 




disorders” or “affective disorders.”  Of these 19 pages, there was only one page that had 
not been analyzed within the examined psychologist postdoctoral psychopharmacology 
program curriculum’s required readings. This particular page was part of the chapter 
entitled 5-Hydroxytrytamine (Serotonin) and Dopamine, and included content which 
focused on research into animal models of depression. For example, Sanders-Bush and 
Hazelwood asserted that “Mutant mice lacking the 5-HT transporter display anxiety and a 
‘depressive-like’ phenotype (Fox et al.., 2007)” (as cited in Brunton et al., 2011, p. 343). 
These authors also noted that 5-HT receptors have been “implicated in the animal models 
of depressions, such as learned helplessness” (p. 343). In what might be seen as a critique 
for the neurotransmitter hypothesis of depression, Sanders-Bush and Hazelwood 
described how manipulated reductions in the amount of serotonin in the brain could 
abruptly reverse the efficacy of SSRI’s for depression. Here, the authors posited that 
“This clinical finding adds credence to somewhat less convincing neurochemical findings 
that suggest a role for 5-HT in the pathogenesis of depression” (as cited in Brunton et al., 
2011, p. 343).    
 In reviewing the index of Pharmacotherapy: A Pathophysiologic Approach 
(2011), the researcher found a combined total of 18 pages with content on depression 
identified via primary headings for “depressive disorder” and “mood disorder”—there 
were no primary headings for “affective disorders” or “major depressive disorder” (Teter, 
Kando, & Wells, as cited in Dipiro et al., 2011). Sixteen of these pages were contained 
within the book’s chapter, Major Depressive Disorder. An analysis of this chapter found 




addressed (i.e., neurotransmitter, neurotrophin, and neuroendocrine hypotheses) and 
critiqued.   
 For example, Teter and colleagues asserted that “It is apparent that no single 
neurotransmitter theory of depression is adequate” and noted that the involvement of 
neurotrophins within the etiology of depression “is a relatively recent theory, which has 
not been firmly established” (as cited in Dipiro et al., 2011, p. 1174). Next, the authors of 
this chapter acknowledged the “high rate of false positive and false negative results 
associated with neuroendocrine abnormalities in depressed patients” (p. 1175).  
 The two additional pages with information on depression as identified within the 
text’s index were both located within the chapter on Pregnancy and Lactation: 
Therapeutic Considerations (Dipiro et al., 2011). This content focused on depression 
within the context of discussing mental health conditions during pregnancy; more 
specifically, epidemiological findings for the disorder and considerations surrounding the 
use of antidepressants during the neonatal period (i.e., p. 1369). This chapter also 
identified considerations pertaining to the psychotropic treatment of post-partum-
depression.  
 DSM.  Variability in DSM content across and within the Non-Semester Project 
books was anticipated. For example, a number of texts dealt with topics largely unrelated 
to the manual (i.e., Seeley’s Anatomy and Physiology, 2011; The Atlas of Functional 
Neuroanatomy, 2005; and Neurosciences, 2012). In addition, as noted elsewhere in this 
analysis, the examined program did not require its students to read all of the curriculum’s 
books in their entirety. Thus, it is possible that partially examined books contained 




  At the same time, the absence of any explicit mentions of the DSM within 
Neuroanatomy through Clinical Cases (Blumenfeld, 2010), warrants mentioning. For 
example, despite having focused on medical conditions, there was a section within the 
textbook’s chapter on the Anatomical and Neuropharmacological Basis of Psychiatric 
Disorders which discussed the symptomatology of schizophrenia, obsessive compulsive 
disorder, anxiety disorders, depression, and mania. The symptoms of major depressive 
disorder and, to a lesser extent mania and anxiety disorders, were also discussed in 
chapter three. 
 Given the amount of content directly related to the DSM (i.e., its disorders and 
respective symptomatologies) it was surprising that the manual was never explicitly 
referenced within Blumenfeld’s (2011) textbook. The use of DSM nomenclature within 
the context of discussing neuroanatomical considerations for psychopathology, without 
explicitly identifying or addressing the manual’s shortcomings could be interpreted as an 
implicit message to readers that the limits of the DSM’s diagnostic validity and reliability 
are secondary to the very findings that the manual is used to conceptualize. This might 
lead students to conclude that these considerations are mutually exclusive, reiterating 
concerns about how prescribing psychologists are being trained when it comes to 
addressing the empirical limits of the DSM as a necessary component of acquiring 
informed consent from clients and prescribing medications with potentially serious health 
risks.    
 Similarly, the absence of explicit references to the DSM within the Clinical 
Handbook of Psychotropic Drugs (2011) was notable because the medications addressed 




validity and inter-rater reliability have implications for the pharmaceutical interventions 
discussed within the handbook (i.e., the issue of informed consent and the ramifications 
of false positive or false negative diagnoses when it comes to psychopharmacological 
interventions).   
 DSM content within the Manual of Clinical Psychopharmacology for Nurses 
(2013) warrants further mention because of the extent to which this text integrated the 
manual within its coverage of mental disorders and psychotropic interventions. For 
example, the text noted within its introduction that “In particular, contents of each 
chapter focus on diagnostic criteria and neurobiology of the relevant disorder(s), 
pharmacological choices, and recommendations on monitoring, side effects to consider, 
and treatments with special populations and those with medical illnesses” (Leahy & 
Kohler, 2013, p. xxvi).   
 Further, despite discussing the manual to varying degrees within 55 pages of text, 
there was only one instance in which the DSM’s empirical rigor was critiqued in a 
manner that met coding framework requirements for this topic (Leahy & Kohler, 2013). 
The omission of any thorough critiques of the DSM therein gives the impression that the 
manual is a safe and effective tool for empirically diagnosing patients and prescribing 
psychotropic drugs based on these prescriptions.   
 Similarly, despite having briefly identified limitations with the manual’s 
classification of general anxiety disorder and acknowledged that the clinical features of 
bipolar disorder may differ between adolescents and youths, there were no thorough 
critiques of the DSM’s empirical rigor with the 17 examined chapters of the American 




 In Stahl’s Essential Psychopharmacology (2013), the author explicitly noted on a 
few occasions that the reader should obtain an additional reference source for a 
comprehensive description of diagnostic considerations including “ongoing debates” 
about diagnostic criteria (p. 573). Thus, while the reader was not provided with any 
information about where to find these critiques, Stahl had made an effort to highlight the 
reader’s responsibility in augmenting their readings of his text to address these 
considerations  
 In considering the possibility that DSM content was addressed within the 
unexamined chapters of the Non-Semester Project book readings, the researcher reviewed 
their indices for listings under the primary headings “DSM,” “Diagnostic and Statistical 
Manual of Mental Disorders” and “Diagnosis.” In doing so, the researcher found two 
additional pages with critiques of the DSM within portions of the required texts that 
students did not have to read—both occurred in Stahl (2013).   For example one page 
within the preface of Stahl’s Essential Psychopharmacology (2013) identified the manual 
within the context of discussing its limitations relative to the Research Domain Criteria 
(RDoC). Here, Stahl (2013) noted that many of the manual’s diagnoses: 
‘travel’ transdiagnostically without respecting the DSM (Diagnostic and 
Statistical Manual) of the American Psychiatric Association or the ICD 
(International  Classification of Diseases). This is the future of psychiatry—the 
matching of symptom endophenotypes to hypothetically malfunctioning brain 
circuits, regulated by genes, the environment and neurotransmitters. (p. x)  
 
 The second of the aforementioned pages from Stahl’s Essential 
Psychopharmacology (2013) mentioned the RDoC developer’s efforts to correlate 
diagnostic schemes with neuroimaging and genetic findings. In this regard, the content 




capacity to discern between symptom domains that cut across a variety of different 
disorders.  
 C/S/X. The absence of any information about the c/s/x movement within the 
examined Non-Semester Project books’ analyzed chapters was not unexpected given that 
the primary focus of these texts pertained to psychopharmacology and neuroscience. 
However, it was surprising that McGrath and Moore’s (2010) book, Pharmacotherapy 
for Psychologists: Prescribing and Collaborative Roles did not address the movement 
within any of its chapters (required or otherwise), given the extent to which Sammons et 
al. (2003) had addressed the c/s/x movement within their seminal text, Prescriptive 
Authority for Psychologists: A History and Guide.  
 It warrants considering that there may have been content on the c/s/x movement 
within unexamined sections of the other partially analyzed texts. In an effort to address 
this, the researcher reviewed the indices of these texts using the terms “consumers”, 
“survivors,” “ex-patients,” and “c/s/x.”  However, no additional content on the c/s/x 
movement was located via this analysis of the indices.   
Semester Project Books  
 Neurobiological etiology of depression. There were some important differences 
among the Semester Project books with regard to the topics covered and the depth of 
their respective analyses. For example, Healy’s (2003) book focused on Prozac and the 
purported increase in suicidal ideation and completed suicides linked to SSRIs. By 
contrast, Carlat’s (2010) Unhinged provided a critical examination of psychiatry as a 
profession and made recommendations about improving client care (i.e., longer visits 




 Next, Moynihan and Cassels (2006) centered their analysis on the pharmaceutical 
industry and the negative impacts of marketing strategies on consumers.  By comparison, 
in The Medicalization of Society, Conrad (2007) focused more attention on the processes 
by which human conditions are transformed into medical disorders. In Dubovsky and 
Dubovsky’s (2007), Psychotropic Drug Prescriber’s Guide, examination of the 
pharmaceutical industry, relatively more attention was focused on the issue of bias within 
academic publications relative to the other SP books. In addition, this text provided 
specific recommendations for how to critically interpret drug research. Robert Whitaker’s 
(2010), Anatomy of an Epidemic, sought to address the question of why increasing 
numbers of Americans are disabled by mental illness.  
 Whitaker’s (2010), Carlat’s (2010), and Healy’s (2003) books provided 
considerably more content on individual cases and stories relative to the other SP books. 
These heterogeneities meant that students’ exposure to certain issues was largely 
dependent on which SP book they had selected. 
 It was noteworthy that half of the Semester Project books focused solely on the 
monoamine hypothesis of depression without addressing any other neurobiological 
hypotheses for the etiology of mood disorders. The potential reasons for this are worth 
considering.  For instance, Prozac’s mechanism of action has traditionally been 
conceptualized as inhibiting the reuptake of serotonin which is consistent with the 
chemical imbalance hypothesis for depression. Consequently, it is not surprising that 
Healy (2003) would focus attention on deconstructing this particular hypothesis. In 
addition, Healy concentrated on sociopolitical factors surrounding antidepressants, 




was less space for reviewing other neurobiological hypotheses of depression. 
Nonetheless, the absence of content pertaining to additional hypotheses for the disorder 
limited the scope of Healy’s analysis.  
 In discussing Anatomy of an Epidemic, Whitaker (2010) reported having focused 
his attention on the monoamine hypothesis because: 
a) this chemical imbalance theory was the prevailing theory that has been told to 
the public about why the drugs are effective. And so, if you are going to put that 
public story under scrutiny, you need to review whether it is so; b) second, the 
research into the chemical imbalance hypothesis led researchers to come to an 
understanding of how the drugs affect the brain over the longer term, and that is 
they induce compensatory changes the opposite of what was originally intended. 
Thus, by focusing on the chemical imbalance theory, the research provides a 
fairly clear picture of how the drugs act on the brain, short term and long term. 
Thus, you can then frame the question: how does this drug action, which includes 
compensatory changes, affect people over the long term?  And the point here is 
this: I am not really focused on hypotheses for the disorder—that would  be a 
different book. I am focused on how the drugs affect the brain, and then what 
science tells us about their long-term effects. (Personal communication, July 19, 
2015)   
 
 In considering potential differences between these books it is also worth noting 
that Healy and Carlat’s prescription practices may be more liberal than the ones Whitaker 
would subscribe to.  For example, Healy (20030 described himself as:  
someone committed to both pharmacotherapy and ECT. In my opinion the idea of 
getting by without physical treatments, hoping psychotherapy alone will do the 
job is a romantic notion. Romance is nice but doesn’t make people well. Drug 
therapies have done a great deal to improve things, to the point where critics of 
psychiatry are taken seriously when they argue there is no such thing as mental 
illness. Sadly, the history of  psychiatry does not bear out arguments that all of 
this is just a matter of social control, or that the problems for which physical 
treatments are given would respond to psychotherapies if sufficient time and 
skilled therapists were available. (2003, pp. 17–18) 
  
 Similarly, Carlat (2010) described psychopharmacological interventions as being 




(p. 16). Conversely, while Whitaker (2010) agreed that psychotropic prescription drugs 
might be helpful in some circumstances, he raised relatively more concerns than Healy 
(2003) and Carlat (2010), about the long-term safety risks and questionable efficacy of 
psychotropic medications.  
 In describing his assessment of Anatomy of an Epidemic, Carlat (2011) asserted 
that “My overall take is that Whitaker has his basic facts right, and that he communicates 
them in a compelling style that I envy. But I disagree with his interpretation of the facts” 
(para. 5). Further, Carlat noted that “Whitaker does a great job documenting an 
astonishing rise in psychiatric disability, but he erroneously blames the drugs, when the 
actual causes are more nuanced and multifactorial” (Carlat, 2011, Cause #3, para. 2).   
 It was notable that Dubovsky and Dubovsky (2007) chapter on How to Identify 
and Deal With Marketing did not discuss how the chemical imbalance hypothesis had 
been used to advertise, sell, and prescribe psychotropic medications—an arguably 
pertinent issue within the context of this particular discussion. If a student from the 
examined iteration of the psychologist  postdoctoral psychopharmacology training 
program had selected the Dubovskys’ (2007) or Conrad’s (2007) book for the Semester 
Project, their exposure to critiques of this hypothesis within the context of this particular 
assignment would have been extremely limited in the first case and non-existent in the 
second. There was also a strong possibility that students would not be exposed to critical 
analyses of other neurobiological hypotheses of depression during this assignment 
because only one of the three SP texts addressing alternatives to the monoamine 




 Differences in the authors’ training and professional experiences are also 
noteworthy. For example, Steven Dubovsky, Daniel Carlat and David Healy are 
psychiatrists, and Amelia Dubovsky was a medical student when the book she co-
authored with her father was published. Robert Whitaker and Ray Moynihan are 
journalists, Peter Conrad a sociologist, and Alan Cassels is a pharmaceutical policy 
researcher. Diversity in the backgrounds of these authors has the potential to expose 
students to a variety of perspectives—but only if they are required to read more than one 
book for this assignment.    
 DSM.  It is conceivable that students completing the examined iteration of the 
analyzed psychologist postdoctoral psychopharmacology program, within the context of 
the Semester Project and its six recommended books (of which students were required to 
select one book), could have missed being exposed to more critical perspectives about the 
DSM. For example, the Dubovskys’ (2007) text only briefly mentioned the manual on 
one page and without the provision of a critique. Next, despite noting that changes in 
diagnostic nosology made it difficult to compare research over time (via content that did 
not meet coding category framework requirements), the rest of the book used DSM 
nomenclature without examining the manual’s rigor. Further, four of the six Semester 
Project texts did not address the manual’s inter-rater reliability at all, meaning that 
students’ exposure to this particular issue could also have been missed within the context 
of their book selection for the Semester Project.    
 Apparent differences between the SP books’ assessments of the DSM’s utility 




the manual’s limitations, he was less critical in this regard than Whitaker. For example, 
Carlat (2010) stated that:  
Over the years, the various versions of the DSM have been criticized and 
ridiculed. The  book has been called a tool of the pharmaceutical industry and a 
collection of arbitrary  labels based on shaky science. But with all its 
imperfections, it actually evolved out of a crying need in the profession for more 
precise descriptions of disorders, and it has done a great service by providing 
them. DSM actually represents the culmination of a  profession’s noble struggle to 
categorize the inner anarchy that is psychiatric illness. (pp. 47–48) 
   
 In contrast, Whitaker (2010) focused most of his analysis on the DSM’s shortfalls. 
For example, while Whitaker noted that a DSM diagnosis could facilitate the provision of 
special services for children with ADHD, there was little indication that the author 
considered this to be a positive recourse given the potentially harmful pharmaceutical 
intervention(s) that would likely follow.  
 C/S/X. The dearth of c/s/x information within all but two of the Semester Project 
books suggests that students were unlikely to be introduced to the c/s/x movment unless 
they read Whitaker’s (2010) or Carlat’s book. Further, while Unhinged provided a brief 
discussion of Julie Lawrence’s personal reservations about the use of electroconvulsive 
therapy, no other activists from the c/s/x movement were mentioned (Carlat, 2010). Nor 
did Carlat explicitly focus on other aspects of the c/s/x movement (i.e., concerns about 
forced drugging, forced hospitalization, ECT, and the limited involvement of 
consumers/survivors/ex-patients within the mental health care system).     
 Whitaker’s (2010) book stood out in this regard because it addressed the c/s/x 
movement’s history, activism, campaigns, events, advocacy efforts, and organizations 
within 40 pages of text. Further, Whitaker made a concerted effort to integrate the 




  It also warrants mentioning Healy’s and Carlat’s references to “fringe groups” 
and organizations linked to the Church of Scientology which have been involved in 
critiques of psychiatry. Regardless of their respective intentions, the use of the term 
“fringe,” without clarifying its parameters more effectively could be interpreted as 
discrediting consumer/survivor/ex-patient organizations and their initiatives to critique 
the discipline of psychiatry and center mental health practices. For example, c/s/x activist 
David Oaks (2006) noted that some academics “Align the history of our movement with 
the ‘radical left’ to a great extent, ignoring decades of outstanding work by conservatives 
and libertarians in fighting psychiatric abuse” (p. 1212).   
Non-Textbook Readings 
 Neurobiological etiology of depression. There was limited content about 
hypotheses for a neurobiological etiology of depression, within the non-textbook 
readings. This was not particularly surprising given that the majority of these readings 
dealt with topics indirectly related to depression’s etiology. It could be argued that more 
space should have been afforded to the provision of caveats challenging the disorder’s 
neurobiological etiology—particularly since four of the five papers which did identify a 
hypothesis for depression did not integrate critiques therefore (e.g., the American 
Academy of Child and Adolescent Psychiatry’s Guidelines for the Assessment and 
Treatment of Children and Adolescents with Depressive Disorders, 2007, which 
specifically focused on depression and its psychopharmacological treatment). 
 DSM.  It was anticipated that only a minority of the non-textbook readings would 
contain information about the DSM. Many of these articles addressed issues related to 




disorders (i.e., avoiding medication errors, surveys of mental health coverage, lab values, 
and dangerous abbreviation lists). Nonetheless, the researcher was surprised at the 
number of non-textbook readings which discussed DSM diagnoses without actually 
referencing the manual. For example, the Harvard Medical School Algorithms for 
Bipolar Depression (Ansari & Osser, 2010a), Bipolar Mania (Ansari & Osser, 2010b), 
Post Traumatic Stress Disorder (Bajor, Ticlea, & Osser, 2011), Social Anxiety Disorder 
(Osser & Dunlop, 2010), Psychotic Depression (Tang & Osser, 2012), and Schizophrenia 
(Osser, Roudsari, & Manschreck, 2013) made no mention of the manual or its limitations. 
Similarly, one might assume that research papers on the effectiveness of antidepressants 
and antipsychotic drugs would reference the manual and briefly review controversies 
surrounding its applications within the contexts of drug trials and clinical practice. By not 
examining issues with the manual’s construct validity and inter-rater reliability, an 
important methodological limitation and potential confound to these studies’ data was 
overlooked. Further, there is an implicit message to readers that these considerations are 
not particularly relevant to the topic. 
 It was also notable that 55 of the 57 non-textbook readings (i.e., 96.5%) did not 
address the issues surrounding the DSM’s inter-rater reliability levels and only one of the 
five papers dealing with the manual’s construct validity did so in any detail (i.e., less than 
1% of the non-textbook readings). Next, this latter paper focused more on developmental 
considerations in diagnosing bipolar disorder among children than in critiquing the 
manual itself.  It is concerning that the researcher could not find any thorough 
examinations of the DSM’s limitations across the entire body of the examined 




lack of any findings that comprehensively addressed problems with the manual’s 
construct validity and inter-rater reliability within this subset of materials raises questions 
about the importance being afforded to this issue.  
 C/S/X. The absence of information about the c/s/x movement within the Non-
Textbook readings was not particularly surprising given these papers’ respective foci.  
Videos  
 Neurobiological etiology of depression. The finding that the Biological Basis of 
Depression video focused considerable attention on the etiology of depression and 
critiqued one of the six neurobiological theories for depression disseminated is notable 
because it sends a message to students that the information can be interpreted without 
attendance to its shortcomings. Further, the aforementioned critique was limited by its 
brevity (i.e., in noting that there were also some negative studies). While this presentation 
focused on the purported relationships between genes, proteins, neurocircuitry and 
depression, it was particularly notable that the chemical imbalance hypothesis was 
introduced as one of the leading theories for depression and referenced on a variety of 
occasions during the video—without the provision of any critiques acknowledging the 
lack of empirical support for the hypothesis.  
   Another concern was the extent to which neuroimaging research was simplified 
in order to elucidate neurobiological hypotheses for the etiology of depression. For 
example, in asserting that “we’re starting to develop these neuroimages that really show 
that brains operate differently when you have a psychiatric illness versus when you 
don’t” (i.e., from 39:09 to 39:19 in the video).  The same argument could be made of the 




depressive disorder. There are hormonal ones, there are neurodegenerative ideas. And 
again it may come down to what genes you have, what proteins you have, what circuits 
are hot and cold” (Anonymous, n.d.) (i.e., from 31:35 to 31:44 in the video).   
 Despite the absence of any thorough critiques of neurobiological theories for the 
etiology of depression, the second presenter’s concluding statement within the 
Pharmacotherapy for Depressive Disorder video broadly challenged the extent literature 
surrounding the neurochemistry of mental disorders. For example, he noted that, 
The chemistry involved in complex biopsychosocial operations is well beyond our 
present day ability to calculate let al.one measure and control. Key to appreciating 
this complexity nevertheless is the acknowledgement of interplay and multiple 
feedback systems at the molecular as well as global levels. For the time being it 
takes deductive reasoning and an act of faith to understand the complex role of 
neurochemistry and even  the simplest of mental operations (Anonymous, n.d.) 
(i.e., from 39:11 to 39:44 in the video) 
 
 At the same time, the lack of more consistent and detailed critiques of hypotheses 
for depression’s neurobiological etiology raises concerns about the impact that this video 
may have had on new prescribers and their respective levels of certainty afforded to the 
presented evidence on this topic.     
 DSM.  In the Biological Basis of Affective Disorders video, the DSM was 
primarily referenced within the context of linking the symptomatology of depression to 
hypotheses for its neurobiological etiology. While the presenter noted that the manual’s 
categorical approach was unlikely to match the brain’s functioning, no further critique of 
the DSM was provided. There was a similar dearth of information within the 
Pharmacotherapy of Depression video. The absence of a thorough critique for the DSM 
suggests that the manual’s empirical shortcomings were considered to be outside of the 




assumption that students were already well versed in this information. It could be argued 
that pharmacological interventions should not be considered without acknowledging 
problems with the construct validity and inter-rater reliability of depression and bipolar 
disorder within the context of obtaining informed consent and prescribing psychotropic 
medications.  
 C/S/X. The examined videos focused on the neurobiology and psychotropic 
treatment of depressive disorders. Again, it was not expected that this content would 
yield information about the c/s/x movement. However, it is noteworthy that none of the 
other 54 video titles were indicative of c/s/x content either.    
Division 55 PEP Review DVD  
 Neurobiological etiology of depression. The limited extent to which 
neurobiological hypotheses of depression’s etiology were addressed and the absence of 
critiques for these hypotheses within the Division 55 PEP Review DVD is noteworthy 
because these materials represent the breadth of knowledge required to safely prescribe.  
A definitive neurobiological etiology for the disorder has not been established. Further, 
antidepressants’ mechanisms of action remain uncertain. Moreover, depression is one of 
the most commonly diagnosed mental disorders in the United States (National Institute of 
Mental Health, 2015). In addition, the Centre for Disease Control and Prevention found 
that 11% of Americans aged 12 years and over were using an antidepressant (Pratt, 
Debra, & Qiuping, 2011). While the DVD recommended within its Research Module and 
resource list that students read the Carlat Report, student’ compliance in this regard is 




 DSM.  The absence of any explicit references to the DSM within the Division 55 
PEP Review DVD’s learning module’s slide presentations is worthy of mention for the 
same reasons identified above. On the one hand, the DVD did encourage students to read 
the Surgeon General’s Report—a document that contained critiques of the DSM’s 
construct validity on a number of pages and also acknowledged problems with the 
manual’s inter-rater reliability (Rockville, 2001). Conversely, no statistical analyses of 
the DSM were provided within these critiques.  However, it is possible that students may 
have encountered this information with the recommended Carlat Report.  
 C/S/X. The absence of information about the c/s/x movement within the Division 
55 PEP Review DVD and PEP Practice Questions—save one brief mention of the 
phenomenon’s nomenclature within a footnote of the Surgeon General’s Report, strongly 
indicates that this topic was completely overlooked within the training DVD. Reasoning 
behind the absence of this content and the implications of this will be discussed in further 
detail within the integrated discussion.  
PEP Practice Questions  
 Possible explanations for the absence of any PEP Practice Questions addressing 
the limits of the DSM’s empirical rigor, critiques of neurobiological hypotheses for 
depression’s etiology, and information about the c/s/x movement, will be provided within 
the integrated discussion.  
Listed Critics 
 The fact that three of the Semester Project books from the examined psychologist 
postdoctoral psychopharmacology program were authored by members of the study’s 




there are shortcomings associated with having students select only one of these books 
which will be discussed further within the Integrated Discussion. The absence of any 
listed critics within the two analyzed videos and the PEP Review DVD suggest that the 
perspectives of the study’s listed critics were not considered as pertinent to the content 
being addressed therein.  
 It is not surprising that the study’s listed critics were well represented with the 
Semester Project Books which cited these experts’ to support their own critiques of 
conventional perspectives about psychopharmacology. While one might not have 
anticipated finding works by the study’s critics within the examined program’s Non-
Textbook readings given their focus on prescription related information, it is noteworthy 
that the curriculum did not consider assigning an article by one or more of these 
authors—particularly since that would have been a more efficient approach to integrating 
a broader range of critical perspectives than the Semester Project.  
Content Falling Outside of the Coding Category Frameworks 
 The content falling outside of the coding category frameworks largely mirrored 
the coded data and did not appear to change the overall findings. However, there are 
some important implications for the study’s validity and inter-reliability in this regard, 
particularly for relevant uncoded content pertaining to the DSM. This will be addressed 
in greater detail within the Limitations and Delimitations. 
Integrated Discussion and Implications  
 Findings from the examined body of psychologist postdoctoral 
psychopharmacology training materials indicated that critiques of neurobiological 




Further, more detailed analyses of etiological hypotheses of depression focused solely on 
the monoamine hypothesis which is no longer considered a viable explanation for the 
disorder. Of particular note here was the examined program’s video presentation on the 
neurobiology of depression which highlighted but never deconstructed the chemical 
imbalance hypothesis or any of the other hypotheses that were discussed therein.  
 Next, critiques of the DSM primarily dealt with its construct validity versus 
problems with the manual’s inter-rater reliability. Additionally, the researcher only found 
one example within the entire body of examined materials where a critique of the DSM 
integrated statistical data (i.e., one sentence within the recommended book Unhinged). 
This was surprising given the well documented empirical problems with the manual and 
the implications of using DSM to inform decisions about psychotropic drug interventions 
that have the potential to cause serious health problems, particularly for already 
marginalized groups like the c/s/x population.  
 Additionally, there was only one resource (i.e., the recommended book Anatomy 
of an Epidemic) with substantial content about the c/s/x movement. It is unclear why a 
well-established movement and cultural phenomenon representing some of the most 
marginalized members of our population and alleging human rights violations from 
coercive psychiatric practices would not be a topic of focus within the training that 
psychologists receive in order to prescribe.    
 These conclusions about the extent of critical discourse on a neurobiologically 
based hypothesis for depression’s etiology and challenges to the DSM are consistent with 
comments made by Marlin Hoover (M. Hoover, personal communications, November 23 




Psychological Association’s Division 55 PEP Review DVD, and Sean Ransom—another 
psychologist with prescriptive authority.   For example, in describing his own 
psychologist postdoctoral psychopharmacology training experience, Ransom noted that 
critiques of neurobiological hypotheses of depression and challenges to the DSM’s rigor 
were almost entirely limited to Carlat’s (2010) book, Unhinged.  Ransom indicated that 
the curriculum he completed primarily focused on treatment approaches, drugs’ 
mechanisms of action, and other information pertaining to the safe and effective 
prescription of psychotropic medications (S. Ransom, personal communications,  
November 7, 15, and 17, 2015).  
 When queried about his knowledge  surrounding the c/s/x movement, Ransom 
responded that he was aware of groups funded by the Church of Scientology that had 
critiqued psychiatry and the discipline of psychopharmacology (S. Ransom, personal 
communications, November 7 and 15, 2014). Further, he was aware that psychiatric 
patients had spoken out against the discipline of psychiatry. However, Ransom indicted 
that he was unfamiliar with the consumer/survivor/ex-patient movement per se. Next, 
Ransom asserted that neurobiologically based etiological hypotheses of depression and 
challenges to the DSM’s rigor should be addressed within graduate programs for 
psychologists versus psychologist postdoctoral psychopharmacology training. In this 
regard, Ransom reported having been sufficiently exposed to critiques of 
psychopharmacology during his own graduate training (S. Ransom, personal 
communications. November 7 and 15, 2014).  
 Hoover shared Ransom’s belief that psychologists should be well versed in the 




empirical rigor of the DSM, prior to starting psychologist postdoctoral 
psychopharmacology training (M. Hoover, personal communications, November 23 and 
December 10, 2014). This argument notwithstanding, Hoover asserted “I think doctoral 
clinical psychologists SHOULD be well versed in all of the literature, including the 
critical literature, about psychopharmacology (and all treatment options, by the way.)  I 
would not assert that they ARE”  (M. Hoover, personal communications, November 23 
and December 10, 2014).   
 When queried about the seemingly limited extent to which the DSM’s 
shortcomings were being addressed in the examined curriculum and within the Division 
55 PEP Review DVD, Hoover stated “It’s about treating symptoms not diagnoses. This 
may make it appear that I don’t think the limits of the DSM are important—they are. But 
psychopharmacologists treat symptoms not diagnoses.” Hoover also asserted that “The 
review class may have some acknowledgement of the DSM, [but] it does not play heavily 
in course work and the review process” (M. Hoover, personal communications,  
November 23 and December 10, 2014). 
 In addition, Hoover noted that critical perspectives about psychopharmacology 
should be addressed within the “regular clinical coursework and introductory 
coursework” that psychologists complete during their graduate studies (M. Hoover, 
personal communication, December 10, 2014). Similarly, Hoover asserted that: 
 all clinical psychologists need to be introduced to criticism of ALL treatment 
options . . . and when an already practicing licensed clinical psychologist is 
electing to take training in psychopharmacology that education must be devoted 
to safe and effective psychopharmacology practice that meets the standard of care. 




 The researcher could not find any data confirming the integration of critiques for 
conventional perspectives about psychopharmacology within psychology’s graduate or 
undergraduate training programs’ curricula. However, the American Psychological 
Association’s Guiding Principles for Accreditation of Programs in Professional 
Psychology noted within its section on Science and Practice that: 
all programs should enable their students to understand the value of science for 
the practice of psychology and the value of practice for the science of psychology, 
recognizing that the value of science for the practice of psychology requires 
attention to the empirical basis for all methods involved in psychological practice 
(2013b, p. 3) 
 
 It also warrants mentioning that doctoral training programs in psychology are not 
homogeneous. For example, according to the American Psychological Association, PhD 
programs typically take longer to complete than PsyD training and focus relatively more 
attention on research—although findings by Morgan and Cohen (2008) suggested more 
similarities than differences in their study which compared psychology graduate 
programs via a survey developed by the researchers. Dissimilarities between the 
disciplines of clinical psychology and counseling psychology also exist (e.g., more 
attention on testing versus psychotherapy, respectively). In addition, Association of 
Psychology Postdoctoral and Internship Centers (APPIC) accredited programs meet 
curriculum requirements that non-APPIC accredited programs may not be adhering to. 
Finally, even if one assumes that students across the diverse spectrum of doctoral level 
training programs in psychology are being exposed to critical perspectives about 
psychopharmacology, it is unclear whether sufficient attention is being paid to the 
implications that these critical viewpoints might have on prescribing psychotropic drugs 




 There are important health related implications when it comes to limiting or 
ignoring critical discourse about the neurobiological etiology of depression and the rigor 
of the DSM, within the materials used to train psychologists for prescriptive authority.  
For example, gaps within the body of evidence used to support diagnostic and 
psychotropic interventions mean that treatment errors are possible. Further, these 
treatment mistakes can negatively impact the health of patients based on their potential 
for consequent iatrogenic drug effects and the negative impacts of diagnoses. If 
psychologists are not being trained in the limits of diagnostic assessment for 
psychopathology and shortcomings in the evidence supporting neurobiological 
hypotheses used to justify medications, it is conceivable that they may over diagnose and 
over prescribe. However, one could also argue that an overly conservative approach to 
diagnosing and prescribing psychotropic drugs could prevent some patients from 
receiving pharmacological treatments that would help them. In this regard, a balanced 
approach is needed—one that considers a variety of perspectives surrounding psychiatric 
practices and the evidence upon which these interventions are based. Training for 
prescriptive authority which integrates the critiques of the DSM’s rigor and shortcomings 
surrounding neurobiological hypotheses for the etiology of depression is integral to this 
effort.  
 There are also ethical and socio-cultural implications for basing psychiatric 
interventions on inconclusive evidence—particularly when it comes to considering their 
impacts on marginalized groups like the c/s/x population and the importance of obtaining 
informed consent from all patients. The American Psychological Association’s Ethical 




2010) and Practice Guidelines for Psychologists’ Involvement in Psychopharmacological 
Issues (American Psychological Association, 2011) highlight the importance of cultural 
sensitivity, informed consent, beneficence, and non-maleficence. Non-adherence to these 
principles of practices could ostensibly result in a breach of ethical principles. Of interest 
here is Paula Caplan’s (2012) formal complaint to the American Psychiatric 
Association’s Ethics Committee in an effort to have the organization explicitly recognize 
that psychiatric diagnoses resulted in harm (i.e., due to job loss, child custody issues, loss 
of health insurance, and revocation of the right to make decisions about one’s own 
medical and legal affairs). In this regard, it is worth noting that the American Counselling 
Association (2014) recently revised its Code of Ethics to permit counselors to refrain 
from making and/or reporting a diagnosis if the clinician believes that the diagnosis 
would be harmful to the client or others.   
 In terms of the legal implications of obtaining informed consent, Tenenbaum 
(2012) noted “Patients are also significantly less likely to bring malpractice actions if 
they are included in the treatment process and there is effective communication between 
the physician and patient” (p. 8). Being clear and upfront with patients about the limits of 
the DSM’s rigor in diagnosing psychological distress and shortcomings in the etiological 
evidence upon which psychotropic interventions are based would presumably help to 
protect prescribing psychologists against ethical complaints and malpractice suits 
stemming from the informed consent process.   
 The apparent dearth of information about the c/s/x movement within this body of 
examined training materials has implications for advocacy efforts. While the Practice 




psychologist may play a role in forced drugging and forced confinement, it is unclear 
whether increased knowledge about the c/s/x population’s history and stance against 
coercive psychiatric practices might impact this. The limited amount of information about 
the c/s/x population within the body of examined psychologist postdoctoral 
psychopharmacology training materials suggests that current advocacy efforts between 
psychologists and the c/s/x movement are limited at best. A search of the 
MindFreedomInternational website did not locate any information about prescribing 
psychologists and there was no indication from the c/s/x activists that the researcher has 
spoken to about advocacy efforts between the c/s/x population and prescribing 
psychologists. If this is true it would be interesting to know what happened to the 
recommendations of the psychologist prescriptive authority movement’s early founders 
who made such a concerted effort to outline the importance of advocating for the c/s/x 
population within the seminal text by Sammons et al. (2003).     
 In Talking Back to Psychiatry, Morrison (2005) concluded that: 
The challenge of gaining support from the general public and of joining with 
other movements is of strategic importance for the future of this movement. The 
everyday realities of its members are driven by their own internal identities as 
activists who resist the power of psychiatry to define their lives, in the various 
ways they do their advocacy  work. The [c/s/x] movement will continue, as it has 
for thirty years, shaped by their choices, their alliances, and the responses of 
psychiatry, policymakers, and the public. (p. 174) 
 
 Similarly, Crossley and Crossley (2001) asserted that “the ‘voices’ of mental 
patients or users constitute a social, historical, and political construct” and posited that:  
[the] formulation of voice remains dependant on specific schemas of habitus 
which shape it in various ways. Simultaneously, however, it depends on the 
existence of audiences and relations of symbolic power which allow it to be 
heard. And both of these factors are, in turn, related to the growth of social 




activity outside of that field; and changes within the structure of the health field 
itself. (p. 1488)  
 
Limitations and Delimitations 
 The results of this study were based on a partial analysis of one psychologist 
postdoctoral psychopharmacology program’s curriculum, the Division 55 PEP Review 
DVD, and 160 PEP Practice Questions. In addition, not all of the textbooks were 
analyzed in their entirety. According to the examined program’s website, there were also 
online resources, chats and discussion boards, as well as case formulations and 
presentations. Consequently, it is possible that these other learning materials and formats 
may have provided additional examples of critiques for neurobiological hypotheses of 
depression, challenges to the DSM’s rigor, and information about the c/s/x movement. As 
such, this study’s findings should not be interpreted as an exhaustive analysis of the 
examined program’s curriculum, of any other psychologist postdoctoral 
psychopharmacology program’s curriculum. Further, curricula are dynamic and more 
current syllabi from the examined program likely differ from the iteration examined by 
this researcher. Similarly, some of the information within the Division 55 PEP Review 
DVD may be outdated.  
 It also warrants mentioning that content analysis and the process of determining 
coding frameworks and categories are inherently subjective processes.  For example, 
another researcher might have conceptualized this study’s topics using different 
categories or elected to measure the existence of critiques in different ways. Indeed, they 




researcher’s list of critics was not exhaustive and other researchers might have added or 
removed certain experts from this particular list.  
 A number of important limitations surrounding inter-rater reliability levels also 
require further consideration. For example, four of the American Academy of Child and 
Adolescent Psychiatry Practice Parameters were mistakenly excluded from the random 
selection of required non-textbook reading materials for the second coder and this may 
have impacted kappa scores. In addition, inter-rater reliability levels were not established 
for the examined psychologist post-doctoral psychopharmacology program’s syllabi, the 
examined videos, or for the Division 55 PEP Review DVD—meaning that the reliability 
of the researcher’s findings for these materials was unconfirmed.   
 Additionally, difficulties in establishing inter-rater agreement for content that fell 
outside of the coding categories, particularly with regard to the DSM, raises questions 
about the coding framework’s reliability and validity. For example, it is possible that the 
researcher missed or misinterpreted DSM content, including critiques of the manual’s 
empirical rigor, within the examined materials.    
 In terms of delimitations, it should be noted that the study’s collective findings 
from the mass of examined materials was consistent with feedback from two prescribing 
psychologists—one of whom developed the Division 55 PEP Review DVD.  Next, while 
the researcher omitted certain materials, the study did analyze all of the examined 
program’s syllabi, non-textbook readings, and Semester Project books. Further, examined 
recommended books were read in their entirety. Also, the researcher only omitted 
textbooks that were unlikely to address the etiology of depression, the DSM, or the c/s/x 




prescriber’s guide). Additionally, the researcher was informed by the examined 
program’s Director that the omitted article on ADHD from Childhood and Adolescent 
Psychiatry (2002) had been excluded from the curriculum. Finally, the examined 
syllabi’s course titles and objectives indicated that the two examined video presentations 
were the best exemplars of content on neurobiological theories of depression (see 
Appendix M).   
 The likelihood that the examined psychologist postdoctoral psychopharmacology 
program’s omitted training materials contained additional information about the three 
topics of analysis warrants further consideration. While it is possible that relevant 
information was missed in this analysis, the titles and topics of the omitted readings 
strongly indicated that these materials would not have focused on any of the study’s three 
topics of analysis. Next, there was some indication that the omitted chapters from the 
partially examined Non-Semester Project books (i.e., chapters that were not identified 
within the curricula) contained a limited amount of relevant content pertaining to the 
DSM and etiology of depression. For example, as noted in reviewing the indices of 
partially examined texts the researcher found one instance in which a brief critique of the 
DSM’s construct validity was included. However, no examples in which the manual’s 
inter-rater reliability was challenged were located in this regard.  
 The examination of these texts’ indices also found seven pages across four of the 
Non-Semester Project books in which a hypothesis for a neurobiological etiology for 
depression was discussed within an omitted chapter. Critiques of these four hypotheses 




content may still have been missed despite student’s efforts to conceivably read some but 
not all of the additional chapters .   
 Based upon the assertions within the examined syllabi that psychologists be well 
versed in using the DSM prior to starting the program, it seems unlikely that any of the 
aforementioned videos would have discussed the manual in depth (i.e., via a 
comprehensive analysis of the manual’s empirical limits). Further, as noted, the apparent 
dearth of information about the DSM was consistent with findings from the analysis of 
the Division 55 PEP Review DVD, the PEP Practice Questions, and feedback from 
Hoover and Ransom about psychologist postdoctoral psychopharmacology program 
curricula content.  
 Next, the two analyzed videos which focused on the neurobiology and 
psychopharmacological treatment of affective disorders provided a critique for one (i.e., 
genetics) of the six neurobiological theories for the etiology of depression that were 
discussed. In this case the critique lacked specificity and was disseminated within a single 
sentence. While it is possible that additional critiques of these and other hypotheses for a 
neurobiological etiology of depression were contained within one of the other videos, the 
probability seems low given that the video on affective disorders was ostensibly the 
primary resource in terms of presentations, for this information.  
 Finally, based on the analysis of the syllabi, the examined psychologist 
postdoctoral psychopharmacology program’s analyzed readings, the Division 55 PEP 
Review DVD, the PEP Practice Questions, and feedback from Hoover and Ransom, there 
is little evidence to suggest that the c/s/x movement was addressed within any of the 





 There are many possibilities for additional research in this area. For example, an 
analysis of other psychologist postdoctoral psychopharmacology programs is warranted 
to ascertain how their curriculums compare with this study’s findings. In examining the 
syllabi from another psychologist postdoctoral psychopharmacology program the 
researcher did not find any textbooks by well-known critics of conventional perspectives 
(i.e., like the books within the examined psychologist postdoctoral psychopharmacology 
program’s Semester Project) and the program’s syllabi did not require students to read 
any primary source research articles. 
 Similarly, another psychologist postdoctoral psychopharmacology training 
program—which was unwilling to provide a complete set of syllabi for the study—did 
send five documents in response to the researcher’s request for materials pertaining to the 
three topics of analysis. In this case, the Director of the program sent one syllabus for the 
“Psychopharmacology” class. The course description noted that the class would provide 
an “overview of neurochemistry” and indicated that students would learn to “Identify 
clinical signs and symptoms of neurobiologically based psychopathology.” The Director 
of this program also sent a study guide on research issues associated with 
pharmacotherapeutics. This paper identified internal and external validity as topics for 
review. There were no explicit references to the DSM within this document.  
 Next, the forwarded materials included a second “study guide” also focusing on 
research issues pertaining to prescription psychotropics. This document identified a 
number of research terms, and listed a variety of “Research Factors” including confounds 




research designs and a chart outlining the Federal Drug Administration’s medication 
approval process. In addition, the Director sent an exam review document for the 
treatment of depression, which identified “Diagnostic Issues” (i.e., “depression versus 
grief” and “psychotic depressions”), “Neuroprotection and the role of BDNF,” and noted 
“The impact of increased serotonin on dopamine neurons in both the frontal lobes and 
basal ganglia.”  
 Finally, the package contained a PowerPoint on Psychopharmacology, comprised 
of 85 slides focusing on professional, legal, ethical, and interpersonal considerations. 
This presentation referenced a number of articles and books that critiqued the disciplines 
of psychiatry and psychopharmacology including, The Americanization of Mental Illness 
(Watters, 2010), Head Case: Can Psychiatry be a Science (Menand, 2010), Battling the 
Growing Influence of the Pharmaceutical Industry (Johnson, 2008), Against Therapy 
(Masson, 1994), The Myth of Mental Illness (Szasz, 1960),  The Dark Side of Psychiatric 
Drugs (Bibeau, 1994), and Exposing the Myth Makers: How Soft Sell has Replaced Hard 
Science (Duncan, Miller, & Sparks, 2000). A paper by Carey (2008) titled Change Urged 
in Antipsychotics Given to Kids was also referenced but the exact source was not 
identified and the researcher could not locate the document. Next, the presentation noted 
that “inaccurate diagnosis” was a “potential shortcoming with practice guidelines.”  
 A thorough analysis of all psychologist postdoctoral psychopharmacology 
training programs would help to clarify the extent to which these curriculums are 
integrating critical content that challenges conventional perspectives about 
psychopharmacology. Additionally, it would be worth investigating how psychologist 




compares with the psychopharmacy training that physicians, psychiatrists, pharmacists 
and nurse practitioners receive. For example, are the concerns indentified herein limited 
to one discipline or are they reflective of the training that other prescribers of 
psychotropic drugs receive?     
 Further, in addition to the topics examined by this study, it would be useful to 
know the extent to which psychologist postdoctoral psychopharmacology training 
programs and the prescription training programs of other disciplines, address critiques of 
neurobiological theories for a wider spectrum of disorders (i.e., schizophrenia, bi-polar 
disorder, and AD/HD).  Additionally, research could focus on how these programs and 
their respective readings and videos conceptualize the history of psychopharmacology. 
For example, do these materials make a concerted effort to identify alternative 
perspectives which challenge conventional narratives about the history of 
psychopharmacology (i.e., the conventional belief that psychopharmacological 
interventions were responsible for emptying the asylums)?  
 It would also be of interest to learn how the acquisition of prescription privileges 
impacts a prescribing psychologist’s continuing education choices. For example, in 
Illinois psychologists with prescriptive authority must complete “24 required hours of 
instruction relevant to prescriptive authority during the 24 months prior to application for 
renewal” (98th General Assembly State of Illinois 2013 and 2014 HB3704, n.d., p. 6). It 
is unclear whether the need to maintain psychopharmacological knowledge impacts 
prescribing psychologists’ continuing education surrounding non-pharmaceutical 
interventions?  Further, what are the implications of continuing education choices on 




 Other analyses might focus on the extent to which graduate training programs in 
psychology are integrating critical perspectives within psychopharmacology classes. 
Particularly since concerns have been raised about whether psychopharmacology is being 
addressed at all within some doctoral psychology programs. For example, Dunivan and 
Southwell (2000) noted “it is estimated that less than half of the APA-accredited doctoral 
programs and internships mention psychopharmacology training in self-studies” (S. 
Zlotlow, personal communication, February 8, 2000, as cited in Dunivan & Southwell, 
2000, p. 610). Further, in proposing a psychopharmacology curriculum for pre-doctoral 
internships, Dunivan and Southwell (2010) posited that “For a considerable number of 
psychology interns, this seminar might represent their first formal coursework in 
psychopharmacology” (p. 613).  
 More recently, Julien (2011), a vocal supporter of prescriptive authority for 
psychologists, asserted “Psychopharmacology deficiencies both in psychology training 
programs and in post-graduate continuing education have long been noted” (p. 446). 
Further, Julien stated that,  
no matter one’s position on this contentious issue, clinical psychologists in 
general suffer  a critical deficiency in pharmacology knowledge, which impedes 
their ability to evaluate their patient’s cognitive abilities (at a minimum), to 
evaluate medication side effects, and  to recommend modification of existing 
treatments. Worst of all it impedes optimal and comprehensive care for their 
patients. (p. 446) 
  
To address this, Julien recommended that the discipline make a concerted effort to offer 
“more comprehensive [psychopharmacology] training” to graduate and post-graduate 




Similarly, an article by Jaffe (2010) cited a Psychological Science in the Public 
Interest Report asserting that the doctoral psychology program accreditation system had 
failed to ensure that graduates were sufficiently versed in scientifically validated 
interventions. In the same vein, Julien and colleagues (2011) faulted many training 
programs in clinical psychology for not upholding high academic admission standards 
and not emphasizing science in the curricula.  
Tavris (2004) extended the critique beyond the discipline of psychology in 
asserting that failure to sufficiently address core principles of critical and scientific 
thinking was “widespread in graduate clinical psychology programs and psychiatric 
residencies, where students can earn a PhD or an MD without ever having considered the 
basic epistemological assumptions and methods of their profession” (p. xi). In addition, 
Tavris cited findings from ethnographic research, and asserted that “rarely do [psychiatric 
residents] learn to be skeptical about questions, analyze research, or consider alternative 
explanations or treatments” (p. xi). Thus, the researcher is not alone in suggesting that an 
analysis of curricula content is warranted in order to ascertain whether mental health 
practitioner training programs are making sufficient efforts to challenge conventional 
viewpoints about psychopharmacology.        
The Psychological Clinical Science Accreditation System (PCSAS) has been 
recommended as a means to critically examine psychology curricula and determine 
whether or not programs are sufficiently science based (Jaffe, 2010; Julien et al., 2011). 
According to the organization’s website:  
PCSAS is an independent, non-profit body incorporated in December 2007 to 
provide rigorous, objective, and empirically based accreditation of Ph.D. 




science and scientific  clinical psychology are used interchangeably). PCSAS was 
created to promote superior science-centered education and training in clinical 
psychology, to increase the quality and quantity of clinical scientists contributing 
to the advancement of public health, and to enhance the scientific knowledge base 
for mental and behavioral health care. (http://www.pcsas.org/ ) 
     
 In conversation with the researcher, the PCSAS’s executive Director stated that 
“The PCSAS Review Committee looks at the full curriculum of each applicant program 
and judges the scientific foundations of the courses being taught in the program by 
examining the scientific rigor reflected in the syllabi for the courses” (R. McFall, 
personal communication,  December 5, 2014). In addition, McFall asserted: 
I can say with confidence that no position is barred from legitimate criticism in a  
scientific investigation, whether it be questions of etiology or assessment or 
intervention . . . The issue is not whether a given program presents a particular 
perspective on this or any other issue, but whether the perspective is treated in a 
scholarly, empirically supported, and critical way that encourages the students to 
help advance the science. (R. McFall, personal communication, December 5, 
2014)  
 
 In this regard, and considering the findings from this study, it is notable that the 
PCSAS’s primary sources of information are syllabi. This study found that the 
examination of required and recommended readings, are integral to establishing how 
content is being disseminated (i.e., the extent to which mainstream readings and course 
videos integrate critiques of popular hypotheses and whether additional readings by 
critics who challenge conventional perspectives are being included). It is also noteworthy 
that the “PCSAS accredits only doctoral training programs that grant Ph.D. degrees and 






 If psychologist postdoctoral psychopharmacology training materials and curricula 
are not sufficiently integrating thorough critiques of both the DSM and theories for a 
neurobiological etiology of depression, this should be rectified. Further, if this 
information was excluded based upon the assumption that it is being addressed within 
graduate level psychology training, there needs to be empirical evidence to support this.  
 Additionally, this study’s findings suggest that a number of mainstream 
psychopharmacology textbooks are not providing thorough and consistent critiques of the 
DSM and challenges to neurobiological hypotheses for the etiology of depression.  
Further, if psychologist prescriptive authority training programs elect to include critics’ 
works as a means to compensate for this, the heterogeneity of the critics’ perspectives 
must be considered—the complexity and breadth of the critical literature on 
psychopharmacology should not be overlooked.  
 Ideally, if the examined program’s reading project is being used to integrate 
critiques of conventional perspectives, the assignment should include a variety of 
different “critical” readings. Additionally, requiring that students compare and contrast 
these viewpoints with those found within the mainstream textbooks would ostensibly 
foster a more critical examination of the extent literature and research.  It is also 
recommended that the examined psychologist  postdoctoral psychopharmacology 
program’s video on the neurobiological underpinnings of affective disorders incorporate 
thorough critiques of the hypotheses being disseminated—including a deconstruction of 
the chemical imbalance hypothesis for depression that notes, as Stahl and others have 




 This particular video ostensibly had some impact on students’ communications 
with patients about the neurobiological etiology of depression—particularly since the 
rationale behind prescribing an antidepressant is commonly based upon these etiological 
hypotheses. This has important implications for informed consent and whether or not 
clinicians are attending to this responsibility in a thorough manner. In their article about 
the chemical imbalance hypothesis, France, Lysaker, and Robison (2007) asked “how 
much information should be provided to clients concerning the validity (or potential lack 
thereof) of chemical imbalance explanations of depression? Is it unethical to gloss over 
the complexities of this and related (i.e., antidepressant vs. placebo efficacy) issues?” 
(p. 418). Presumably, this statement also applies to other hypotheses about the etiology of 
depression and other forms of mental distress.  
 The study’s integrated analysis also raises questions about program evaluations 
that focus solely on the examination of syllabi (e.g., the Psychological Clinical Science 
Accreditation System). While analyses of syllabi provide important information about the 
duration of classes, credits, assignments, course objectives, and the types of required and 
recommended training materials (i.e., books, articles, and videos), they do not provide 
any substantial details about the content of these readings and videos. Consequently, 
important information about the ways in which textbooks and articles are disseminating 
topics (i.e., with regard to thoroughness, and the integration of critiques and citations) 
might be missed.  
 Incorporating content analyses of textbooks into curricula research adds important 
information to these examinations and, in the case of psychologist postdoctoral 




list of textbooks and articles that adequately critique conventional perspectives about 
psychopharmacy.  While a definition or standard of what constitutes a balanced approach 
to textbook writing has yet to be established, the provision of citations within 
psychopharmacology textbooks is a feasible objective that is consistent with mainstream 
scientific standards. Moreover, it is a target that publishers, authors, and editors could 
easily uphold and adhere to. The requirement that neurobiological hypotheses of mental 
disorders be consistently and thoroughly critiqued would ostensibly garner considerable 
support within the academic community as well.  
 It also warrants mentioning here that the American Psychiatric Publishing 
Textbook on Psychopharmacology (2009) included a chapter on Ethical Considerations 
in Psychopharmacological Treatment and Research (not a required reading for the 
examined psychologist postdoctoral psychopharmacology training program) (Schatzberg 
& Nemeroff, 2009). This chapter reflects a willingness to examine issues surrounding 
public trust, research methodology, conflicts of interest, informed consent, the patient-
doctor relationship, and implications of prescribing powerful medications. Next, the 
chapter cited works by a number of critics (i.e., Joanna Moncrieff, Daniel Carlat, Thomas 
Szasz, and Gardiner Harris), which reflects a consideration of non-conventional 
viewpoints about psychopharmacology. Consequently, the provision of an additional 
chapter focusing on controversial issues in psychopharmacology could be an effective 
strategy, among others, for increasing critical content within psychopharmacology 
textbooks.   
 Another recommendation is that psychologist postdoctoral psychopharmacology 




to academic publications, this might include stories and perspectives of c/s/x activists 
(e.g., from Madness Radio’s, 2015, audio archives or through reading the Community 
Consortium Interviews, 2015, of various c/s/x activists like the late Judi Chamberlin and 
Larry Roberts). Next, these programs should consult with c/s/x activists about how best 
to educate prescribing psychologists about the c/s/x population and its movement. Here, 
instructors might reach out to c/s/x activists that teach classes in Mad History (i.e., David 
Reville from Ryerson University and Geoffrey Reaume from York University’s 
Disability Studies programs).  
 Curriculum materials for introducing students to the c/s/x movement could also 
include an exploration of c/s/x history. For example, psychologist postdoctoral 
psychopharmacology programs could require students to examine the websites of 
MindFeedom (www.MindFreedomInternational.org), The National Empowerment Center 
(www.power2u.org) and the National Coalition for Mental Health Recovery 
(www.ncmhr.org).  In addition, Pat Deegan’s 
(www.patdeegan.com/blog/categories/consumersurvivorexpatient-history) and Pat 
Risser’s (www.patrisser.com/~PatRisser/index.html) websites, the Psychiatric Survivor’s 
Archives of Toronto (www.psychiatricsurvivorarchives.com/), and Judi Chamberlin’s 
(1990) article, The Ex-patients ' Movement: Where We've Been and Where We Are Going, 
address important aspects of c/s/x history that could be helpful in this regard.  
 The diversity of perspectives within the c/s/x movement requires that students be 
exposed to a variety of c/s/x activists’ voices. Here, an edited volume like Mad Matters, 
where a number of different authors examine and discuss a spectrum of c/s/x issues from 




this book provides the reader with a variety of c/s/x viewpoints on issues including, but 
not limited to, the language used for conceptualizing mental distress, identity politics, 
experiences of women in asylums during the 19th century, and the diversity of the c/s/x 
community based upon differing “priorities, needs, identities, experiences, and strategies” 
(Diamond, as cited in LeFrancois et al., 2013, p. 67).  Further, the book includes articles 
which explore the importance of celebrating the c/s/x movement’s successes, challenges 
to the concept of sanity, critiques of electroshock therapy, and civil rights within the 
context of mental health, the law, and public policy. 
 Information challenging the legitimacy of the c/s/x movement should also be 
integrated within psychologist postdoctoral psychopharmacology training materials. To 
access this information, students could visit the website for the Treatment Advocacy 
Center (www.treatmentadvocacycenter.org) in addition to reading articles by critics of 
the c/s/x movement like Edwin Fuller Torrey (1997), and Sally Satel (2000). In this 
regard, consideration should be given to the potential risks of abolishing forced 
hospitalization and forced drugging and, conceivably, about the systemic issues which 
curtail the analysis of safety to such limited options. 
Conclusion 
 This study was unique because it was the first to analyze the extent to which 
critiques of conventional perspectives about psychopharmacology (i.e., surrounding a 
neurobiological etiology of depression and the rigor of the DSM) were being critiqued 
within psychologist postdoctoral psychopharmacology training materials.  The findings 
suggest that critical discourse about neurobiological hypotheses for the etiology of 




within the examined materials being used to train psychologists for prescriptive authority. 
It also appeared that the implications of these gaps in scientific evidence were not being 
considered within the context of treating marginalized groups like the c/s/x population 
whose voice was not prioritized within the examined syllabi, readings, and videos. This 
indicates that additional attention to critical discourse and the consideration of the c/s/x 
population is warranted when it comes to developing curricula to train psychologists for 
prescriptive privileges. These findings should be interpreted conservatively in light of the 
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The neurobiological etiology of depression refers to any brain based hypotheses or 
theories about the causes of depression.  
 
Inclusion Criterion     
The sentence/paragraph is likely making a specific reference to a neurobiological 
hypothesis/theory for the etiology of depression if:  
 
1) A neurobiological hypothesis/theory for the etiology of depression is a header (title) 
for a section. 
E.g., a paragraph or set of paragraphs headed by the phrase “The Monoamine 
Hypothesis of Depression.”  
 
2) References to studies appear to be clearly related to the text’s goals of elucidating a 
particular neurobiological hypothesis/theory of depression’s etiology.  
E.g., “Other studies suggest that neuropeptides impact brain chemistry and depressive 
symptomatology”, is an example of content elucidating the neuropeptide/neuroendocrine 
hypothesis for depression.    
 
3). When words and phrases including, but not limited to, “pathophysiology”, 
“pathogenesis”, “etiology”, “aetiology”, “influences”, “source”, “cause”, “mediate” 
“leads to”, “candidate mechanism”, “predict”, “molecular basis”, “implicate”, “role of”, 
“regulators of”, and “linked to”, are clearly used to describe a particular neurobiological 
hypothesis/theory for the etiology of depression. 
E.g., “The source of depressive symptomatology has also been linked to encephalins”, is 
an example of content which refers to the neuropeptide hypothesis of depression.       
 
4. When words or phrases including, but not limited to, “deficiency”, “inefficient”, 
“malfunctioning”, “abnormality”, “out of tune”, “problem”, “magnification” and 
“pathological”, are clearly used to describe a particular neurobiological hypothesis/theory 
of depression. 
E.g., “Historically, depression has been conceptualized as a deficiency involving 
neurotransmitters …” refers to the neurotransmitter hypothesis of depression.   
 
5. When depression is clearly referred to via terms like “depression”, “mood disorder”, 
“affective disorders”, “unipolar depression” “dysthymia”, and “major depressive 
episode”, in conjunction with comments about the proposed neurobiological determinants 
of the disorder.      
 
Also note that references to neurobiological hypotheses/theories for the etiology of bi-







Next, references to antidepressant treatment and the respective mechanisms of action of 
antidepressants will not be considered as meeting the criteria for inclusion unless these 
discussions clearly reference a neurobiological etiology of depression. For example, a 
text might discuss a neurobiological hypothesis/theory for depression in the midst of 
mentioning research findings on antidepressants. 
  
E.g., “SSRIs have been shown to raise serotonin levels which are thought to be lower in 
depressed individuals”, uses evidence from studies on antidepressants to discuss the 
aminergic hypothesis of depression.   
 
Hypotheses/theories which are not clearly neurobiological in nature will not be 
considered as meeting criteria for content about a neurobiological hypothesis/theory for 
the etiology of depression (e.g., environmental factors like low omega-3 fatty acids). 
 
Next, neurobiological illnesses which may include depressive symptomatology will not 
be counted as content. Thus, depression’s etiology discussed within the context of 
Parkinson’s, Alzheimer’s, Cushing Syndrome, and Huntington’s disease will not meet 
criteria for coding unless the content clearly and explicitly elucidates what the 
neurobiological source of the depression is. 
 
Breadth 
The coder must read each of the pages selected for their analysis (i.e., start at the 
beginning of the first sentence even if it commences on the previous page, and end your 
reading at the completion of the last sentence even if it terminates on a subsequent page).  
 
Coding Categories   
Once it has been established that the content refers to a neurobiological hypothesis/theory 
for the etiology of depression, it is time to choose which of the categories apply. 
Remember to look for clues surrounding which hypothesis or hypotheses is/are being 
discussed. For example, there may be a header or title introducing the section, and/or the 
hypothesis/theory may be explicitly identified within the paragraph (“e.g., the 
neurogenesis hypothesis...”).  
 
In other cases the author(s) will include discussions about aspects of a particular 
hypothesis/theory which won’t be identified as  hypotheses/theories in and of themselves. 
For example, irregularities with the HPA-Axis or glucocorticoid levels may be mentioned 
within a discussion about the neurogenesis  hypothesis of depression. In this case, unless 
those factors are being clearly discussed as separate hypotheses - don’t document these 
mechanisms – simply code for the primary  hypothesis/theory.   
 
One of the challenges in coding for this topic is that the author’s do not always explicitly 
identify a hypothesis as such. For example, they may simply refer to Glutamate, Gaba, 
Neuropeptides, Neurotrophins, etc. as potential mechanisms involved in depression 





should still document these mechanisms under the appropriate coding category for 
neurobiological based hypotheses/theories for depression’s etiology.  
     
1) Neurotransmitters      
There have been a variety of different theories and nomenclature used to discuss  
neurotransmitter hypotheses/theories of depression. These include the aminergic, 
chemical imbalance, monoamine, catecholamine, and Adrenergic-Cholinergic Balance 
hypotheses. In other cases the text may simply refer to low levels of a particular 
neurotransmitter like serotonin, dopamine, or norepinephrine,  or allude to “chemical” 
abnormalities or “chemical  problems” which should also be coded as  
“neurotransmitters.”    
 
2) Neurotransmitter Receptors 
Neurotransmitter receptors have also been implicated in depression’s etiology.  
 
3) Neurotrophins/Proteins (i.e., BDNF, P11, CREB, cAMP) 
Neurotrophins are a family of proteins that facilitate the survival, development, and  
functioning  of neurons. They belong to a class of growth factors that have the capacity to  
signal cell survival, differentiation, and growth.  Growth factors such as neurotrophins,    
which are involved in promoting the survival of neurons are known as neurotrophic 
factors.  
 
Neurotrophic factors are secreted by target tissue and prevent neurons from initiating  
programmed cell death (apoptosis). Neurotrophins also initiate the differentiation of  
progenitor cells,which results in the formation of neurons. The majority of neurons in the  
mammalian brain develop prenatally. However, parts of the adult brain retain the ability 
to grow new neurons from neural stem cells - a process known as neurogenesis.  
 
Neurotrophins are chemicals that help to stimulate and control neurogenesis. 
 
4) Neuroendocrine/Neuropeptide (i.e., HPA-Axis, HPT-Axis, glucocorticoids, estrogen, 
CRF, CRH, Corticosteroid Receptor Hypothesis; Hormone Receptor Hypothesis; VGF, 
NPY, Tachykinins, Hypothalmic Peptides, Enkaphalins). 
 
The Neuroendocrine system consists of various glands that produce and secrete hormones   
including Neuropeptides, steroids, and neuroamines.     
 
Neuropeptides are small protein-like molecules (peptides) used by neurons to 
communicate   with each other.  Neuropeptides modulate neuronal communication by 
acting on cell surface receptors.  
 
5) Inflammation – Immunological 
Neurobiologically based inflammation and immunological processes are hypothesized to 
play a role in depression. Cytokines have been implicated in this process. Cytokines are a 





They act through receptors and are especially important in the immune system 
modulating the balance between humoral and cell-based immune responses in order to 
regulate the maturation, growth, and responsiveness of particular cell populations.  
 
6) Genetics 
Research suggests that neurobiological abnormalities associated with depression are 
linked to genetics. 
 
7) Glutamate (i.e., NMDA; glutamate receptors) 
Glutamate is an excitatory neurotransmitter located within the nervous system. Glutamate 
is stored in vesicles within chemical synapses. Nerve impulses facilitate glutamate’s 
release from the pre-synaptic cell. Glutamate acts on ionotropic and metabotropic (G-
protein coupled) receptors. Glutamate receptors like NMDA receptor or the AMPA 
receptor, bind glutamate.  
 
Glutamate plays a role in synaptic plasticity whereby it facilitates long-term potentiation 
at glutamatergic synapses in the hippocampus, neocortex, and other parts of the brain.    
 
In brain injury or disease, excess glutamate can accumulate outside cells. This process 
causes calcium ions to enter cells via NMDA receptor channels damaging neurons  and 
eventual cell death (apoptosis) – a process called excitotoxicity. Excitotoxicity due to 
excessive glutamate  release and impaired uptake occurs as part of the ischemic cascade 
and has been linked to the neurobiological etiology of depression.  
 
8) GABA 
GABA acts at inhibitory synapses through binding to transmembrane receptors in the 
plasma  membrane. It is involved in both pre- and postsynaptic neuronal processes. 
GABA helps to facilitate the opening of ion-channels to permit the flow of either 
negatively charged chloride ions into the cell or positively charged potassium ions out of 
the cell. This action leads to a negative change in the transmembrane potential, typically 
resulting in hyperpolarization.  
 
GABA is a regulator of many CNS processes including neurogenesis. Some research 
suggests that GABAergic neurotransmission may be altered in mood disorders.  
 
9) Neurogenesis/Neurogenic Hypothesis  
Research indicates that the brain can form new neurons in a process called neurogenesis,  
and that existing neurons can repair and remodel themselves. Research also suggests that 
the hippocampus is particularly vulnerable to stress/trauma, and that stress has the 
capacity to damage neurons in the hippocampus and the frontal cortex. Further, damage 
in these regions  has been linked to increased amounts of glucocorticoids, abnormalities 
within the HPA-Axis and decreased levels of BDNF – all of which are associated with 
depression.  Sometimes  neurogenesis is described as a remodeling process (“synaptic 





discussions about the neurogenic hypothesis may highlight the degradation of the 
hippocampus resulting from insufficient  amounts of Neurotrophins.  
 
10) Circadian Rhythm 
A circadian rhythm is any biological process that displays an endogenous, entrainable,  
 oscillation of about 24 hours. Disturbances in the circadian rhythm governing sleep are  
 implicated in depression’s etiology. Note that circadian rhythms may be referred to as   
 “chronobiological aspects.”    
 
11) Neuroanatomical/Circuits  
 Neuroanatomy has been implicated in the neurobiological etiology of depression. This       
 includes particular regions of the brain (e.g., frontal cortex) as well as specific parts like 
the hippocampus or  amygdale. Circuits refers to neural circuitry that some researchers 
suggest is dysfunctional in depression.  
 
12) Enzymes/Cofactors    
Enzymes are highly selective macromolecular biological catalysts which can accelerate 
both the rate and specificity of metabolic chemical reactions. A number of enzymes are 
thought to play a role in depression’s etiology including Monoamine-Oxidase and 
Dopamine Beta-Hydroxylase. 
 
13) Other    
In cases where the coder comes across a hypothesis or theory for the neurobiological     
etiology of depression that has not been addressed within the researcher’s list of   
hypotheses/theories, the coding category of “Other” can be selected. The coder should  
document their reasoning for choosing this category, within the “Comments” section of 




If there are any cases in which content which does not fit within the existing framework   
including the “Other” category, make note of this within the “Comments” section.  
 
Critiques 
Critiques include any challenges to a particular neurobiologically based 
hypothesis/theory for the etiology of depression. This includes any comments about the 
limitations of associated research evidence. 
 
E.g., “In spite of these research findings implicating Neuropeptides in the etiology of 
depression the results are far from definitive...” indicates that empirical support for the 







The coder will also be required to document which, if any, of the researcher’s listed 
critics are explicitly mentioned or cited within content about the neurobiological etiology 
of depression.  A complete list of critic’s works will be provided to help facilitate this.    
 
Cases in which a listed critic was explicitly mentioned or cited within content that is 
outside of the 3 topic areas being studied (i.e., not about a neurobiological etiology for 
depression, the DSM, or the C/S/X movement), should also be documented.   
 
Reference Pages 
The coder must check every reference within selected reference pages to establish 














The Diagnostic and Statistics Manual of Mental Disorders (DSM) is published by the 
American Psychiatric Association. There are five editions of the DSM, plus two formal 
revisions (I, II, III, III-R, IV, IV-TR, and V).   
 
Inclusion Criteria 
In order to meet the criteria for one of the coding categories, the DSM must be explicitly 
mentioned and/or cited within the page being analyzed. Discussions about, or references 
to, the International Classification of Diseases (ICD) manual are not considered part of 
this topic unless these discussions clearly reference the DSM.  
 
Breadth 
The coder must read each of the chapters or in some cases individual pages, selected for 
the analysis. 
 
Coding Categories   
The coder will need to identify which of the DSM coding categories apply for each of the 
pages read. In some cases more than one coding category will apply. The coder only 
needs to record a coding category once on any particular page.   
 
1) Guidelines/Applications/General  
Note that ANY explicit mention of the DSM meets the criteria for 
Guidelines/Applications/ General and must be coded as such. This category is also a 
catch-all for any discussions surrounding the DSM criterion for disorders, general 
comments about the structure of the manual, the manual’s applications with other 
screening tests, and research involving the DSM. 
 
2) Development  
This category is for any content which discusses the process of how the DSM was 
developed and revised. It is also the category by which ANY versions of the DSM that 
predate the DSM-IV (i.e., DSM I, II, III, III-R) should be identified. Similarly, this 
category should be used to document content about the DSM V. Note that comments 
about a “new condition” or “young disorder” are indicative of development when it 
comes to discussions about the manual and its disorders.  
 
3) Benefits/Merits  
Any positive aspects of the DSM should be assigned this category. Examples of 
benefits/merits include but are not limited to assertions that the manual aids research, 





aids assessment, informs treatment, enables billing and insurance coverage, and 
facilitates program support. 
 
 
4) Criticisms/Limitations/Controversy  
This category should be assigned to any content which critiques the DSM in any way. For 
example, any content which identifies problems with the manual’s inter-rater reliability 
and construct validity. Content which discusses limitations of using the manual (e.g., that 
the DSM requires considerable training to utilize and there is considerable overlap 
between disorders) or controversy (e.g., disagreements about a category based approach), 
should be documented via this coding category.      
 
5) Other   
In cases where the discussion about the DSM is not effectively captured by the four 
aforementioned coding categories the coder should identify this as “Other.” The coder 
should then document their reasoning for choosing this category, within the “Comments” 
section of the spreadsheet.    
 
Anomalies 
In cases where the coder determines that the DSM is clearly being discussed, albeit 
without any explicit mention or citation of the manual itself, this must be documented 
within the comments section. The coder must still make sure to note what topics were 
discussed, whether or not the DSM was critiqued, whether inter-rater reliability and/or 
construct validity were addressed and whether any of the researcher’s listed critics were 
cited on the topic.  
 
Note that simple mentions of a diagnosis (e.g., depression, schizophrenia, bipolar) do not 
meet the requirements for documentation within the comments section (when the manual 
has not been explicitly mentioned. However, the discussion of any DSM disorder’s 
symptomatology (e.g., sleep difficulties, appetite change, loss of interest for depression, 
or hallucinations, delusions, or more general mentions of positive/negative symptoms for 
schizophrenia, or comments about low mood or mania in bipolar, the mention of 
inattention for ADHD, and/or noting sleep problems in PTSD), are considered worthy of 
inclusion within the comments section for the DSM topic in cases where the manual was 
not explicitly cited or mentioned. References to animal models of depression do not meet 
criteria for content. 
 
Any problems or concerns with the overall coding framework should be indentified 
within the comments section of the excel spreadsheet. 
 
Critiques 






1) If the DSM is explicitly mentioned, the coder should document any associated 
critiques for that page within the DSM spreadsheet via the coding category of 




 DSM Inter-Rater Reliability 
and/or Construct Validity 
Challenged  
Critic(s) cited on Topic  
 
2) If the content about the DSM contains a critique that clearly challenges the 
DSM’s levels of inter-rater reliability and/or construct validity, this must be 
documented under “DSM Inter-Rater Reliability and/or Construct Validity 
Challenged” within the DSM spreadsheet (make sure to document which of these 
two measures of scientific rigor apply). See below. 
 
DSM Topics  DSM Inter-Rater Reliability 
and/or Construct Validity 
Challenged  
Critic(s) cited on Topic  
 
Inter-Rater Reliability pertains to the likelihood that different clinicians or coders 
will obtain similar results when diagnosing the same patient. Note that comments 
about a clinician’s choice of DSM diagnoses potentially differing based on their 
level of training would be considered as a challenge to the manual’s level of inter-
rater reliability.    
 
 E.g., “There is considerable variation in the diagnoses different clinicians will 
assign to the same case”, is an example of a critique that is challenging the manual’s level 
of inter-rater reliability. 
 
Construct Validity pertains to whether or not the construct – in this case any of 







 E.g., “Some critics have pointed out that DSM diagnoses are not based on 
objective evidence”, is an example of a critique that is challenging the construct validity 
of the manual. 
 
 In addition, the coder must document whether or not any statistics on the 
reliability and  validity of the DSM were identified.  See below. 
 
DSM Inter-Rater Reliability 
and/or Construct Validity 
Challenged 
Critic(s) cited on Topic Statistics on 
Reliability/Validity of DSM 
Presented Y/N 
 
3) If a critique occurs on a page with content about the DSM, albeit without any 
explicit mention or citation of the manual, this should be documented within the 




Critic(s) cited on Topic Statistics on 
Reliability/Validity of DSM 
Presented Y/N 
Comments  
E.g., The DSM's construct 




The coder will also be required to document which, if any, of the researcher’s listed 
critics are explicitly mentioned or cited within content about the DSM. The critic(s) 
should be documented under the heading “Critic(s) cited on Topic.”  
 
DSM Topics DSM Inter-Rater Reliability 
and/or Construct Validity 
Challenged 






A list of critic’s works will help to facilitate this.  In particular, the list of papers where 
the first author is not a critic will be helpful when the references list uses “et al.” instead 
of including the names of all of the writers.   
 
In cases where a listed critic is explicitly mentioned or cited within content that is outside 
of the 3 topic areas being studied (i.e., not about the a neurobiological etiology for 
depression, the DSM, or the C/S/X movement), this should be documented within the 
“REFERENCES” spreadsheet under “Critics cited OUTSIDE of 3 topic areas.” The 
coder must document both the critic’s(s’) name(s) and the topic(s) being discussed.  See 
highlighted boxes below from the DSM spreadsheet.  
 
Critic(s) cited OUTSIDE of 
3 topic areas 
 Topic(s)   Reference Page Critics  
 
For reference pages, the coder should document any of the researcher’s listed critics 
under the REFERENCES spreadsheet via the “References Page Critics” box. 
 
Critic(s) cited OUTSIDE of 
3 topic areas 
 Topic(s)   Reference Page Critics  
 
In some cases a page will contain discussions about a topic and some portion of the 
chapter’s reference section (i.e., the first page of the reference list also includes the 
conclusion of the article or chapter). In this case the discussion should first be coded for 
content under the usual three spreadsheets (ETXD, DSM, C/S/X), and then the 















C/s/x content is defined as content about the Consumer/Survivor/Ex-Patient movement. It 
also refers to materials or comments by individuals who identify or are deemed to 
identify as C/s/x members.  
 
Inclusion Criterion 
In order for content to meet the criteria for inclusion, the sentence/paragraph must 
explicitly mention the C/s/x movement, C/s/x organizations, and/or C/s/x identified 
members.   
 
Inclusions of the terms “consumer(s)”, “survivor(s)”, or “ex-patient(s)” on their own do 
not meet the criteria for C/s/x content unless the statement in which they’re embedded is 
clearly referring to the C/s/x movement. Clues that these terms used in isolation are 
intended to describe the C/s/x movement are, 1) the c/s/x movement is mentioned in that 
particular chapter’s title or subtitle(s), 2) the particular section in question is identified as 
having c/s/x content within the book’s index, and 3) the reference to consumers, 
survivors, or ex-patients is clearly building upon prior mention(s) of the c/s/x movement 
outlined in previous sentences/paragraphs within the chapter.  
 
C/s/x organizations include but are not limited to the following groups: MindFeedom, 
Support Coalition International, MadPride, Icarus Project, Hearing Voices Network, 
National Empowerment Center, National Disability Rights Network, National Mental 
Health Consumers, Self-Help Clearing House, Mental Health Consumer/Survivor 
Network, European Network of (Ex-) Users and Survivors of Psychiatry, Psych-Rights, 
The Community Consortium – Building Inclusive Communities for People with 
Psychiatric Disabilities, World Network of Users and Survivors of Psychiatry, the 
Citizens Commission for Human Rights, and the Center for Human Rights of Users and 
Survivors of Psychiatry. Given the size of the c/s/x movement it is possible that a text 
might mention an organization that was not included within this list. If in any doubt about 
whether a particular group is affiliated with the c/s/x movement, the organization should 
be called or emailed for confirmation. 
 
Determining who identifies as c/s/x may take some work given the possibility that an 
explicit reference to an individual having formally identified themselves as such may not 
exist. Consequently, for the proposes of this study, any individual who has been 
diagnosed with a mental illness and, a) works or volunteers for a c/s/x organization 
and/or, b) attends c/s/x functions, and/or c) openly endorses c/s/x initiatives (e.g., 
increased collaboration between mental health consumers and mental health 






Individuals who meet this criteria and may be referred to within the literature include, but 
are not limited to, Linda Andre, David Armes, George Badillo, Clifford W. Beers, Frank 
Blankenship, Monica Briggs, Jean Campbell, Ted Chabasinksi, Judi Chamberlin, Oryx 
Cohen, Pat Deegan, Sasha Altman DuBrul, Erick Fabris, Alison Faulkner, Dr. Daniel 
Fischer, Leonard Roy Frank, Howard Geld, Jim Gottstein, Will Hall, Gail Hornstein, 
Joan Hughes, Rachel Klein, Peter Lehmann, Dr. Nathaniel Lehrman, Cathy Levin, Dr. 
Rufus May, Jacks Ashley McNamara, Kate Millet, John Modrow, Linda Morrison, David 
Oakes, Theresa Parkes, Dr. Geoffery Reaume, David Reville, Pat Risser, Joe and Susan 
Rogers, Jasna Russo, Melissa Sances, Judene Shelley, Ruth Ruth Stackhouse, Heather 
Johnson Straughn, Jan Wallcraft, David Webb, and Don Weitz. 
 
In cases where the rater is uncertain about whether or not an individual being discussed 
and/or referenced in association with the c/s/x movement meets the criteria for someone 
who identifies as c/s/x, further investigation will be required. This can include internet 
searches, academic literature searches or, when feasible, contacting the individual 
themselves.   
 
Breadth 
The coder must read each of the examined chapters and/or specifically identified pages in 
their respective entirety.  
 
Coding Categories   
The coder will need to identify which of the following coding categories apply for each 
of the pages being examined. In some cases more than one coding category will apply. A 
coding category only needs to be recorded once on any particular page. In the c/s/x 





Criticisms About c/s/x 
Critiqued? Y/N  
Critic(s) cited on Topic  
 
1) C/s/x History 
  
2) C/s/x Organizations 
 
3) C/s/x Campaigns/Events/Activism  
Some examples of content that meets the requirement for this category are the 
MindFeedom hunger strike, MadPride marches and concerts, and PsychRights court 
cases. 
 





This includes criticisms levied against the C/s/x movement. For example, conceptualizing 
the C/s/x movement as being anti-psychiatry or anti-medication, argument that the C/s/x 
movement undermines the constructive efforts of organizations like the American 
Psychiatric Association and NAMI, asserting that the C/s/x movement and its 
organizations might increase the likelihood of harm to self and others due to its purported 
anti-medication message, and arguing that C/s/x members and their organizations are 
uninformed.  
 
5) Personal Stories of C/s/x Members  
This category refers to any individual who identifies as C/s/x or who a) works or 
volunteers for a C/s/x organization and/or, b) attends C/s/x functions, and/or c) openly 
endorses C/s/x initiatives (e.g., increased collaboration between mental health consumers 
and mental health professionals). This category does not include advocates or allies who 
support the movement and its initiatives but who do not self-identify as C/s/x themselves.   
 
f) Other  
The “Other” category should be selected for C/s/x content that cannot be conceptualized 
by one of the other coding categories.  
 
Anomalies  
Cases in which the coder encounter problems with the coding framework including when 
the “other” coding category is selected, should be identified within the “Comments” 
section of the Excel coding spreadsheet for c/s/x content.  
 
Page # What Topic? Comments 
 
Critiques 
The coder will be required to document whether or not any critiques were levied against 
the C/S/X movement under “C/s/x Topics” via the coding category of “Challenges to the 
Legitimacy of the C/s/x.”  The coder must also identify whether or not any criticisms 
about the c/s/x were in turn critiqued by noting this under “Criticisms about the C/s/x 




Criticisms About C/s/x 
Critiqued? Y/N 







The coder must document whether or not any of the researcher’s listed critics were 
explicitly mentioned or cited within content about the c/s/x, under the column headed 




Criticisms About C/s/x 
Critiqued? Y/N 
Critic(s) cited on Topic 
 
In cases where a listed critic is explicitly mentioned or cited within content that is outside 
of the 3 topic areas being studied (i.e., not about a neurobiological etiology for 
depression, the DSM, or the c/s/x movement), this should be documented within the 
“REFERENCES” spreadsheet under “Critics cited OUTSIDE of 3 topic areas.” Both the 
critic’s(s’) name(s) and the topic(s) being discussed should be documented.    
 
Critic(s) cited OUTSIDE of 
3 topic areas 
 Topic(s)   Reference Page Critics  
 
In some cases a page will contain discussions about a topic and some portion of the 
chapter’s reference section (i.e., the first page of the reference list also includes the 
conclusion of the article or chapter). In this case the discussion should first be coded for 
content under the usual three spreadsheets (ETXD, DSM, C/S/X), and then the 
REFERENCE spreadsheet to document nay of the researcher’s listed critics.   
 
Critic(s) cited OUTSIDE of 
3 topic areas 
 Topic(s)   Reference Page Critics  
 
For cases in which a page contains discussions about a topic and some portion of the 
reference section for the chapter or article (i.e., the first page of the reference list also 
includes the conclusion of the article or chapter), the coder should document the 
discussion under the usual three spreadsheets (ETXD, DSM, C/S/X). The coder should 
than go to the REFERENCE spreadsheet to code for any of the researcher’s listed critics 
identified within the reference list. 
 





The coder must record any cited works by c/s/x individuals. These works and their 
authors should be documented within the C/S/X spreadsheet under “Cited Works from 
C/s/x Identified Individuals (Title/Author).”    
 
Critic(s) cited on Topic  Criticisms About C/S/X 
Critiqued? Y/N 
 



















I’m a doctoral student at Antioch University’s clinical psychology program in Seattle, 
WA, and a member of the American Psychological Association and Division 55. I am 
writing to request your support with my dissertation study which is researching the extent 
to which alternative perspectives about psychopharmacology are being integrated within 
current prescription privilege training programs for psychologists in the United States.  
 
More specifically, I’m hoping to analyze psychologist  psychopharmacology training 
materials for alternative perspectives surrounding a neurobiological etiology for 
depression, the DSM’s rigor, the idea that, overall, antidepressants’ risks outweigh their 
benefits, the legitimacy of c/s/x organizations, and the rigor of using inert placebos within 
antidepressant drug trials.  
 
I am not looking to prove that these alternative perspectives represent the entire truth. 
Rather, I’m interested in determining the extent to which non-conventional ideas about 
the aforementioned topics are being integrated within existing psychologist postdoctoral 
psychopharmacology program curricula materials.  
 
I’m requesting a complete set of syllabi from your most recent psychologist postdoctoral 
psychopharmacology training curriculum. I’m also hoping that you, as the program 
Director, will consider taking part in a telephone interview subsequent to the initial 
quantitative analysis of the data. The goal of the interview would be to shed additional 
light on the reasoning behind which alternative perspectives are being addressed or 
excluded.  
 
To address concerns I’m anticipating with regard to the ownership and protection of your 
respective psychologist postdoctoral psychopharmacology curriculum materials, only 
three copies of your program’s syllabi would be printed and all would be kept in locked 
filing cabinets when not being actively used by the researcher or other dissertation 
committee members. Next, subsequent to my analysis, two sets of the syllabi would be 
destroyed and the remaining one would be placed in a sealed envelope within a locked 
filing cabinet within the researcher’s home office.  The syllabi would then be destroyed 
seven years thereafter. 
 
If you were to send these materials online, the downloaded syllabi would be erased after 
three complete paper copies were made. If the requested materials were sent by postal 
mail, only two additional copies of the original document would be made. The reason for 
requesting three copies is that the researcher lives in Port Moody, British Columbia, 







The name of your university and your identity as the psychologist postdoctoral 
psychopharmacology program’s Director would also be kept confidential by the use of a 
nondescript numeric code. At no time would the university or the identity of a program’s 
Director be revealed, either within the study’s write-up or any other verbal or written 
discussions thereof.   
 
I also appreciate that you might have other concerns and/or questions you would like 
addressed and I’m hoping that, if this is the case, you’ll contact me or my committee 
chair, Dr. Alex Suarez P.M.S.P., at your soonest convenience. Many thanks for your 





___________________      








     
Alex Suarez, Ph.D., P.M.S.P     
Dissertation Chair    
Antioch University, Seattle, WA 
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Title Chapters Read/Total 
Chapters  
Required 
Pathophysiology: The Biological Basis for Disease  23/47 Yes 
A Primer of Drug Action  11/20 Yes 
Neuroscience 7 + 8 pg.’s & 
Appendix, & Atlas/ 
31, appendix & 
Atlas 
Yes 
Goodman & Gillman’s: The Pharmacological Basis 
of Therapeutics 
38 & 1 Appendix/67 
& 2 Appendixes  
Yes 
Pharmacotherapy for Psychologists: Prescribing & 
Collaborative Roles  
5/13 Yes 
Stahl’s Essential Psychopharmacology: 
Neuroscientific Basis and Practical Applications 
8/14 Yes 
Case Studies: Stahls’ Essential 
Psychopharmacology  
10/40 Yes 
Essential Evidence Based Psychopharmacology 2/14 Yes 
Clinical Handbook of Psychotropic Drugs 19/19 Yes 
American Psychiatric Publishing Textbook of 
Psychopharmacology  





Manual of Clinical Psychopharmacology for Nurses 14/14 No 
Pharmacotherapy: A Pathophysiological Approach  2/18 Yes 
Seeley’s Anatomy and Physiology  29/29 No 
Atlas of Functional Anatomy  25/25 No 
Neuroanatomy through Clinical Cases 19/19 & Epilogue Yes 
Study Guide to Psychopharmacology  18/67 Yes 
Unhinged: The Trouble with Psychiatry  10/10 No 
The Medicalization of Society  8/8 No 
Selling Sickness 10/10 No 
Let Them Eat Prozac 13/13 No 
Psychotropic Drug Prescriber’s Survival Guide  9/9 No 















Title Pages/Read Required 
Following the Script: How Drug Reps Make Friends & Influence Doctors 5 Yes 
Simple strategies to avoid medication errors 7 Yes 
Psychotropic drug prescriptions by medical specialty 1 Yes 
Avoiding medical errors: JCAHO documentation requirements 3 Yes 
Do Not Use List 2 Yes 
Annual research review: Impact of advances in genetics   9 Yes 
Genetic testing for psychiatric disorders 5 Yes 
County-level estimates of need for mental health professionals   8 Yes 
County-level estimates of mental health professional supply   8 Yes 
County-level estimates of mental health professional shortage   6 Yes 
Mental illness surveillance among adults in the United States 30 Yes 
What price prescribing?   6 Yes 
Prescribing and primary care psychology 8 Yes 
Practice guidelines regarding psychologists' involvement   15 Yes 
Prescriptive authority for psychologists. 27 Yes 
Malpractice claims experiences of psychologists 3 Yes 
Helping doctors and patients make sense of health statistics 44 Yes 
Antidepressant drug effects and depression severity 7 Yes 
Relative effects of CBT and pharma in depression versus anxiety 8 Yes 
What doctors don’t know about the drugs they prescribe 1 Yes 
Research shows that all too often, Americans are taking Rx   4 Yes 
Psychotherapy and psychopharmacology 11 Yes 
Buproprion - SR, Sertraline, Venlafaxine 12 Yes 







Serotonin Syndrome 4 Yes 
MAOIs 5 Yes 
NEJM lab values  17 Yes 
Warfarin  6 Yes 
Harvard Medical School Algorithm 12 Yes 
Texas Medication Algorithm Project 68 Yes 
The choice of antipsychotic drugs for schizophrenia 3 Yes 
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia 15 Yes 
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia 12 Yes 
Treatment of acute agitation in psychiatric disorders   9 Yes 
Pharmacological Management of Acutely Agitated Pediatric Patients 10 Yes 
DOD VA PTSD Guidelines  253 Yes 
Dangerous Abbreviations List  1 Yes 
Error Prone Abbreviations List  2 Yes 
Jack Wiggins’ RxP Fact Sheet 2 Yes 
Ax Template 1 3 Yes 
Tx Plan Template  1 Yes 
Clinical Note Template 1 Yes 
Clinical Note Template 1 Yes 
Pharmaceutical Abbreviations  1 Yes 
Rx Form Template  1 Yes 
Drug References  1 Yes 
Measurement Conversions 1 Yes 
Medwatch Form 2 Yes 
AACAP Guideline for Ax and TX of Children and Adolescents with ADHD 28 Yes 
Title Pages/Read Required 







AACAP Guideline for Ax and TX of Children and Adolescents with Anxiety 
Disorders 
17 Yes 
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for Neurobiological Hypotheses for the Etiology of Depression Content 
IS there a heading/title identifying a particular hypothesis or theory for a neurobiological 
etiology of depression?  
 
IF NO, still look for any content about the neurobiological etiology for depression and, if 
located, determine which of the coding categories applies. If there is no such content 
simply record this as “0” and then make sure to complete the analysis for DSM and c/s/x 
content before proceeding to the next page for analysis.    
 
IF YES, document the hypothesis or theory using the coding categories provided. Also 
make sure to check the section for other theories that may be explicitly mentioned.  Do 
not document all of the sub-hypotheses/theories for a hypothesis/theory when these other 
mechanisms are primarily being used to describe the main hypothesis/theory. For 
example, CREB, Neurotrophins (i.e., BDNF), and irregularities with the HPA-Axis or 
glucocorticoid levels may be mentioned within a discussion about the neurogenesis 
hypothesis for depression. In this cases, unless those factors are explicitly identified as 
another hypothesis/theory, do not document these mechanisms – simply code for the 
primary hypothesis/theory.   
 
In some cases the authors(s) will not use a header or title to identify a particular 
hypothesis or theory. Further, they may simply refer to Glutamate, GABA, 





without explicitly referencing them as hypotheses or theories. Regardless, the coder 
should still document these mechanisms as hypotheses using the coding categories. 
 
IF UNSURE, look again to see whether or not there is a heading to the section which 
helps identify which hypothesis or theory is being discussed. Next, revisit the question, 
“is this content making a comment about a proposed neurobiological etiology for 
depression?” If the coder’s answer is affirmative then code accordingly. If the answer is 
negative, code accordingly. If still unsure, document this within the “Comments” section. 
 
IF the coder discovers a hypothesis or theory for the etiology of depression which can’t 
be conceptualized via the existing list of hypotheses within the coding categories, select 
“other” and do your best to identify what the hypothesis is. The “Comments” section is 
another place where you can indentify any problems encountered with the overall coding 
framework.   
 













IS the DSM explicitly mentioned and/or cited? 
 
IF NO, still look for any content about the DSM (i.e., about diagnosis and references to 
DSM symptomatology for a particular disorder – i.e., hallucinations for schizophrenia) 
that you feel is relevant to the topic. If such content is located, document this within the 
“Comments” section. Note that simple mentions of a disorders name (i.e., depression) 
does not warrant mentioning within the comments section. Also make sure to note 
whether or not the inter-rater reliability and/or construct validity of the manual was 
challenged, whether or not any critics were listed, and whether any statistics about the 
reliability and/or construct validity were included.  If there is no content about the DSM 
then code this as “0” under “DSM Topics.” 
 
IF YES, document this content via the appropriate coding categories provided. 
Remember that EVERY mention of the DSM warrants coding for 
Guidelines/Applications/General. Also remember that a coding category must only be 
documented once for any given page even if there are a number of instances where it 
occurs within that page.  
 
IF UNSURE: revisit the question, “is this content clearly related to a discussion about the 







IF the existing coding categories do not capture a topic about the DSM, document this as 
“Other” within the “DSM Topics” column and explain this decision within the 
“Comments” section. Similarly use the “Comments” section to document cases in which 
the DSM is clearly being discussed but not explicitly mentioned. 
    












IS some aspect of the c/s/x movement clearly addressed?  
 
IF NO, proceed to the next page of analysis.   
 
IF YES, document this content via the appropriate Coding Categories provided.   
 
IF UNSURE, revisit the question, “is this content clearly related to a discussion about the 
c/s/x movement?” If the answer is affirmative then code accordingly. If the answer is 
negative, code accordingly. If still unsure, document this clearly in the “Comments” 
section. 
 
IF the coding framework does not capture a topic about the c/s/x within the page being 
analyzed, document this as “Other” within the “C/s/x Topics” column and identify what 
category is most appropriate. The “Comments” section is another place any problems 
encountered with the overall coding framework can be documented.   
 












   
ARE there any citations, mentions of a particular individual, or references? 
 
IF NO, code applicable columns with a “0” and complete analysis for DSM and ETXD 
content before moving on to the next page of analysis.   
 
IF YES, clarify whether or not the citation is from a critic and, if it is, whether or not the 
citation is being used to discuss one of the 3 topics being analyzed (i.e., ETXD, 
DSM,C/S/X). If it is, document the critic’s name under “Critic(s) Cited on Topic” within 
the appropriate spreadsheet for that topic. If the citation is for a critic but the topic they 
are being cited for lies outside of the three topic areas, document this within the 
REFERENCES spreadsheet under “Critics Cited OUTSIDE of 3 Topic Areas.”  
 
IF UNSURE, revisit the question, “is this citation clearly related to a discussion about the 
C/S/X movement?” If the answer is affirmative then code accordingly. If the answer is 
negative, code accordingly. If still unsure, document this clearly in the “Comments” 
section. 
 
IF the coding categories do not capture some aspect of the references effectively, 
 document this within the “Comments” section of the appropriate spreadsheet.  
    
REMEMBER to use the list of references for each of the listed critics including the list in 




















Basic Cellular Concepts  
Cardiovascular System  
Respiratory System  
Renal/Genitourinary System  
Acid/Base Balance  
 
7915 
Hematology and Immunology  
Gastrointestinal and Hepatic Systems  
Endocrine System  




Neuroanatomy    
Neuron and Electrical Transmission    
Synaptic Transmission    
Classical Neurotransmitters in Synaptic Transmission      
Neurological Examination and Assessment    
Nervous System Pathology: Sensory    
 
7925 
Nervous System Pathology: Motor & Memory   
Basic Pharmacology    
Introduction to Psychotropics   
Other Transmitter Substances    




General Principles of Pharmacology   
Drug Metabolism and Pharmacogenomics    
Drugs Affecting the Autonomic Nervous System    
Drugs Affecting the Cardiovascular and Respiratory Systems    
Drugs Affecting the Central Nervous System    
Anti-Infectives, Antibiotics, and Antivirals   
Drugs Affecting the Endocrine System    
Lifestyle Drugs    







Prescriptions and Medical Orders   
Professional Relationships and Communications   
Professional Issues and Bioethics  
Issues in Prescriptive Practice  
Being an Informed Consumer of Drug Research  
Integrating Psychotherapy with Pharmacotherapy 
 
7940 
Biological Basis of Affective Disorders *   
Pharmacotherapy of Depression * 
Pharmacotherapy of Bipolar Disorders   
Treatment Guidelines and Considerations for Bipolar Disorder 
 
7945 
Neurobiology of Schizophrenia and Other Psychotic Disorders  
Neuropharmacology of Antipsychotics 	 
Antipsychotic Medications 		
Evidence Based Management of Acute Agitation  
 
7950 
Overview of the Anxiety Disorders  
General Pharmacology of the Anxiety Disorders  
Special Populations  
Confounding Drugs and Disease States  
Generalized Anxiety and Panic 




Cognitive Disorders  
Sleep Disorders  
Substance-Related Disorders  
Personality Disorders  
Childhood/Adolescent Disorders  
 















Critiques in Brackets = ( ) 
NT = neurotransmitter; NTREC = neurotransmitter receptor; NTROP = neurotrophins; N/C = neuroanatomy/circuits;  
GEN = genetics; GABA; GLUT = glutamate; NE/NP = neuroendocrine/neuropeptides; NGEN = neurogenesis;  
IMM = immunological; CR = circadian rhythms; ENZ = enzymes. 
 
 



























P: T. Biological Basis for Disease 1 (1) 0 0 0 1 (1) 1 (1) 0 2 (1) 0 0 0 0 
A Primer of Drug Action 4 (2) 3 (1) 2 0 0 1 3 2 8 0 1 0 
Neuroscience 2 0 0 0 0 0 0 0 0 0 0 0 
Goodman & Gilman's 2 0 0 0 1 0 0 2 (1) 0 0 0 0 
Pharmacotherapy for Psychol. 0 0 0 0 0 0 0 0 0 0 0 0 
Ess. Psychopharm: N.B & A. 18 
(3) 
7 (2) 3 6  13 (3) 0 1 6 5 0 4 1 
Case Studies 0 0 1 2 0 0 0 0 1 0 0 0 
Essential E. Based Psychopharm. 0 0 0 0 0 0 1 0 0 0 0 0 
Clinical Handbook 0 0 0 0 0 0 0 0 0 0 0 0 
American Psychiatric Publishing 9 3 (1) 0 0 4 (1) 0 3 (1) 11 4 (2) 0 1 0 
Manual of Clinical Psychopharm* 5 (1) 0 0 2  0 0 0 1 (1) 0 0 0 0 
Pharmacotherapy* 0 0 0 0 0 0 0 0 0 0 0 0 
Seeley’s Anatomy & Physiology* 0 0 0 0 0 0 0 0 0 0 0 0 
Atlas of Fx Neuroanatomy* 0 0 0 0 0 0 0 0 0 0 0 0 
Neuroanatomy* 3 0 1 1 0 0 0 2 0 1 0 0 





Pathophysiology: The Biological Basis for Disease, 6th ed. (23 chapters) 
A Primer of Drug Action, 12th ed. (11chapters) 
Essential Psychopharmacology: Neuroscientific Basis & Practical Applications, 4th ed. (9 chapters) 
The American Psychiatric Publishing Textbook of Psychopharmacology (16 chapters) 
Neurosciences, 5th ed. (7 chapters; 8 pages from 3 other chapters; Appendix and Atlas) 
Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed. (38 chapters; Appendix 1) 
Pharmacotherapy for Psychologists (5 chapters) 
Case Studies: Essential Psychopharmacology (10 chapters)  
Essential Evidence Based Psychopharmacology, 2nd ed. (3 chapters) 
Clinical Handbook of Psychotropic Drugs 19th ed. (Entire Book Examined) 
Manual of Clinical Psychopharmacology for Nurses (Entire Book Examined)* 
Pharmacotherapy: A Pathophysiological Approach, 8th ed. (2 chapters) * 
Seeley’s Anatomy & Physiology, 9th ed. (Entire Book Examined)* 
Atlas of Functional Neuroanatomy, 2nd ed. (Entire Book Examined)* 
Neuroanatomy Through clinical cases, 2nd ed. (Entire Book Examined)* 
Study guide to Clinical Psychopharmacology: A Companion (16 chapters)*  








SP Books: Number of Pages in which Depressive Etiological Content  










NT NTRE NTROP N/C GEN GABA GLUT NE/NP NGEN IMM CR ENZ
Unhinged 10(9) 0 1(1) 2(2) 2(2) 0 1(1) 1(1) 0 0 0 0
Medicalizatio
n of Society
0 0 0 0 1 0 0 0 0 0 0 0
Selling Sicknes 5(5) 0 0 0 0 0 0 0 0 0 0 0
Let Them Eat 
Prozac
20(13) 0 0 0 1 0 0 0 0 0 0 0
Psychotropic 
RX Guide
1(1) 0 0 0 0 0 0 0 0 0 0 0
 
NT = neurotransmitter; NTREC = neurotransmitter receptor; NTROP = neurotrophins; N/C = neuroanatomy/circuits;  
GEN = genetics; GABA; GLUT = glutamate; NE/NP = neuroendocrine/neuropeptides; NGEN = neurogenesis;  















I’m wondering if you’d be willing to begin by telling me some of the ways in which the 
curriculum has changed since the 2013/2014 iteration that I analyzed?  In particular, I’m 
wondering if there have been any changes to the semester project which required students 
to read a book that critiqued some aspects of psychopharmacology? For example, have 
you added or removed any of the books on the reading list? 
 
How did you choose the titles for the semester project readings? 
 
Etiology of Depression 
 
In the Biological Basis of Affective Disorders video you sent me, the presenter discussed 
the chemical imbalance hypothesis of depression without explicitly challenging this 
hypothesis. With regard to the serotonin transporter gene implicated in depression, the 
presenter did note that these findings had been, “replicated by a few labs” and that, “there 
have also been some negative findings...so this is still theoretical.” However, no details 
about the negative findings were addressed. Can you comment on these observations? 
 
The presenter also noted that, “so these are theories – too many receptors, too little 
transmitters, but when you look at parts of the brain being hyper or hypoactive these are 
real findings in real patients.” Nonetheless, there were no discussions about reductionism 
or the limitations of neuroimagery and animal models frequently used to support 
hypotheses about the etiology of depression. If my findings are correct, and students are 
not being sufficiently exposed to critical viewpoints about neurobiologically based 
theories for the etiology of depression within the Program’s training video for the 
Biological Basis of Affective Disorders, where would they encounter such information in 
the curriculum?  
 
My analysis indicated that neurobiologically based hypotheses for the etiology of 
depression were not consistently critiqued within the examined required and 
recommended readings. For example, in Stahl’s Essential Psychopharmacology: 
Neuroscientific Basis and Practical Applications, four of the ten hypotheses presented 
were challenged. In a Primer of Drug Action, eight hypotheses were discussed but I could 
only find critiques for the monoamine hypothesis and neurotransmitter receptor 
hypothesis for depression. Next, other than Carlat’s, Unhinged, the semester project 
books only presented and critiqued the monoamine and genetic hypotheses for 








A number of the required readings provided challenges to the rigor of the DSM. 
However, these instances were rare within the non-semester project readings. For 
example, in the eighteen chapters of required readings within the American Psychiatric 
Publishing Textbook, I could only find three examples where the DSM’s rigor was 
critiqued. In one case this textbook noted that the clinical features of bipolar disorder in 
children might differ from adolescents and adults. In another instance the textbook noted 
uncertainties about the best ways to classify GAD. In the Manual of Clinical 
Psychopharmacology for Nurses, there were two brief examples of a critique on two 
pages. In the eleven Primer of Drug Action chapter readings I could not find any cases 
where the DSM was challenged.     
 
There were no examples of the DSM’s kappa scores being discussed in any of the 
materials and, based on my analysis, the only substantive critiques about the manual 
occurred within four of the six semester project books. Was a more thorough critique of 
the DSM’s rigor covered in any of the videos I didn’t watch? 
 
The PEP Training DVD talked about treating symptoms and not diagnoses, which is 
consistent with Stephen Stahl’s approach. I’m wondering if there is a particular 
philosophical leaning in this regard within your program and I’m also wondering what 
your thoughts are about the RDoC (Research Domain Criteria) and its implications for 
training prescribing psychologists? 
 
C/s/x 
My analysis found that information about the c/s/x movement was discussed with some 
detail in Anatomy of an Epidemic and it was briefly mentioned within David Healy and 
Daniel Carlat’s books.  However, I couldn’t find any other mentions of the movement 
within the other curriculum readings I analyzed. Can you comment on the apparent dearth 




How confident are you that psychologists are well versed in the literature which critiques 
conventional viewpoints about psychopharmacology, prior to their enrolling in a 
psychologist postdoctoral psychopharmacology training program? 
 
Stephen Stahl’s book, Essentials of Psychopharmacology, included some suggested 












Table Non-Textbook Articles: Number of Pages with Neurobiological Etiology of 




























script:   
0 0 0 0 0 0 0 0 0 0 0 0 
Simple strategies to 
avoid med. errors 
0 0 0 0 0 0 0 0 0 0 0 0 
Psychotropic drug 
Rx’s by medical 
spec. 
0 0 0 0 0 0 0 0 0 0 0 0 
Avoiding medical 
errors: JCAHO   
0 0 0 0 0 0 0 0 0 0 0 0 
Do not use list: 0 0 0 0 0 0 0 0 0 0 0 0 
 Annual Research 
Review 
0 0 0 0 0 0 0 0 0 0 0 0 
Genetic testing for 
psychiatric 
disorders: 
0 0 0 0 1 
(1) 
0 0 0 0 0 0 0 
County-level est. 
mental health prof. 
US 
0 0 0 0 0 0 0 0 0 0 0 0 
County-level est. 
mental hlth prof. S. 
US  
0 0 0 0 0 0 0 0 0 0 0 0 
County-level est. 
mental hlth prof. S. 
US  
0 0 0 0 0 0 0 0 0 0 0 0 
Mental illness 
surveillance among 
adults   
0 0 0 0 0 0 0 0 0 0 0 0 
What price 
prescribing?   







psychology:   
0 0 0 0 0 0 0 0 0 0 0 0 
Practice g-lines 
regarding 
psychologists'   








0 0 0 0 0 0 0 0 0 0 0 0 
Helping doctors and 
patients   
0 0 0 0 0 0 0 0 0 0 0 0 
AD rx effects & 
depression severity 
0 0 0 0 0 0 0 0 0 0 0 0 
Relative effects of 
CBT and pharma   
0 0 0 0 0 0 0 0 0 0 0 0 
What doctors don’t 
know about  
0 0 0 0 0 0 0 0 0 0 0 0 
Research shows that 
all too often   
0 0 0 0 0 0 0 0 0 0 0 0 
Psychotherapy and 
psychopharmacolog
y:    
0 0 0 0 0 0 0 0 0 0 0 0 
Buproprion - SR, 
Sertraline, 
Venlafaxine    
0 0 0 0 0 0 0 0 0 0 0 0 
The efficacy of 
psychotherapy and 
0 0 0 0 0 0 0 0 0 0 0 0 
Serotonin Syndrome 
Article 
1 0 0 0 0 0 0 0 0 0 0 0 
Monoamine 
Oxidase Inhibitors 





NEJM lab values 0 0 0 0 0 0 0 0 0 0 0 0 
Warfarin   0 0 0 0 0 0 0 0 0 0 0 0 
Harvard Medical 
School Algorithm 
0 0 0 0 0 0 0 0 0 0 0 0 
Texas Medication 
Algorithm Project 
0 0 0 0 0 0 0 0 0 0 0 0 
The choice of 
antipsychotic drugs   
0 0 0 0 0 0 0 0 0 0 0 0 
Effectiveness of 
antipsychotic drugs   
0 0 0 0 0 0 0 0 0 0 0 0 
Comparative 
efficacy and 
tolerability    
0 0 0 0 0 0 0 0 0 0 0 0 
Treatment of acute 
agitation    
0 0 0 0 0 0 0 0 0 0 0 0 
Pharm. Mgmt of 
Acutely Agitated    
0 0 0 0 0 0 0 0 0 0 0 0 
DOD VA PTSD 
Guidelines   
0 0 0 0 2 0 0 0 0 0 0 0 
AACAP Guideline 
for ADHD 
0 0 0 0 0 0 0 0 0 0 0 0 
AACAP Guideline 
for Bipolar Disorder 








0 0 0 0 2 0 0 0 0 0 0 0 
Wiggins RxP Fact 
Sheet 
0 0 0 0 0 0 0 0 0 0 0 0 






NT = neurotransmitter; NTREC = neurotransmitter receptor; NTROP = neurotrophins; N/C = neuroanatomy/circuits;  
GEN = genetics; GABA; GLUT = glutamate; NE/NP = neuroendocrine/neuropeptides; NGEN = neurogenesis;  
IMM = immunological; CR = circadian rhythms; ENZ = enzymes. 





















Ax Template 2 0 0 0 0 0 0 0 0 0 0 0 0 
Tx Plan Template 0 0 0 0 0 0 0 0 0 0 0 0 
Clinical Note 
Template 
0 0 0 0 0 0 0 0 0 0 0 0 
Rx Form Template  0 0 0 0 0 0 0 0 0 0 0 0 
Drug References  0 0 0 0 0 0 0 0 0 0 0 0 
Measurement 
Conversion Sheet 
0 0 0 0 0 0 0 0 0 0 0 0 





























4 1 0 0 0 0
Neuroscien
ce
1 0 0 0 0 0
Goodman 
& Gilman's









12 0 0 3 2 0
Case 
Studies





0 0 0 0 0 0
Clinical 
Handbook










55 6 0 4 2 0
Pharmacot
herapy*










0 0 0 0 0 0
Neuroanato
my*
0 0 0 0 0 0
Study 
Guide*







G/A/G = general/applications/guidelines; DEV = development; BEN = benefits; C/L/C = 
criticisms/limitations/controversy’s; CV = construct validity; IR = inter-rater  
 
Pathophysiology: The Biological Basis for Disease, 6th ed. (23 chapters) 
A Primer of Drug Action, 12th ed. (11chapters) 
Essential Psychopharmacology: Neuroscientific Basis & Practical Applications, 4th ed. (9 chapters) 
The American Psychiatric Publishing Textbook of Psychopharmacology (16 chapters) 
Neurosciences, 5th ed. (7 chapters; 8 pages from 3 other chapters; Appendix and Atlas) 
Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed. (38 chapters; Appendix 1) 
Pharmacotherapy for Psychologists (5 chapters) 
Case Studies: Essential Psychopharmacology (10 chapters)  
Essential Evidence Based Psychopharmacology, 2nd ed. (3 chapters) 
Clinical Handbook of Psychotropic Drugs 19th ed. (Entire Book Examined) 
Manual of Clinical Psychopharmacology for Nurses (Entire Book Examined)* 
Pharmacotherapy: A Pathophysiological Approach, 8th ed. (2 chapters) * 
Seeley’s Anatomy & Physiology, 9th ed. (Entire Book Examined)* 
Atlas of Functional Neuroanatomy, 2nd ed. (Entire Book Examined)* 
Neuroanatomy Through clinical cases, 2nd ed. (Entire Book Examined)* 
Study guide to Clinical Psychopharmacology: A Companion (16 chapters)*  







SP Books: Number of Pages for DSM Content that  







Semester Project Book Title G/A/G DEV BEN C/L/
C 
CV REL 
 Unhinged  37 18 11 22 19 1 
 The Medicalization of Society 27 21 3 12 8 0 
 Selling Sickness 20 12 4 10 11* 0 
 Let them Eat Prozac 3 2 0 2 2 0 
Psychotropic Drug Prescriber’s Guide 1 0 0 0 0 0 
Anatomy of an Epidemic 19 15 3* 7 6 1 
G/A/G = general/applications/guidelines; DEV = development; BEN = benefits; C/L/C = 







Non-Textbook Articles: Number of Pages for DSM Content that  







NSP Book Title G/A/G DEV BEN C/L/C CV REL 
Following the script:   0 0 0 0 0 0 
Simple strategies to avoid med. errors 0 0 0 0 0 0 
Psychotropic drug Rx’s by medical spec. 0 0 0 0 0 0 
Avoiding medical errors: JCAHO   0 0 0 0 0 0 
Do not use list: 0 0 0 0 0 0 
 Annual Research Review 2 2 1 1 0 0 
Genetic testing for psychiatric disorders: 0 0 0 0 0 0 
County-level est. mental health prof. US 0 0 0 0 0 0 
County-level est. mental health prof. US  0 0 0 0 0 0 
County-level est. mental health prof. US  0 0 0 0 0 0 
Mental illness surveillance among adults   3 1 1 2 1 1 
What price prescribing?   0 0 0 0 0 0 
Prescribing and primary care psychology:   0 0 0 0 0 0 
Practice g-lines regarding psychologists'   0 0 0 0 0 0 
Prescriptive authority for psychologists  0 0 0 0 0 0 
Malpractice claims exp. of psychologists 0 0 0 0 0 0 
Helping doctors and patients   0 0 0 0 0 0 
AD rx effects & depression severity 0 0 0 0 0 0 
Relative effects of CBT and pharma   0 0 0 0 0 0 
What doctors don’t know about  0 0 0 0 0 0 
Research shows that all too often   0 0 0 0 0 0 
Psychotherapy and psychopharmacology:    0 0 0 0 0 0 
Buproprion - SR, Sertraline, Venlafaxine    1 0 0 0 0 0 
The efficacy of psychotherapy and 1 0 0 0 0 0 
Serotonin Syndrome Article 0 0 0 0 0 0 
Monoamine Oxidase Inhibitors 0 0 0 0 0 0 
NEJM lab values 0 0 0 0 0 0 
Warfarin   0 0 0 0 0 0 







Texas Medication Algorithm Project 2 0 0 0 0 0 
The choice of antipsychotic drugs   0 0 0 0 0 0 
Effectiveness of antipsychotic drugs   2 0 0 0 0 0 
Comparative efficacy and tolerability    0 0 0 0 0 0 
Treatment of acute agitation    0 0 0 0 0 0 
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